≡ Risteys
R14

Documentation Changelog GitHub Contact & Feedback

Pneumocystosis

EFO Endpoint Browser PheWeb

AB1_PNEUMOCYSTOSIS

Endpoint definition

↥

Report an error or suggest an improvement for this endpoint codes

Endpoint definition steps

FinnGen

Phenotype data

519870

1. Apply sex-specific rule

None

519870

2. Check conditions

None

519870

3. Check pre-conditions, main-only, mode, registry filters

Registry filters:

  • Hospital discharge: ICD-10 — B59
  • Hospital discharge: ICD-9 — 1363
  • Hospital discharge: ICD-8 — 13601
  • Cause of death: ICD-10 — B59
  • Cause of death: ICD-9 — 1363
  • Cause of death: ICD-8 — 13601

2 out of 7 registries used, show all original rules.

701

4. Check minimum number of events

None

701

5. Include endpoints

None

701

6. Filter based on genotype QC (FinnGen only)

677

Control definitions (FinnGen only)

Control exclude
AB1_PROTOZOAL

Extra metadata

Level in the ICD hierarchy
3
First used in FinnGen datafreeze
DF5

Case counts by codes

↥

FinnGen case counts by registry codes:

generic upset plot

Upset plot

Full data table

Summary Statistics

↥

-FinRegistry-

Key figures

All Female Male
Number of individuals
Whole population 2264 930 1311
Only index persons 1857 788 1069
Unadjusted period prevalence (%)
Whole population 0.03 0.03 0.04
Only index persons 0.04 0.03 0.04
Median age at first event (years)
Whole population 65.64 66.13 65.45
Only index persons 67.08 67.10 67.08

-FinnGen-

Key figures

All Female Male
Number of individuals 677 304 373
Unadjusted period prevalence (%) 0.14 0.11 0.17
Median age at first event (years) 68.91 68.36 69.36

-FinRegistry-

Age distribution of first events

-FinnGen-

Age distribution of first events

-FinRegistry-

Year distribution of first events

-FinnGen-

Year distribution of first events

-FinRegistry-

Cumulative Incidence Function

-FinnGen-

Cumulative Incidence Function

CodeWAS

↥

CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.

This is a new tool, please reach out using the contact form for feedback and improvement ideas.

First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.

Matched cohort

Matched cases
701
Matched controls
7010
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
TGC00
NOMESCO Finland
Bronchial lavation
54.9
307.7
312
101
GD1DD
NOMESCO Finland
High resolution CT examination of lungs
23.1
307.7
293
211
J17.3*B59
ICD-10 Finland
Pneumonia due to Pneumocystis carinii
+∞
307.7
608
*
UGC12
NOMESCO Finland
Flexible bronchoscopy
18.9
307.7
349
349
117
Kela drug reimbursment
Leukaemia and other malignant diseases of the blood and bone marrow, and malignant diseases of the lymphatic tissue
20.0
274.4
243
181
J01EE01
ATC
sulfamethoxazole and trimethoprim; systemic
17.7
261.4
250
213
J18.9
ICD-10 Finland
Pneumonia, unspecified
11.3
218.0
511
1352
R50.9
ICD-10 Finland
Fever, unspecified
8.7
181.8
341
686
ZX108
NOMESCO Finland
Inhalation
48.4
169.2
100
24
XW000
NOMESCO Finland
Bone marrow biopsy
13.5
165.2
174
167
A49.9
ICD-10 Finland
Bacterial infection, unspecified
8.4
162.1
284
523
L03AA02
ATC
filgrastim; parenteral
16.2
155.7
143
109
WW500
NOMESCO Finland
Blood transfusion
12.5
140.8
154
155
J84.9
ICD-10 Finland
Interstitial pulmonary disease, unspecified
17.6
134.6
116
78
GD1AD
NOMESCO Finland
Thorax CT examination
8.9
133.3
197
294
B59
ICD-10 Finland
Pneumocystosis
+∞
129.3
120
*
JN4AD
NOMESCO Finland
Body CT examination
6.7
127.4
276
616
ZX120
NOMESCO Finland
Intravenous
7.5
123.7
221
405
H02AB06
ATC
prednisolone; systemic
7.7
115.6
576
2618
GD1AA
NOMESCO Finland
Thorax X-ray examination
9.1
111.9
610
2971
R91
ICD-10 Finland
Abnormal findings on diagnostic imaging of lung
6.5
111.5
235
504
WD405
NOMESCO Finland
Simple antiboidy therapy of methastized malignancy
14.0
110.5
108
90
WD125
NOMESCO Finland
Demanding cystostatic therapy of methastized malignancy
9.1
109.9
152
207
J84.8
ICD-10 Finland
Other specified interstitial pulmonary diseases
22.3
100.7
76
38
FB1BD
NOMESCO Finland
Extensive CT examination of arteria pulmonalis
6.9
99.3
183
341
H02AB02
ATC
dexamethasone; systemic
5.8
96.8
232
554
L04AA06
ATC
mycophenolic acid; systemic
15.6
91.8
83
60
L03AA13
ATC
pegfilgrastim; parenteral
8.7
90.2
126
172
A04AA01
ATC
ondansetron; systemic, rectal
6.3
89.8
181
366
WD105
NOMESCO Finland
Cystostatic therapy of methastized malignancy
9.0
89.8
122
161
DM1QA
NOMESCO Finland
Paranasal sinuses X-ray examination in one projection
8.7
89.8
126
173
WD415
NOMESCO Finland
Demanding antibody therapy of methastized malignancy
18.3
89.5
74
45
M04AA01
ATC
allopurinol; systemic
5.2
88.6
241
637
D70.82
ICD-10 Finland
Drug-induced neutropenia
17.4
88.4
75
48
GD1UA
NOMESCO Finland
Thorax X-ray examination outside radiological department
4.8
88.3
292
904
J01MA14
ATC
moxifloxacin; systemic
6.2
87.7
182
378
TPH15
NOMESCO Finland
Insertion of central venous catheter through external or internal jugular vein
7.3
86.5
145
243
J15.9
ICD-10 Finland
Bacterial pneumonia, unspecified
6.2
85.5
173
350
127
Kela drug reimbursment
Transplant complication
17.8
85.0
71
44
JN4BD
NOMESCO Finland
Extensive body CT
5.4
84.1
208
505
J84.1
ICD-10 Finland
Other interstitial pulmonary diseases with fibrosis
13.2
79.4
79
67
GD1ED
NOMESCO Finland
Extensive high resolution CT examination of lungs
9.8
79.4
98
114
GCA98
NOMESCO Finland
Other bronchoscopic procedure on bronchus
30.1
79.2
53
19
A03FA01
ATC
metoclopramide; systemic, rectal
4.3
78.4
311
1089
Z51.5
ICD-10 Finland
Palliative care
5.4
76.3
181
421
L04AX01
ATC
azathioprine; systemic
8.7
71.0
96
125
C83.31
ICD-10 Finland
Diffuse lymphoma with large B cells
14.5
69.9
65
49
DM1AA
NOMESCO Finland
Paranasal sinuses X-ray examination without contrast
8.8
67.9
91
117
NK6QA
NOMESCO Finland
Measurement of bone density from two or more locations with X-ray
6.1
67.8
134
262
C91.1
ICD-10 Finland
Chronic lymphocytic leukaemia of B-cell type
18.6
67.6
55
32
A12AX
ATC
Calcium, combinations with vitamin D and/or other drugs
3.8
67.5
403
1827
J01MA12
ATC
levofloxacin; systemic
4.1
66.1
262
899
J01FF01
ATC
clindamycin; systemic
3.8
65.9
330
1328
202
Kela drug reimbursment
Connective tissue diseases, rheumatoid arthritis and comparable disease
4.8
63.4
174
452
D70.89
ICD-10 Finland
Neutropenic splenomegaly
18.9
63.3
51
29
WD135
NOMESCO Finland
Demanding cystostatic therapy of methastized malignancy
25.2
63.3
45
19
C03CA01
ATC
furosemide; systemic
3.6
60.8
368
1653
GD1PA
NOMESCO Finland
X-ray examination of the lungs in one projection
4.5
60.3
183
513
TPX10
NOMESCO Finland
Implantation of vascular injection port
8.6
57.6
78
101
TK800
NOMESCO Finland
Hemodialysis
10.6
57.1
65
67
A04AA02
ATC
granisetron; systemic, transdermal
5.3
56.5
131
294
L04AD01
ATC
ciclosporin; systemic
12.6
56.5
57
49
JN6AD
NOMESCO Finland
CT of torso and neck
10.7
55.9
63
64
JN3AE
NOMESCO Finland
Abdominal ultrasound examination
3.9
53.5
198
637
J05AB11
ATC
valaciclovir; oral
3.9
53.1
201
656
9823/3-C42.1
ICD-O-3
B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma of bone marrow
21.1
52.4
40
20
TNE25
NOMESCO Finland
Drill biopsy of bone marrow, pelvis
15.3
51.5
46
32
WW200
NOMESCO Finland
Immunization
9.3
50.2
63
74
WZC00
NOMESCO Finland
Treatment plan or consultation
3.2
49.0
385
1953
TPH04
NOMESCO Finland
Cathetrisation of vein
3.2
46.6
271
1149
313
Kela drug reimbursment
Abatacept, adalimumab, anakinra, certolizumab pegol, etanercept, golimumab, infliximab, ixekizumab, sarilumab, secukinumab, tocilizumab and ustekinumab (rheumatoid diseases)
9.0
44.8
57
68
TPH90
NOMESCO Finland
Removal of fixed intravenous catheter
13.9
44.6
42
32
TPH20
NOMESCO Finland
Insertion of central venous catheter through subclavian or brachiocephalic vein
7.5
44.0
66
96
WD115
NOMESCO Finland
Multiple cystostatic therapy of methastized malignancy
9.6
43.9
53
59
L03AA14
ATC
lipegfilgrastim; parenteral
9.6
43.9
53
59
L04AA01
ATC
[U] ciclosporin
15.2
43.7
39
27
A02BC02
ATC
pantoprazole; systemic
4.1
42.6
600
4127
D69.6
ICD-10 Finland
Thrombocytopenia, unspecified
9.1
41.3
52
61
WD305
NOMESCO Finland
Simple therapy of methastized malignancy with biomodifiers
11.7
41.0
43
39
NK4XE
NOMESCO Finland
Joint ultrasound examination not elsewhere classified
4.9
41.0
100
232
ZX112
NOMESCO Finland
Subcutaneous
7.5
40.4
60
86
N02AA05
ATC
oxycodone; systemic
3.1
40.1
235
987
L04AX03
ATC
methotrexate; systemic
4.0
40.1
133
390
GD1BD
NOMESCO Finland
Thorax extensive CT-examination
4.8
40.0
98
228
R06.0
ICD-10 Finland
Dyspnoea
2.9
39.9
304
1474
GD1QA
NOMESCO Finland
Supine thorax X-ray examination
3.1
39.7
231
966
281
Kela drug reimbursment
Abatacept, adalimumab, anakinra, certolizumab pegol, etanercept, golimumab, infliximab, ixekizumab, sarilumab, secukinumab and tocilizumab
8.8
39.4
51
62
138
Kela drug reimbursment
Severe anaemia associated with chronic renal failure
8.6
39.3
52
65
A41.9
ICD-10 Finland
Sepsis, unspecified
6.0
38.8
73
134
Z94.0
ICD-10 Finland
Kidney transplant status
14.0
38.5
36
27
WX892
NOMESCO Finland
Monitored bed care
4.2
38.4
117
322
Z51.1
ICD-10 Finland
Chemotherapy session for neoplasm
11.7
38.3
40
36
A07EC01
ATC
sulfasalazine; oral, rectal
4.3
36.3
105
278
M05.8
ICD-10 Finland
Other seropositive rheumatoid arthritis
4.8
36.0
88
204
Z49.1
ICD-10 Finland
Extracorporeal dialysis
10.8
35.4
39
38
B03XA01
ATC
erythropoietin; parenteral
13.8
35.0
33
25
I26.9
ICD-10 Finland
Pulmonary embolism without mention of acute cor pulmonale
4.6
34.5
89
215
123
Kela drug reimbursment
Chronic disorders of vitamin D metabolism
7.3
34.4
52
76
A07AA09
ATC
vancomycin; oral
11.1
34.2
37
35
JN6BD
NOMESCO Finland
Extensive CT of torso and neck
13.9
34.2
32
24
L01BA01
ATC
methotrexate; systemic
6.3
34.1
60
103
B03XA02
ATC
darbepoetin alfa; parenteral
7.3
33.5
51
75
L04AD02
ATC
tacrolimus; systemic
12.8
33.5
33
27
N17.9
ICD-10 Finland
Acute renal failure, unspecified
5.1
33.3
74
158
H02AB09
ATC
hydrocortisone; systemic
7.6
33.0
48
67
C90.0
ICD-10 Finland
Multiple myeloma
10.5
33.0
37
37
H02AB07
ATC
prednisone; oral
3.2
32.1
154
569
XG470
NOMESCO Finland
Measurement of diffusion capastity of the lungs
5.9
30.9
58
106
J01CR02
ATC
amoxicillin and beta-lactamase inhibitor; systemic
2.5
30.8
443
2822
A11CC03
ATC
alfacalcidol; systemic
6.8
29.8
48
75
A04.7
ICD-10 Finland
Enterocolitis due to Clostridium difficile
6.8
29.3
47
73
JN1AE
NOMESCO Finland
Ultrasound examination of upper part of abdomen
3.4
28.8
120
405
L04AA13
ATC
[U] leflunomide
7.2
28.7
44
65
Z94.8
ICD-10 Finland
Other transplanted organ and tissue status
27.4
28.7
39
15
JN4JR
NOMESCO Finland
Whole body extensive metabolic PET with CT
11.6
28.6
30
27
WZC20
NOMESCO Finland
Multidisciplinary treatment meeting
3.9
28.5
92
262
UJD10
NOMESCO Finland
Esophagoscopy, gastroscopy and duodenoscopy
2.5
28.2
284
1521
M05BX04
ATC
denosumab; parenteral
3.9
27.6
89
253
PH2AE
NOMESCO Finland
Ultrasound examination of lower leg veins
3.1
27.6
138
519
KA3AT
NOMESCO Finland
Biopsy of kidney with ultrasound guidance
9.6
27.6
33
36
B01AB10
ATC
tinzaparin; parenteral
3.1
27.5
137
514
WF049
NOMESCO Finland
Radiotherapy of metastasis
4.9
27.4
64
142
JN3AD
NOMESCO Finland
Abdominal CT examination
2.9
27.3
153
613
TNX10
NOMESCO Finland
Arthrocentesis, unspecified region, unspecified region
3.8
27.2
89
256
P01BA02
ATC
hydroxychloroquine; oral
3.5
27.1
102
322
TPH07
NOMESCO Finland
Cathetrisation of artery
3.0
27.1
145
566
PJD41
NOMESCO Finland
Excision of cervical lymph nodes
8.9
26.8
34
40
XG412
NOMESCO Finland
Flow-volume spirometry with bronchospasmolysis
4.0
26.8
81
220
Z2446
NOMESCO Finland
Social worker
3.9
26.5
85
241
H02AB04
ATC
methylprednisolone; systemic
2.9
26.2
152
619
1CX01, ,
NOMESCO Finland
62.6
26.2
30
5
J05AB01
ATC
aciclovir; systemic
2.5
26.0
208
996
WW300
NOMESCO Finland
Transfer of autologic stem cells
29.7
25.6
34
12
N18.9
ICD-10 Finland
Chronic kidney disease, unspecified
3.8
25.5
84
242
PBL10
NOMESCO Finland
Construction of arteriovenous fistula from radial artery
10.8
25.5
28
27
R59.0
ICD-10 Finland
Localized enlarged lymph nodes
5.3
25.1
52
104
A12AA04
ATC
calcium carbonate; oral
7.2
24.4
37
54
WD325
NOMESCO Finland
Demanding therapy of methastized malignancy with biomodifiers
9.2
24.3
30
34
D64.9
ICD-10 Finland
Anaemia, unspecified
2.9
24.1
128
496
1XC02, ,
NOMESCO Finland
22.3
23.6
34
16
M06.9
ICD-10 Finland
Rheumatoid arthritis, unspecified
5.5
23.3
46
88
EB1HA
NOMESCO Finland
Panorama tomography of teeth and jaws or similar X-ray examination
2.2
23.1
351
2190
PJA10
NOMESCO Finland
Exploration of lymph nodes
7.9
23.1
32
42
B48.5
ICD-10 Finland
Pneumocystosis
+∞
23.0
22
*
J17.3
ICD-10 Finland
Pneumonia in parasitic diseases
+∞
23.0
22
*
M05.9
ICD-10 Finland
Seropositive rheumatoid arthritis, unspecified
6.2
22.4
39
66
L04AB04
ATC
adalimumab; parenteral
7.3
22.2
33
47
GD5AD
NOMESCO Finland
Thorax and upper abdomen combined CT examination of
7.6
22.2
32
44
AA1CG
NOMESCO Finland
Extensive MRI examination of brain with high intensity magnet
3.2
22.2
99
346
J22
ICD-10 Finland
Unspecified acute lower respiratory infection
3.5
22.1
84
266
A05AA02
ATC
ursodeoxycholic acid; oral
8.0
21.8
30
39
J20.9
ICD-10 Finland
Acute bronchitis, unspecified
2.4
21.7
186
910
R4110
NOMESCO Finland
Physiotherapy
2.2
21.6
259
1462
WX720
NOMESCO Finland
Own respiration
3.7
21.3
73
216
AA1BD
NOMESCO Finland
Extensive CT of head and brain
5.4
21.2
43
84
Z3231
NOMESCO Finland
Registered nurse
2.2
21.0
246
1371
J96.0
ICD-10 Finland
Acute respiratory failure
7.3
20.9
31
44
NA3AA
NOMESCO Finland
Lumbar spine X-ray examination without contrast
2.8
20.8
119
477
WF004
NOMESCO Finland
Palliative radiotherapy
5.8
20.8
39
71
R59.1
ICD-10 Finland
Generalized enlarged lymph nodes
8.5
20.6
27
33
D80.1
ICD-10 Finland
Nonfamilial hypogammaglobulinaemia
43.1
20.6
25
6
FB1AD
NOMESCO Finland
CT examination of arteria pulmonalis
5.1
20.4
44
91
TQX10
NOMESCO Finland
Biopsy of skin and subcutaneous tissue
2.9
20.3
108
417
A04AA55
ATC
palonosetron, combinations; systemic
4.3
20.0
53
130
SPAT1255
SPAT
Intravenous administration of medicine
3.4
20.0
78
251
C79.8
ICD-10 Finland
Secondary malignant neoplasm of other specified sites
4.0
19.6
57
150
XX3DW
NOMESCO Finland
Time consuming IT work
2.6
19.4
125
532
B25.9
ICD-10 Finland
Cytomegaloviral disease, unspecified
32.3
19.4
25
8
L04AB01
ATC
etanercept; parenteral
8.6
19.4
25
30
FM1AE
NOMESCO Finland
Standard cardiac ultrasound examination
2.3
19.3
187
959
FM1EE
NOMESCO Finland
Extensive structural and functional ultrasound examination of heart
2.1
19.2
243
1388
C83.1
ICD-10 Finland
Mantle cell lymphoma
23.3
19.2
27
12
ZXE00
NOMESCO Finland
One hour or less
2.1
19.1
309
1935
6BA02, ,
NOMESCO Finland
56.7
19.0
22
*
TPH30
NOMESCO Finland
Insertion of central venous catheter through periferal vein
6.0
19.0
34
59
A07AA02
ATC
nystatin; oral
3.5
19.0
70
217
ZXE10
NOMESCO Finland
More than one and less than three hours
2.1
18.9
301
1873
QX2XE
NOMESCO Finland
Ultrsound examination of soft tissue not elsewhere classified
4.4
18.9
48
114
B01AB05
ATC
enoxaparin; parenteral
2.1
18.8
283
1722
C91.0
ICD-10 Finland
Acute lymphoblastic leukaemia [ALL]
71.9
18.8
21
*
R81
ICPC
Pneumonia
4.0
18.8
56
150
A03
ICPC
Fever
2.4
18.7
146
681
KH1AE
NOMESCO Finland
Urinary tract ultrasound examination
3.2
18.5
78
263
WX700
NOMESCO Finland
Respiratory and circulatory monitoring
2.3
18.0
158
775
TGD04
NOMESCO Finland
Needle biopsy of the lungs in bronchoscopy
18.7
17.9
27
15
PJ2AT
NOMESCO Finland
Biopsy of lymphnode with ultrasound guidance
18.7
17.9
27
15
B02.9
ICD-10 Finland
Zoster without complication
3.0
17.8
84
302
ZXE03
NOMESCO Finland
Procedure duration 20 to 29 minutes
3.5
17.5
63
192
J02AC03
ATC
voriconazole; systemic
24.8
17.4
24
10
A46
ICD-10 Finland
Erysipelas
2.4
17.3
146
702
212
Kela drug reimbursment
Gout
5.6
17.3
33
61
WZC30
NOMESCO Finland
Teaching
2.3
17.1
162
819
ZX120, ,
SPAT
7.4
17.0
25
35
XZZ00
NOMESCO Finland
Active surveillance of a diagnosed cancer
5.9
16.9
31
55
U07.1
ICD-10 Finland
Emergency use of U07.1 | COVID-19, virus identified
2.3
16.9
147
716
R03AC02
ATC
salbutamol; inhalant
2.0
16.4
418
3012
J01MA02
ATC
ciprofloxacin; systemic
1.9
16.3
317
2087
390
Kela drug reimbursment
Ibrutinib
48.7
16.1
19
*
B25.8
ICD-10 Finland
Other cytomegaloviral diseases
21.6
16.1
23
11
HA1AE
NOMESCO Finland
Ultrasound examination of mammary glands
3.1
16.0
72
252
J09
ICD-10 Finland
Influenza due to identified zoonotic or pandemic influenza virus
4.5
15.9
40
94
N18.8
ICD-10 Finland
Other chronic renal failure
4.9
15.8
35
74
PH1AE
NOMESCO Finland
Ultrasound examination of upper extremity veins
5.3
15.7
32
63
NH3EA
NOMESCO Finland
Feet X-ray examination with load
5.7
15.4
29
53
N17.8
ICD-10 Finland
Other acute renal failure
7.2
15.3
23
33
N05CF01
ATC
zopiclone; oral
2.0
15.3
256
1593
N10
ICD-10 Finland
Acute tubulo-interstitial nephritis
2.4
15.2
120
559
WX408
NOMESCO Finland
General anesthesy, balanced
2.0
15.1
220
1303
XQ855, ,
SPAT
6.7
15.0
24
37
WX882
NOMESCO Finland
High dependency care
4.2
14.9
40
99
A04AD12
ATC
aprepitant; systemic
5.0
14.9
32
66
L88
ICPC
Rheumatoid/seropositive arthritis
3.7
14.9
48
136
EP1AE
NOMESCO Finland
Neck ultrasound examination
3.0
14.8
69
246
TDM10
NOMESCO Finland
Puncture of maxillary antrum
4.0
14.8
43
113
KA2AE
NOMESCO Finland
Ultrasound examination transplanted kidney
13.6
14.8
25
19
329
Kela drug reimbursment
Lenalidomide
18.9
14.8
22
12
L01AA02
ATC
chlorambucil; oral
25.7
14.7
20
8
Z3226
NOMESCO Finland
Physiotherapist
2.1
14.7
160
851
KAS10
NOMESCO Finland
Allogenic transplantation of kidney from cadaver donor
12.2
14.7
26
22
A10AC01
ATC
insulin (human); parenteral
2.8
14.5
77
295
KA1AE
NOMESCO Finland
Kidney ultrasound examination
4.4
14.5
37
88
WX726
NOMESCO Finland
High-flow oxygen therapy
36.9
14.5
18
5
153
Kela drug reimbursment
Lenalidomid
12.9
14.5
25
20
M05BA04
ATC
alendronic acid; oral
2.7
14.4
86
350
R05
ICD-10 Finland
Cough
2.0
14.2
182
1026
I50.9
ICD-10 Finland
Heart failure, unspecified
2.2
14.2
133
665
1512
Kela drug reimbursment
Ibrutinib
43.4
14.2
17
*
JN3BD
NOMESCO Finland
Extensive abdominal CT
2.5
14.1
96
417
J01DB01
ATC
cefalexin; oral
2.3
14.0
597
5006
A41.5
ICD-10 Finland
Sepsis due to other Gram-negative organisms
3.6
14.0
47
137
C83.9
ICD-10 Finland
Non-follicular (diffuse) lymphoma, unspecified
24.4
13.8
19
8
C83.3
ICD-10 Finland
Diffuse large B-cell lymphoma
13.9
13.8
23
17
A06AH03
ATC
naloxegol; oral
5.9
13.8
25
44
B99
ICD-10 Finland
Other and unspecified infectious diseases
5.3
13.7
28
55
WZB00
NOMESCO Finland
Telephone prescription or other care instructions
1.9
13.7
220
1340
J01CA04
ATC
amoxicillin; systemic
2.2
13.7
581
4834
L04AX04
ATC
lenalidomide; oral
12.4
13.7
24
20
JN4CD
NOMESCO Finland
Very extensive body CT
3.6
13.7
47
139
GA4YT
NOMESCO Finland
Puncture of pleura with ultrasound guidance
3.6
13.5
46
135
D72.8
ICD-10 Finland
Other specified disorders of white blood cells
16.6
13.5
21
13
WX302
NOMESCO Finland
Thoracal epidural anesthesy
3.1
13.5
59
203
B34.9
ICD-10 Finland
Viral infection, unspecified
4.6
13.4
32
72
L01AA01
ATC
cyclophosphamide; systemic
18.7
13.4
20
11
XG410
NOMESCO Finland
Flow-volume spirometry
3.3
13.4
51
161
N02AB03
ATC
fentanyl; nasal, sublingual, transdermal
3.4
13.4
50
156
WW409
NOMESCO Finland
Other aferesis
21.7
13.4
19
9
XF400
NOMESCO Finland
ECG with 12 standard connections
2.1
13.4
141
738
AA1DG
NOMESCO Finland
Very extensive MRI examination of brain with high intensity magnet
4.0
13.3
39
103
190
Kela drug reimbursment
Lanthanum carbonate, sevelamer and sucroferric oxyhydroxide
10.0
13.3
26
27
R11
ICD-10 Finland
Nausea and vomiting
2.6
13.2
81
334
C82.1
ICD-10 Finland
Follicular lymphoma grade II
12.5
13.2
23
19
AA1AD
NOMESCO Finland
CT of head and brain
1.9
13.2
256
1656
J06.9
ICD-10 Finland
Acute upper respiratory infection, unspecified
1.8
13.1
321
2227
WX725
NOMESCO Finland
Noninvasive ventilation
2.9
13.1
64
234
N18.0
ICD-10 Finland
End-stage renal disease
10.3
13.1
25
25
E87.5
ICD-10 Finland
Hyperkalaemia
5.0
12.9
28
58
N02AA01
ATC
morphine; systemic, rectal
4.7
12.9
30
66
WX002
NOMESCO Finland
Sedation and analgesia
2.0
12.9
170
965
ZXD05
NOMESCO Finland
Urgent procedure
1.9
12.9
227
1422
RD210, ,
NOMESCO Finland
5.6
12.7
24
44
YNB10
NOMESCO Finland
Collection of stem cells for transplant
71.2
12.6
14
*
N02AX02
ATC
tramadol; systemic, rectal
1.8
12.6
341
2429
J17.1*B25.0
ICD-10 Finland
Cytomegaloviral pneumonitis
+∞
12.5
12
*
R06AE07
ATC
cetirizine; oral
1.8
12.3
302
2087
Z2221
NOMESCO Finland
Medical doctor
1.9
12.1
205
1263
399
Kela drug reimbursment
Venetoclax
18.4
12.1
18
10
L27.0
ICD-10 Finland
Generalized skin eruption due to drugs and medicaments
8.9
12.1
25
29
A10AB05
ATC
insulin aspart; parenteral
2.6
12.0
76
318
ZXE11
NOMESCO Finland
Procedure duration 60 to 89 minutes
3.2
12.0
49
162
KA2AT
NOMESCO Finland
Biopsy of transplanted kidney with ultrasound guidance
15.0
11.8
19
13
L01CA04
ATC
vinorelbine; systemic
9.2
11.8
24
27
M01CB01
ATC
sodium aurothiomalate; parenteral
9.2
11.8
24
27
C07AB07
ATC
bisoprolol; oral
1.8
11.8
394
2962
E87.1
ICD-10 Finland
Hypo-osmolality and hyponatraemia
3.1
11.8
50
169
AA1CD
NOMESCO Finland
Very extensive CT of head and brain
5.0
11.8
25
51
3AC01, ,
NOMESCO Finland
12.8
11.7
20
16
C81.9
ICD-10 Finland
Hodgkin lymphoma, unspecified
30.6
11.7
15
5
J70.2
ICD-10 Finland
Acute drug-induced interstitial lung disorders
30.6
11.7
15
5
L01EL01
ATC
ibrutinib; oral
66.1
11.6
13
*
L01XE27
ATC
[U] ibrutinib
66.1
11.6
13
*
WX110
NOMESCO Finland
Infiltration anesthesia
1.8
11.5
511
4157
B20.6
ICD-10 Finland
HIV disease resulting in Pneumocystis jirovecii pneumonia
+∞
11.5
11
*
130
Kela drug reimbursment
Malignant tumour
2.3
11.4
93
437
1518, ,
Kela drug reimbursment
17.4
11.2
17
10
C81.1
ICD-10 Finland
Nodular sclerosis classical Hodgkin lymphoma
17.4
11.2
17
10
C85.1
ICD-10 Finland
B-cell lymphoma, unspecified
25.5
11.2
15
6
GD1CD
NOMESCO Finland
Thorax extensive CT-examination
9.4
11.1
22
24
C85.9
ICD-10 Finland
Non-Hodgkin lymphoma, unspecified
10.3
11.1
21
21
XX6XT
NOMESCO Finland
Other intravascular therapy with radiological guidance
14.2
11.0
18
13
Z01.8
ICD-10 Finland
Other specified special examinations
1.9
10.9
180
1096
R2130
NOMESCO Finland
Counselling and guidance which enhance independent living
2.4
10.9
79
353
R4190
NOMESCO Finland
Nutritional therapy
3.1
10.8
45
150
C83.00
ICD-10 Finland
Lymphocytic lymphoma
28.5
10.8
14
5
YG1BD
NOMESCO Finland
Extensive CT examination of thorax for dose design of radiotherapy
3.2
10.7
42
135
D69.5
ICD-10 Finland
Secondary thrombocytopenia
21.9
10.7
15
7
J06BA01
ATC
immunoglobulins, normal human, for extravascular adm.; systemic
60.9
10.6
12
*
J12.8
ICD-10 Finland
Other viral pneumonia
9.4
10.6
21
23
JN5DR
NOMESCO Finland
PET-CT of upper body metabolism
4.7
10.5
24
52
ZX012
NOMESCO Finland
Radiotherapy with large shaped fields - isocentric therapy
2.5
10.5
66
275
C92.0
ICD-10 Finland
Acute myeloblastic leukaemia [AML]
14.5
10.5
17
12
J04BA02
ATC
dapsone; oral
16.3
10.4
16
10
J10.1
ICD-10 Finland
Influenza with other respiratory manifestations, seasonal influenza virus identified
4.8
10.3
23
49
L01XX52
ATC
venetoclax; oral
19.1
10.3
15
8
V03AE01
ATC
polystyrene sulfonate; oral
5.4
10.2
20
38
J90
ICD-10 Finland
Pleural effusion, not elsewhere classified
3.1
10.1
42
140
ZXA00
NOMESCO Finland
Right side
1.8
10.1
212
1383
N03AX16
ATC
[U] pregabalin
1.8
10.1
182
1135
R28
ICPC
Limited function/disability (R)
5.1
10.1
21
42
ND2AA
NOMESCO Finland
Hand and fingers X-ray examination
2.2
10.1
88
425
M06.0
ICD-10 Finland
Seronegative rheumatoid arthritis
3.8
10.1
31
85
J02AC01
ATC
fluconazole; systemic
1.7
10.0
240
1624
R02
ICPC
Shortness of breath/dyspnoea
2.0
10.0
122
669
TAB00
NOMESCO Finland
Lumbar puncture
3.0
10.0
46
163
ZXD30
NOMESCO Finland
Difficulties in perfomrming procedure
3.0
10.0
44
152
T86.0
ICD-10 Finland
Bone-marrow transplant rejection
40.7
10.0
12
*
ZXE20
NOMESCO Finland
More than three and less than five hours
2.0
9.9
120
656
J01.0
ICD-10 Finland
Acute maxillary sinusitis
1.8
9.9
167
1019
GD1CT
NOMESCO Finland
Biopsy of the lung with CT guidance
4.4
9.9
25
59
A02BC01
ATC
omeprazole; systemic
1.8
9.9
205
1331
7140A
ICD-9 Finland
Rheumatoid arthritis and other inflammatory polyarthropathies, Rheumatoid arthritis[ARTHRITIS RHEUMATOIDES SEROPOSITIVA]
8.3
9.9
21
26
L01BB05
ATC
fludarabine; systemic
26.4
9.8
13
5
L04AA24
ATC
abatacept; parenteral
20.4
9.8
14
7
I80.8
ICD-10 Finland
Phlebitis and thrombophlebitis of other sites
4.8
9.8
22
47
XX1XW
NOMESCO Finland
Extensive written report from radiologist
4.2
9.8
26
64
WX610
NOMESCO Finland
Patient controlled analgesia
13.6
9.7
16
12
N02BE01
ATC
paracetamol; systemic, rectal
2.4
9.7
643
5762
WW400
NOMESCO Finland
Plasmaferesis
55.8
9.7
11
*
ZXE02
NOMESCO Finland
Procedure duration 10 to 19 minutes
3.0
9.7
44
155
ZXE04
NOMESCO Finland
Procedure duration 30 to 39 minutes
2.7
9.6
54
213
NA7DG
NOMESCO Finland
Spine and spinal cord very extensive MRI examination with high intensity magnet
5.1
9.6
20
40
J12.1
ICD-10 Finland
Respiratory syncytial virus pneumonia
8.5
9.6
20
24
JN3AA
NOMESCO Finland
Abdominal X-ray examination without contrast
3.0
9.6
43
150
EB1BI
NOMESCO Finland
Cone beam imaging of teeth and jaws (1–2 quarters)
4.9
9.6
21
44
M31.3
ICD-10 Finland
Wegener granulomatosis
15.3
9.5
15
10
SPAT1262
SPAT
Handing over of treatment supplies
1.9
9.5
148
881
Z94.2
ICD-10 Finland
Lung transplant status
30.5
9.4
12
*
Z03.5
ICD-10 Finland
Observation for other suspected cardiovascular diseases
2.4
9.4
69
309
I15.1
ICD-10 Finland
Hypertension secondary to other renal disorders
7.1
9.4
22
32
IAZ97
NOMESCO Finland
Psychiatric consultation in another specialty
7.1
9.4
22
32
J01AA02
ATC
doxycycline; systemic
1.8
9.4
547
4652
C08CA01
ATC
amlodipine; oral
1.6
9.3
311
2287
A09
ICD-10 Finland
Other gastroenteritis and colitis of infectious and unspecified origin
1.9
9.3
127
723
N19
ICD-10 Finland
Unspecified kidney failure
2.9
9.3
43
153
ZXD10
NOMESCO Finland
Scheduled procedure
1.7
9.2
272
1937
A02BC05
ATC
esomeprazole; systemic
1.6
9.2
295
2145
A41.0
ICD-10 Finland
Sepsis due to Staphylococcus aureus
4.0
9.2
26
67
GDA11
NOMESCO Finland
Thoracoscopic biopsy of lung
13.9
9.2
15
11
UJF32
NOMESCO Finland
Coloscopy
1.7
9.1
207
1374
FM1DE
NOMESCO Finland
Doppler ultrasound examination of heart
2.1
9.1
87
435
PJ2AE
NOMESCO Finland
Lymphnode ultrasound examination
9.2
9.1
18
20
N08.5*M31.3
ICD-10 Finland
Glomerular disorders in Wegener's granulomatosis
37.2
9.0
11
*
J96.1
ICD-10 Finland
Chronic respiratory failure
3.6
9.0
29
82
A41.8
ICD-10 Finland
Other specified sepsis
3.9
9.0
26
68
EBA10
NOMESCO Finland
Operative extraction of tooth
2.2
9.0
84
417
C91.9
ICD-10 Finland
Lymphoid leukaemia, unspecified
24.4
8.9
12
5
XF600
NOMESCO Finland
Bloodpressure measurement
2.5
8.9
58
246
137
Kela drug reimbursment
Uraemia requiring dialysis
8.1
8.9
19
24
9732/3-C42.1
ICD-O-3
Plasma cell myeloma of bone marrow
8.1
8.9
19
24
Z3229
NOMESCO Finland
Other healthcare associate professional
2.3
8.9
70
324
WX602
NOMESCO Finland
Repeated or continuing anesthesia shots throug a catheter
2.4
8.9
64
285
SAA03
NOMESCO Finland
Extended examination of mouth
1.6
8.8
273
1965
PG1DE
NOMESCO Finland
Other extensive ultrasound examination of artery
2.7
8.8
48
187
J47
ICD-10 Finland
Bronchiectasis
3.7
8.8
28
79
OAB73
NOMESCO Finland
Prevention and treatment of malnutrition
6.7
8.7
21
32
120
Kela drug reimbursment
Hypogammaglobulinaemia
50.6
8.7
10
*
ZX070
NOMESCO Finland
Intensity modified radiotherapy
4.0
8.7
24
61
V03AE02
ATC
sevelamer; oral
11.8
8.6
15
13
TQW99
NOMESCO Finland
Other minor procedure on skin
2.6
8.6
52
213
ZXA05
NOMESCO Finland
Left side
1.7
8.6
188
1233
WX402
NOMESCO Finland
General anaesthesia
1.7
8.6
173
1109
C78.7
ICD-10 Finland
Secondary malignant neoplasm of liver and intrahepatic bile duct
3.4
8.6
30
90
B23.8
ICD-10 Finland
HIV disease resulting in other specified conditions
27.9
8.5
11
*
SPAT1325
SPAT
Vaccination
1.6
8.5
255
1817
WX404
NOMESCO Finland
Intravenous generell anesthesy
1.8
8.5
151
934
WD505
NOMESCO Finland
Simple enzyme inhibitor or similar therapy of methastized malignancy
6.8
8.4
20
30
HA1AA
NOMESCO Finland
X-ray mammography
2.3
8.3
66
306
N18.5
ICD-10 Finland
Chronic kidney disease, stage 5
9.6
8.3
16
17
GA1AE
NOMESCO Finland
Ultrasound examination of thorax
3.5
8.3
28
82
E78.0
ICD-10 Finland
Pure hypercholesterolaemia
0.5
8.3
63
1244
ZX121
NOMESCO Finland
Central venous catheter
14.7
8.2
13
9
R03BB04
ATC
tiotropium bromide; inhalant
2.0
8.2
89
467
ZXE05
NOMESCO Finland
Procedure duration 40 to 49 minutes
2.7
8.2
44
170
E0000UV, ,
ATC
1.6
8.2
290
2146
YX9AD
NOMESCO Finland
Other CT eamination for dose design of radiotherapy
3.3
8.2
30
93
A06AD11
ATC
lactulose; oral
1.9
8.1
118
684
N02AA59
ATC
codeine, combinations excl. psycholeptics; systemic
1.6
8.1
319
2417
RS220, ,
NOMESCO Finland
6.9
8.1
19
28
B01AB04
ATC
dalteparin; parenteral
2.7
8.1
43
165
GDG10
NOMESCO Finland
Bilateral transplantation of lung
33.8
8.1
10
*
ZX090
NOMESCO Finland
Other technic of radiotherapy
3.0
8.1
35
120
JN1DG
NOMESCO Finland
Very extensive MRI examination of upper part of abdomen with high intensity magnet
3.7
8.1
25
69
WPB10
NOMESCO Finland
Making a convalescent care decision
9.1
8.1
16
18
GX1K5
NOMESCO Finland
Diffusion capacity
9.1
8.1
16
18
NH3AA
NOMESCO Finland
Foot and toes X-ray examination
2.1
8.1
78
392
K52.9
ICD-10 Finland
Noninfective gastroenteritis and colitis, unspecified
2.8
8.1
40
148
TFB00
NOMESCO Finland
Cathetrisation of pulmonal artery
4.0
7.9
22
56
K65.0
ICD-10 Finland
Acute peritonitis
6.7
7.9
19
29
XGX32
NOMESCO Finland
Bronchoscopic ultrasonography
6.7
7.9
19
29
L04AX05
ATC
pirfenidone; oral
13.2
7.9
13
10
V03AE03
ATC
lanthanum carbonate; oral
13.2
7.9
13
10
RS221, ,
NOMESCO Finland
6.2
7.9
20
33
XQ858
NOMESCO Finland
Oxygen partial pressure measurement
6.2
7.9
20
33
166
Kela drug reimbursment
Dalteparin and tinzaparin (treatment for more than 6 months)
6.2
7.9
20
33
NF1AE
NOMESCO Finland
Hip joint ultrasound examination
3.6
7.9
26
75
Z00.4
ICD-10 Finland
General psychiatric examination, not elsewhere classified
2.3
7.9
59
267
GX1E5
NOMESCO Finland
Flow volume spirometry and bronchodilation test
8.6
7.8
16
19
TND11
NOMESCO Finland
Injection of diagnostic or therapeutic substance in joint, wrist or hand
6.0
7.7
20
34
B74
ICPC
Malignant neoplasm blood other
45.5
7.7
9
*
B73
ICPC
Leukaemia
45.5
7.7
9
*
9691/3-C77.9
ICD-O-3
Follicular lymphoma, grade 2 of lymph node, NOS
45.5
7.7
9
*
R03BA08
ATC
ciclesonide; inhalant
2.2
7.6
67
324
ZX109
NOMESCO Finland
Instruction on medicine inhalation technique
6.8
7.6
18
27
A08.1
ICD-10 Finland
Acute gastroenteropathy due to Norovirus
18.6
7.6
11
6
TPX15
NOMESCO Finland
Removal of vascular injection port
12.0
7.6
13
11
R04.2
ICD-10 Finland
Haemoptysis
2.9
7.5
35
125
Z49.0
ICD-10 Finland
Preparatory care for dialysis
7.2
7.5
17
24
R03AK08
ATC
formoterol and beclometasone; inhalant
2.7
7.5
39
148
GA4AT
NOMESCO Finland
Cathetrisation of pleural cavity with ultrasound guidance
4.5
7.5
18
41
L30.9
ICD-10 Finland
Dermatitis, unspecified
1.7
7.5
146
925
JN1CG
NOMESCO Finland
Extensive MRI examination of upper part of abdomen with high intensity magnet
3.5
7.5
25
73
QDB10
NOMESCO Finland
Major dressing of wound of skin of lower limb
2.5
7.4
48
203
GD2SN
NOMESCO Finland
Lung ventilation SPECT
7.8
7.4
16
21
R2110
NOMESCO Finland
Giving the first information
2.5
7.4
46
191
NG1DA
NOMESCO Finland
X-ray of knees
3.8
7.4
22
59
FM1FN
NOMESCO Finland
Heart function isotope examination
13.5
7.4
12
9
L01BC06
ATC
capecitabine; oral
2.6
7.4
41
161
QX3HE
NOMESCO Finland
Ultrsound examination of lesion close to skin
4.1
7.4
20
50
ED1AA
NOMESCO Finland
Mandibular X-ray examination
8.5
7.3
15
18
ZXE30
NOMESCO Finland
More than five and less than seven hours
2.5
7.3
44
180
B05DB
ATC
Hypertonic solutions
9.5
7.3
14
15
J15.8
ICD-10 Finland
Other bacterial pneumonia
9.5
7.3
14
15
284
Kela drug reimbursment
Nintedanib and pirfenidone
9.5
7.3
14
15
1363A
ICD-9 Finland
Other and unspecified infectious and parasitic diseases, Pneumocystosis
+∞
7.3
7
*
FM1BE
NOMESCO Finland
Cardiac ultrasound examination through oesophagus
2.3
7.3
57
263
OAB74
NOMESCO Finland
Nutritional guidance related to treatment and rehabilitation for medical condition
6.3
7.3
18
29
WX722
NOMESCO Finland
PEEP
2.5
7.3
46
193
WVA20
NOMESCO Finland
Medicine administration
3.0
7.3
32
111
GD5BD
NOMESCO Finland
Thorax and upper abdomen combined extensive CT examination of
3.8
7.2
22
60
J45.9
ICD-10 Finland
Asthma, unspecified
1.7
7.2
143
910
QAA05
NOMESCO Finland
Incision for biopsy of skin of head or neck
3.4
7.2
25
75
GD1BT
NOMESCO Finland
Biopsy of lung with X-ray guidance
30.3
7.2
9
*
D80.8
ICD-10 Finland
Other immunodeficiencies with predominantly antibody defects
30.3
7.2
9
*
D47.1
ICD-10 Finland
Chronic myeloproliferative disease
20.3
7.1
10
5
SPAT1083
SPAT
Initiation and monitoring of IV fluid therapy
2.7
7.1
39
152
NA3CG
NOMESCO Finland
Lumbar spine extensive MRI examination with high intensity magnet
2.7
7.1
39
152
N03AX14
ATC
levetiracetam; systemic
3.1
7.1
29
96
WF002
NOMESCO Finland
Radical radiotherapy
2.2
7.1
59
279
JN5JR
NOMESCO Finland
Extensive PET-CT of upper body metabolism (eyebrows to thighs)
12.2
7.1
12
10
UGC18
NOMESCO Finland
Flexible bronchoscopy with biopsy of lung
8.9
7.1
14
16
R03AL01
ATC
fenoterol and ipratropium bromide; inhalant
2.8
7.0
35
130
WZC10
NOMESCO Finland
Written specialist consultation based on a referral from a dentist or a physician
2.6
7.0
40
160
EE1AA
NOMESCO Finland
X-ray of upper jaw or palate
13.9
6.9
11
8
ZX080
NOMESCO Finland
Image guided radiotherapy
3.3
6.9
25
77
320
Kela drug reimbursment
Lanthanum carbonate, sevelamer and sucroferric oxyhydroxide
8.4
6.8
14
17
TGD00
NOMESCO Finland
Needle biopsy of lung
8.4
6.8
14
17
1CD02, ,
NOMESCO Finland
6.8
6.8
16
24
356
Kela drug reimbursment
Nintedanib and pirfenidone
9.4
6.8
13
14
YA1BD
NOMESCO Finland
Extensive CT examination of head and neck for dose design of radiotherapy
6.2
6.8
17
28
J16.8
ICD-10 Finland
Pneumonia due to other specified infectious organisms
40.5
6.8
8
*
L01BB01, ,
ATC
40.5
6.8
8
*
9673/3-C77.9
ICD-O-3
Mantle cell lymphoma of lymph node, NOS
40.5
6.8
8
*
D50.0
ICD-10 Finland
Iron deficiency anaemia secondary to blood loss (chronic)
2.9
6.8
31
110
JJ2AT
NOMESCO Finland
Biopsy of liver with ultrasound guidance
3.5
6.7
23
68
J01FA06
ATC
roxithromycin; oral
1.5
6.7
269
2023
A49.8
ICD-10 Finland
Other bacterial infections of unspecified site
6.0
6.6
17
29
Z49.2
ICD-10 Finland
Other dialysis
7.9
6.6
14
18
WYA30
NOMESCO Finland
Treatment of a patient needing special arrangements
2.2
6.6
56
267
ND2BA
NOMESCO Finland
Hand and fingers extensive X-ray examination
3.4
6.6
23
69
P01AB01
ATC
metronidazole; oral, rectal
1.5
6.6
263
1976
H05BX01
ATC
cinacalcet; oral
8.8
6.6
13
15
JAH01
NOMESCO Finland
Laparoscopy
2.7
6.6
35
135
D07AC01
ATC
betamethasone; topical
1.5
6.6
253
1886
H05AA02
ATC
teriparatide; parenteral
10.2
6.6
12
12
B23.1
ICD-10 Finland
HIV disease resulting in (persistent) generalized lymphadenopathy
10.2
6.6
12
12
Z71.3
ICD-10 Finland
Dietary counselling and surveillance
2.6
6.5
36
141
A28
ICPC
Limited function/disability NOS
1.7
6.5
142
923
Z51.88
ICD-10 Finland
Other specified medical care
3.7
6.5
20
55
DHA10
NOMESCO Finland
Biopsy of cavity of nose
6.3
6.5
16
26
Y57
ICD-10 Finland
Adverse effects in the therapeutic use of other and unspecified drugs and medicaments
3.6
6.5
21
60
ZX100
NOMESCO Finland
Oral
4.0
6.5
18
46
M31.1
ICD-10 Finland
Thrombotic microangiopathy
70.5
6.4
7
*
1AA09, ,
NOMESCO Finland
70.5
6.4
7
*
L04AA10
ATC
[U] sirolimus
70.5
6.4
7
*
WW402
NOMESCO Finland
Leucoferesis
70.5
6.4
7
*
ZX131
NOMESCO Finland
Intrathecal
70.5
6.4
7
*
J12.9
ICD-10 Finland
Viral pneumonia, unspecified
7.5
6.4
14
19
C82.2
ICD-10 Finland
Follicular lymphoma grade III, unspecified
14.5
6.4
10
7
PG5RT
NOMESCO Finland
PTA of arterio-venous shunt for dialysis
14.5
6.4
10
7
B24
ICD-10 Finland
Unspecified human immunodeficiency virus [HIV] disease
14.5
6.4
10
7
FN1AC
NOMESCO Finland
Angiography of heart and/or coronary arteries
1.6
6.4
185
1292
AA1DM
NOMESCO Finland
Very extensive MRI examination of brain with 3 Tesla magnet
8.3
6.4
13
16
J46
ICD-10 Finland
Status asthmaticus
3.4
6.3
22
66
9680/3-C77.9
ICD-O-3
Diffuse large B-cell lymphoma, NOS, of lymph node, NOS
11.2
6.3
11
10
318
Kela drug reimbursment
Teriparatide
9.4
6.3
12
13
B03XA03
ATC
methoxy polyethylene glycol-epoetin beta; parenteral
9.4
6.3
12
13
WE300
NOMESCO Finland
Profylactive therapy of malignancy with biomoidiers
+∞
6.3
6
*
KAS40
NOMESCO Finland
Excision of transplanted kidney
+∞
6.3
6
*
1XX08, ,
NOMESCO Finland
+∞
6.3
6
*
SPAT1263
SPAT
Sampling
1.5
6.2
283
2177
H26.3
ICD-10 Finland
Drug-induced cataract
7.1
6.2
14
20
B05DA
ATC
Isotonic solutions
7.1
6.2
14
20
293
Kela drug reimbursment
Baricitinib
26.9
6.2
8
*
L04AA37
ATC
[U] baricitinib
26.9
6.2
8
*
3006
Kela drug reimbursment
Baricitinib
26.9
6.2
8
*
XX2RW, ,
NOMESCO Finland
5.1
6.2
18
36
ZXE40
NOMESCO Finland
More than seven and less than nine hours
3.3
6.2
23
72
D69.3
ICD-10 Finland
Idiopathic thrombocytopenic purpura
6.4
6.2
15
24
D43.0
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Brain, supratentorial
7.8
6.1
13
17
ZXA10
NOMESCO Finland
Bilateral
1.7
6.1
133
864
KA1MN
NOMESCO Finland
Glomerular filtration rate (GFR) Isotope mesurement
12.7
6.1
10
8
N08.39*E10.2
ICD-10 Finland
Insulin-dependent diabetes mellitus - Diabetic nephropathy
8.7
6.1
12
14
TK820
NOMESCO Finland
Peritoneal dialysis
8.7
6.1
12
14
N25.8
ICD-10 Finland
Other disorders resulting from impaired renal tubular function
6.8
6.1
14
21
196
Kela drug reimbursment
Paricalcitol and cinacalcet
10.1
6.0
11
11
B37.09
ICD-10 Finland
Unspecified candidal stomatitis
5.6
6.0
16
29

TimeCodeWAS

↥

TODO / Current known limitations:

  • Only showing the top 300 codes, because showing all (sometimes 20k) makes the page too slow.
  • Legend / how to read the glyphs.
  • Show details (e.g. Fisher or Chi-square test, LR+, etc.) when clicking on a row.
  • Explanation on the underlying data / how the TimeCodeWAS is done (e.g. matched cases / controls, eligibility).
  • Download CSV.
  • No filters and sorters.
  • Limited amount of endpoints (~400) having TimeCodeWAS data.
  • Cross-links to Risteys lab test pages for lab test codes.
OMOP concept
ln(OR)
%cases with code / %controls with code
2×2 table
sulfamethoxazole and trimethoprim
J01EE01 [21602961]
2.9e+00
3.3e+00
4.0e+00
—
6.8e+00
5.1e+00
3.7e+00
cases:13.54%
controls:0.87%
cases:13.53%
controls:0.56%
cases:7.49%
controls:0.14%
—
—
cases:46.81%
controls:0.10%
cases:45.54%
controls:0.53%
cases:33.75%
controls:1.26%
94
60
600
6875
94
39
601
6901
52
10
642
6930
—
315
7
358
6914
245
35
293
6614
108
61
212
4796
Neutrophils [#/volume] in Blood by Automated count
751-8 [3013650]
1.2e+00
2.4e+00
3.5e+00
5.8e+00
3.7e+00
2.7e+00
2.0e+00
cases:47.98%
controls:21.63%
cases:64.75%
controls:14.16%
cases:54.32%
controls:3.44%
cases:30.26%
controls:0.13%
cases:61.52%
controls:3.70%
cases:69.52%
controls:13.67%
cases:72.81%
controls:26.85%
333
1500
361
5435
450
983
245
5957
377
239
317
6701
210
9
484
6931
414
256
259
6665
374
909
164
5740
233
1304
87
3553
Diffuse lymphoma with large B cells
C83.31 [2000501224]
2.3e+00
3.6e+00
4.0e+00
—
4.2e+00
3.7e+00
3.5e+00
cases:2.59%
controls:0.26%
cases:7.63%
controls:0.23%
cases:6.34%
controls:0.13%
—
—
cases:6.09%
controls:0.10%
cases:7.99%
controls:0.21%
cases:9.69%
controls:0.33%
18
18
676
6917
53
16
642
6924
44
9
650
6931
—
41
7
632
6914
43
14
495
6635
31
16
289
4841
Monocytes/Leukocytes in Blood
26485-3 [3019069]
1.3e+00
2.4e+00
3.5e+00
5.5e+00
4.0e+00
2.5e+00
1.8e+00
cases:43.52%
controls:17.30%
cases:54.39%
controls:10.07%
cases:39.34%
controls:1.96%
cases:16.86%
controls:0.09%
cases:54.38%
controls:2.23%
cases:59.48%
controls:10.42%
cases:62.19%
controls:21.54%
302
1200
392
5735
378
699
317
6241
273
136
421
6804
117
6
577
6934
366
154
307
6767
320
693
218
5956
199
1046
121
3811
Lymphocytes/Leukocytes in Blood
26478-8 [3002030]
1.3e+00
2.4e+00
3.5e+00
5.5e+00
3.9e+00
2.5e+00
1.8e+00
cases:43.66%
controls:17.43%
cases:54.68%
controls:10.20%
cases:39.19%
controls:1.97%
cases:17.15%
controls:0.09%
cases:54.38%
controls:2.27%
cases:59.85%
controls:10.50%
cases:62.19%
controls:22.17%
303
1209
391
5726
380
708
315
6232
272
137
422
6803
119
6
575
6934
366
157
307
6764
322
698
216
5951
199
1077
121
3780
Basophils/Leukocytes in Blood
30180-4 [3022096]
1.3e+00
2.3e+00
3.5e+00
5.4e+00
3.9e+00
2.5e+00
1.8e+00
cases:43.23%
controls:17.26%
cases:53.24%
controls:10.03%
cases:38.47%
controls:1.93%
cases:16.14%
controls:0.09%
cases:53.05%
controls:2.18%
cases:59.48%
controls:10.35%
cases:62.19%
controls:21.62%
300
1197
394
5738
370
696
325
6244
267
134
427
6806
112
6
582
6934
357
151
316
6770
320
688
218
5961
199
1050
121
3807
Eosinophils/Leukocytes in Blood
26450-7 [3006504]
1.3e+00
2.3e+00
3.4e+00
5.4e+00
3.9e+00
2.5e+00
1.8e+00
cases:43.52%
controls:17.30%
cases:53.96%
controls:10.06%
cases:38.04%
controls:1.96%
cases:16.14%
controls:0.09%
cases:53.19%
controls:2.23%
cases:59.29%
controls:10.38%
cases:62.19%
controls:21.49%
302
1200
392
5735
375
698
320
6242
264
136
430
6804
112
6
582
6934
358
154
315
6767
319
690
219
5959
199
1044
121
3813
Eosinophils [#/volume] in Blood
26449-9 [3013115]
1.2e+00
2.3e+00
3.4e+00
5.3e+00
3.9e+00
2.6e+00
1.9e+00
cases:44.52%
controls:18.92%
cases:56.26%
controls:11.27%
cases:40.35%
controls:2.22%
cases:16.57%
controls:0.10%
cases:55.27%
controls:2.41%
cases:63.94%
controls:11.57%
cases:68.75%
controls:24.19%
309
1312
385
5623
391
782
304
6158
280
154
414
6786
115
7
579
6933
372
167
301
6754
344
769
194
5880
220
1175
100
3682
Simple antiboidy therapy of methastized malignancy
WD405 [2001310688]
2.9e+00
3.7e+00
4.4e+00
1.0e+50
3.7e+00
3.5e+00
2.3e+00
cases:5.33%
controls:0.32%
cases:9.35%
controls:0.24%
cases:5.48%
controls:0.07%
cases:1.44%
controls:0.00%
cases:2.97%
controls:0.07%
cases:7.43%
controls:0.24%
cases:4.38%
controls:0.45%
37
22
657
6913
65
17
630
6923
38
5
656
6935
10
0
684
6940
20
5
653
6916
40
16
498
6633
14
22
306
4835
Lymphocytes [#/volume] in Blood
26474-7 [3019198]
1.2e+00
2.3e+00
3.3e+00
5.2e+00
3.8e+00
2.6e+00
1.9e+00
cases:44.38%
controls:18.63%
cases:56.26%
controls:11.08%
cases:38.18%
controls:2.18%
cases:15.85%
controls:0.10%
cases:52.45%
controls:2.34%
cases:63.38%
controls:11.40%
cases:68.44%
controls:23.94%
308
1292
386
5643
391
769
304
6171
265
151
429
6789
110
7
584
6933
353
162
320
6759
341
758
197
5891
219
1163
101
3694
Basophils [#/volume] in Blood
26444-0 [3006315]
1.3e+00
2.3e+00
3.4e+00
5.1e+00
3.8e+00
2.6e+00
1.9e+00
cases:44.09%
controls:18.08%
cases:55.40%
controls:10.85%
cases:38.18%
controls:2.09%
cases:14.84%
controls:0.10%
cases:52.45%
controls:2.30%
cases:63.01%
controls:11.31%
cases:68.13%
controls:23.53%
306
1254
388
5681
385
753
310
6187
265
145
429
6795
103
7
591
6933
353
159
320
6762
339
752
199
5897
218
1143
102
3714
Monocytes [#/volume] in Blood
26484-6 [3001604]
1.3e+00
2.3e+00
3.4e+00
5.1e+00
3.8e+00
2.6e+00
1.9e+00
cases:43.95%
controls:18.04%
cases:55.40%
controls:10.81%
cases:38.18%
controls:2.10%
cases:14.84%
controls:0.10%
cases:52.45%
controls:2.31%
cases:63.01%
controls:11.26%
cases:68.13%
controls:23.55%
305
1251
389
5684
385
750
310
6190
265
146
429
6794
103
7
591
6933
353
160
320
6761
339
749
199
5900
218
1144
102
3713
Neutrophils/Leukocytes in Blood
26511-6 [3018010]
1.2e+00
2.3e+00
3.3e+00
5.5e+00
3.8e+00
2.5e+00
1.7e+00
cases:41.35%
controls:16.96%
cases:52.23%
controls:10.03%
cases:35.16%
controls:2.03%
cases:15.42%
controls:0.07%
cases:50.37%
controls:2.21%
cases:57.62%
controls:10.33%
cases:61.56%
controls:21.99%
287
1176
407
5759
363
696
332
6244
244
141
450
6799
107
5
587
6935
339
153
334
6768
310
687
228
5962
197
1068
123
3789
Differential panel, method unspecified - Blood
69738-3 [42870588]
1.4e+00
2.2e+00
3.4e+00
5.3e+00
3.9e+00
2.3e+00
1.6e+00
cases:34.29%
controls:11.87%
cases:40.72%
controls:7.05%
cases:29.11%
controls:1.38%
cases:12.68%
controls:0.07%
cases:42.50%
controls:1.44%
cases:44.61%
controls:7.61%
cases:47.50%
controls:15.75%
238
823
456
6112
283
489
412
6451
202
96
492
6844
88
5
606
6935
286
100
387
6821
240
506
298
6143
152
765
168
4092
Medical Oncology
90 [38004507]
1.4e+00
2.4e+00
3.2e+00
5.4e+00
2.9e+00
2.5e+00
2.0e+00
cases:21.47%
controls:6.56%
cases:36.12%
controls:4.70%
cases:28.82%
controls:1.66%
cases:18.73%
controls:0.10%
cases:23.33%
controls:1.60%
cases:34.39%
controls:4.06%
cases:33.13%
controls:6.53%
149
455
545
6480
251
326
444
6614
200
115
494
6825
130
7
564
6933
157
111
516
6810
185
270
353
6379
106
317
214
4540
Cytomegalovirus DNA [Units/volume] (viral load) in Serum or Plasma by NAA with probe detection
72493-0 [43055120]
2.8e+00
3.6e+00
—
1.0e+50
6.2e+00
3.9e+00
3.2e+00
cases:8.65%
controls:0.58%
cases:8.78%
controls:0.27%
—
—
cases:2.59%
controls:0.00%
cases:26.89%
controls:0.07%
cases:13.75%
controls:0.32%
cases:16.25%
controls:0.82%
60
40
634
6895
61
19
634
6921
—
18
0
676
6940
181
5
492
6916
74
21
464
6628
52
40
268
4817
IgG [Mass/volume] in Serum or Plasma
2465-3 [3005719]
2.0e+00
3.0e+00
3.7e+00
1.0e+50
4.8e+00
3.3e+00
2.7e+00
cases:15.56%
controls:2.39%
cases:18.13%
controls:1.07%
cases:6.92%
controls:0.19%
cases:1.15%
controls:0.00%
cases:15.75%
controls:0.16%
cases:23.79%
controls:1.13%
cases:27.19%
controls:2.43%
108
166
586
6769
126
74
569
6866
48
13
646
6927
8
0
686
6940
106
11
567
6910
128
75
410
6574
87
118
233
4739
Procalcitonin [Mass/volume] in Serum or Plasma
33959-8 [3046279]
2.0e+00
3.2e+00
4.8e+00
1.0e+50
5.4e+00
2.5e+00
1.2e+00
cases:5.62%
controls:0.82%
cases:6.47%
controls:0.27%
cases:7.78%
controls:0.07%
cases:4.76%
controls:0.00%
cases:15.60%
controls:0.09%
cases:7.62%
controls:0.69%
cases:6.56%
controls:2.00%
39
57
655
6878
45
19
650
6921
54
5
640
6935
33
0
661
6940
105
6
568
6915
41
46
497
6603
21
97
299
4760
Demanding cystostatic therapy of methastized malignancy
WD125 [2001310680]
2.2e+00
3.5e+00
4.3e+00
—
3.8e+00
3.3e+00
1.8e+00
cases:5.76%
controls:0.66%
cases:13.09%
controls:0.45%
cases:6.92%
controls:0.10%
—
—
cases:4.31%
controls:0.10%
cases:9.67%
controls:0.39%
cases:3.13%
controls:0.54%
40
46
654
6889
91
31
604
6909
48
7
646
6933
—
29
7
644
6914
52
26
486
6623
10
26
310
4831
Bilirubin.total [Moles/volume] in Serum or Plasma
14631-6 [3006140]
1.1e+00
2.2e+00
3.3e+00
5.0e+00
3.6e+00
2.3e+00
1.4e+00
cases:41.93%
controls:19.24%
cases:51.08%
controls:10.71%
cases:38.18%
controls:2.23%
cases:12.54%
controls:0.10%
cases:47.85%
controls:2.43%
cases:52.42%
controls:10.24%
cases:57.19%
controls:24.62%
291
1334
403
5601
355
743
340
6197
265
155
429
6785
87
7
607
6933
322
168
351
6753
282
681
256
5968
183
1196
137
3661
Fever, unspecified
R50.9 [45582716]
1.9e+00
3.2e+00
5.4e+00
1.0e+50
3.5e+00
2.9e+00
1.8e+00
cases:11.96%
controls:2.03%
cases:14.82%
controls:0.69%
cases:13.54%
controls:0.07%
cases:8.50%
controls:0.00%
cases:3.86%
controls:0.12%
cases:10.41%
controls:0.63%
cases:15.00%
controls:2.76%
83
141
611
6794
103
48
592
6892
94
5
600
6935
59
0
635
6940
26
8
647
6913
56
42
482
6607
48
134
272
4723
Emergency Room Visit
ER [9203]
7.0e-01
1.9e+00
3.6e+00
7.0e+00
2.7e+00
1.8e+00
1.0e+00
cases:54.76%
controls:37.61%
cases:48.20%
controls:12.05%
cases:32.71%
controls:1.34%
cases:45.10%
controls:0.07%
cases:17.38%
controls:1.36%
cases:41.08%
controls:10.21%
cases:49.38%
controls:26.44%
380
2608
314
4327
335
836
360
6104
227
93
467
6847
313
5
381
6935
117
94
556
6827
221
679
317
5970
158
1284
162
3573
Multiple myeloma
C90.0 [45600562]
2.9e+00
3.1e+00
3.1e+00
—
3.2e+00
3.1e+00
3.2e+00
cases:3.17%
controls:0.17%
cases:3.74%
controls:0.17%
cases:2.88%
controls:0.13%
—
—
cases:3.71%
controls:0.16%
cases:4.28%
controls:0.20%
cases:4.38%
controls:0.19%
22
12
672
6923
26
12
669
6928
20
9
674
6931
—
25
11
648
6910
23
13
515
6636
14
9
306
4848
Influenza virus B RNA [Presence] in Specimen by NAA with probe detection
40982-1 [3038288]
1.6e+00
2.7e+00
4.9e+00
1.0e+50
5.4e+00
2.4e+00
1.4e+00
cases:12.82%
controls:2.77%
cases:18.13%
controls:1.43%
cases:24.35%
controls:0.23%
cases:20.61%
controls:0.00%
cases:31.05%
controls:0.20%
cases:17.29%
controls:1.82%
cases:20.00%
controls:5.95%
89
192
605
6743
126
99
569
6841
169
16
525
6924
143
0
551
6940
209
14
464
6907
93
121
445
6528
64
289
256
4568
Hematology
82 [38004501]
2.3e+00
3.1e+00
3.6e+00
—
3.6e+00
3.1e+00
2.7e+00
cases:15.99%
controls:1.79%
cases:21.15%
controls:1.24%
cases:14.27%
controls:0.46%
—
—
cases:13.37%
controls:0.43%
cases:21.56%
controls:1.20%
cases:23.75%
controls:2.14%
111
124
583
6811
147
86
548
6854
99
32
595
6908
—
90
30
583
6891
116
80
422
6569
76
104
244
4753
Chronic lymphocytic leukaemia of B-cell type
C91.1 [45600564]
3.3e+00
3.7e+00
—
—
4.2e+00
3.5e+00
3.6e+00
cases:6.05%
controls:0.25%
cases:6.91%
controls:0.19%
—
—
—
—
cases:4.61%
controls:0.07%
cases:6.69%
controls:0.21%
cases:7.50%
controls:0.23%
42
17
652
6918
48
13
647
6927
—
—
31
5
642
6916
36
14
502
6635
24
11
296
4846
Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma
6768-6 [3035995]
8.8e-01
2.1e+00
3.2e+00
4.7e+00
3.5e+00
2.2e+00
1.5e+00
cases:56.05%
controls:34.68%
cases:68.49%
controls:21.43%
cases:52.02%
controls:4.03%
cases:19.31%
controls:0.22%
cases:60.03%
controls:4.28%
cases:70.26%
controls:21.12%
cases:74.69%
controls:40.83%
389
2405
305
4530
476
1487
219
5453
361
280
333
6660
134
15
560
6925
404
296
269
6625
378
1404
160
5245
239
1983
81
2874
Influenza virus A RNA [Presence] in Specimen by NAA with probe detection
34487-9 [3044938]
1.6e+00
2.5e+00
4.8e+00
1.0e+50
5.3e+00
2.3e+00
1.4e+00
cases:16.57%
controls:3.89%
cases:21.15%
controls:2.18%
cases:28.53%
controls:0.33%
cases:24.21%
controls:0.00%
cases:35.36%
controls:0.26%
cases:20.45%
controls:2.50%
cases:26.25%
controls:8.11%
115
270
579
6665
147
151
548
6789
198
23
496
6917
168
0
526
6940
238
18
435
6903
110
166
428
6483
84
394
236
4463
Respiratory syncytial virus RNA [Identifier] in Specimen by NAA with probe detection
40987-0 [3043924]
1.6e+00
2.6e+00
4.8e+00
1.0e+50
5.2e+00
2.3e+00
1.4e+00
cases:12.25%
controls:2.77%
cases:17.70%
controls:1.50%
cases:23.20%
controls:0.26%
cases:19.31%
controls:0.00%
cases:27.34%
controls:0.20%
cases:17.10%
controls:1.99%
cases:20.94%
controls:6.28%
85
192
609
6743
123
104
572
6836
161
18
533
6922
134
0
560
6940
184
14
489
6907
92
132
446
6517
67
305
253
4552
C reactive protein [Mass/volume] in Serum or Plasma
1988-5 [3020460]
5.5e-01
1.8e+00
3.4e+00
5.7e+00
3.6e+00
1.9e+00
8.4e-01
cases:62.82%
controls:49.24%
cases:74.24%
controls:32.52%
cases:68.73%
controls:7.02%
cases:58.07%
controls:0.46%
cases:71.47%
controls:6.47%
cases:75.46%
controls:32.23%
cases:77.19%
controls:59.48%
436
3415
258
3520
516
2257
179
4683
477
487
217
6453
403
32
291
6908
481
448
192
6473
406
2143
132
4506
247
2889
73
1968
Bacterial infection, unspecified
A49.9 [45590816]
1.8e+00
2.8e+00
4.8e+00
1.0e+50
4.0e+00
2.6e+00
1.5e+00
cases:8.93%
controls:1.56%
cases:10.07%
controls:0.71%
cases:9.37%
controls:0.09%
cases:8.36%
controls:0.00%
cases:3.86%
controls:0.07%
cases:9.67%
controls:0.75%
cases:8.75%
controls:2.14%
62
108
632
6827
70
49
625
6891
65
6
629
6934
58
0
636
6940
26
5
647
6916
52
50
486
6599
28
104
292
4753
Pneumonia, unspecified
J18.9 [45601123]
1.5e+00
2.4e+00
4.8e+00
—
4.6e+00
2.5e+00
1.6e+00
cases:16.57%
controls:4.27%
cases:16.83%
controls:1.79%
cases:24.78%
controls:0.26%
—
—
cases:15.90%
controls:0.19%
cases:19.33%
controls:1.85%
cases:24.69%
controls:6.36%
115
296
579
6639
117
124
578
6816
172
18
522
6922
—
107
13
566
6908
104
123
434
6526
79
309
241
4548
Calcium.ionized [Moles/volume] in Serum or Plasma
1995-0 [3021347]
9.8e-01
1.8e+00
3.2e+00
5.1e+00
3.3e+00
1.9e+00
1.0e+00
cases:35.73%
controls:17.29%
cases:39.28%
controls:9.24%
cases:25.07%
controls:1.34%
cases:12.54%
controls:0.09%
cases:31.20%
controls:1.66%
cases:42.01%
controls:9.35%
cases:44.06%
controls:22.22%
248
1199
446
5736
273
641
422
6299
174
93
520
6847
87
6
607
6934
210
115
463
6806
226
622
312
6027
141
1079
179
3778
Fungus identified in Specimen by Culture
580-1 [3000494]
1.2e+00
1.9e+00
4.5e+00
1.0e+50
6.0e+00
2.2e+00
1.5e+00
cases:10.37%
controls:3.48%
cases:7.48%
controls:1.24%
cases:9.51%
controls:0.12%
cases:2.16%
controls:0.00%
cases:29.72%
controls:0.10%
cases:10.04%
controls:1.23%
cases:15.63%
controls:3.81%
72
241
622
6694
52
86
643
6854
66
8
628
6932
15
0
679
6940
200
7
473
6914
54
82
484
6567
50
185
270
4672
IgM [Mass/volume] in Serum or Plasma
2472-9 [3028026]
1.9e+00
2.8e+00
3.4e+00
—
4.2e+00
2.8e+00
2.1e+00
cases:11.53%
controls:1.87%
cases:10.22%
controls:0.69%
cases:3.89%
controls:0.13%
—
—
cases:8.17%
controls:0.13%
cases:11.15%
controls:0.74%
cases:12.50%
controls:1.79%
80
130
614
6805
71
48
624
6892
27
9
667
6931
—
55
9
618
6912
60
49
478
6600
40
87
280
4770
Calcium.ionized [Moles/volume] adjusted to pH 7.4 in Serum or Plasma
19072-8 [3016431]
1.0e+00
2.0e+00
3.2e+00
5.0e+00
3.3e+00
1.9e+00
9.2e-01
cases:39.34%
controls:19.12%
cases:45.04%
controls:10.30%
cases:27.38%
controls:1.56%
cases:12.54%
controls:0.10%
cases:34.18%
controls:1.94%
cases:46.10%
controls:10.86%
cases:46.88%
controls:25.92%
273
1326
421
5609
313
715
382
6225
190
108
504
6832
87
7
607
6933
230
134
443
6787
248
722
290
5927
150
1259
170
3598
Clostridioides difficile toxin genes [Presence] in Stool by NAA with probe detection
54067-4 [3051552]
1.4e+00
2.7e+00
4.0e+00
1.0e+50
5.0e+00
2.6e+00
1.3e+00
cases:8.07%
controls:2.02%
cases:9.35%
controls:0.68%
cases:4.61%
controls:0.09%
cases:1.01%
controls:0.00%
cases:12.93%
controls:0.10%
cases:10.97%
controls:0.87%
cases:10.63%
controls:3.13%
56
140
638
6795
65
47
630
6893
32
6
662
6934
7
0
687
6940
87
7
586
6914
59
58
479
6591
34
152
286
4705
Myelocytes/Leukocytes in Blood
26498-6 [3017181]
1.9e+00
2.4e+00
4.1e+00
1.0e+50
4.1e+00
2.6e+00
1.9e+00
cases:12.68%
controls:2.18%
cases:16.69%
controls:1.74%
cases:13.26%
controls:0.26%
cases:4.61%
controls:0.00%
cases:18.87%
controls:0.39%
cases:19.89%
controls:1.80%
cases:20.63%
controls:3.87%
88
151
606
6784
116
121
579
6819
92
18
602
6922
32
0
662
6940
127
27
546
6894
107
120
431
6529
66
188
254
4669
High resolution CT examination of lungs
GD1DD [2001303632]
2.3e+00
3.8e+00
—
1.0e+50
3.9e+00
4.1e+00
2.7e+00
cases:7.93%
controls:0.88%
cases:8.06%
controls:0.19%
—
—
cases:16.71%
controls:0.00%
cases:4.31%
controls:0.09%
cases:16.54%
controls:0.32%
cases:10.94%
controls:0.82%
55
61
639
6874
56
13
639
6927
—
116
0
578
6940
29
6
644
6915
89
21
449
6628
35
40
285
4817
Infectious Disease
44 [38004484]
1.4e+00
2.3e+00
3.7e+00
1.0e+50
3.9e+00
3.2e+00
2.3e+00
cases:8.07%
controls:2.15%
cases:7.19%
controls:0.75%
cases:5.62%
controls:0.14%
cases:10.66%
controls:0.00%
cases:8.92%
controls:0.20%
cases:17.10%
controls:0.84%
cases:19.38%
controls:2.45%
56
149
638
6786
50
52
645
6888
39
10
655
6930
74
0
620
6940
60
14
613
6907
92
56
446
6593
62
119
258
4738
Intravenous
ZX120 [2001311495]
2.0e+00
3.1e+00
3.9e+00
1.0e+50
2.7e+00
3.0e+00
2.0e+00
cases:11.10%
controls:1.60%
cases:13.09%
controls:0.71%
cases:5.91%
controls:0.13%
cases:0.86%
controls:0.00%
cases:2.08%
controls:0.14%
cases:10.22%
controls:0.56%
cases:8.75%
controls:1.28%
77
111
617
6824
91
49
604
6891
41
9
653
6931
6
0
688
6940
14
10
659
6911
55
37
483
6612
28
62
292
4795
Hemodialysis
TK800 [2001305768]
2.3e+00
1.7e+00
2.1e+00
3.2e+00
2.2e+00
3.0e+00
2.2e+00
cases:3.60%
controls:0.39%
cases:1.73%
controls:0.32%
cases:1.44%
controls:0.19%
cases:1.73%
controls:0.07%
cases:1.49%
controls:0.16%
cases:3.90%
controls:0.21%
cases:3.75%
controls:0.41%
25
27
669
6908
12
22
683
6918
10
13
684
6927
12
5
682
6935
10
11
663
6910
21
14
517
6635
12
20
308
4837
Normoblasts [#/volume] in Blood
715-3 [3021589]
9.2e-01
1.6e+00
2.8e+00
5.0e+00
3.2e+00
1.7e+00
1.3e+00
cases:32.13%
controls:15.86%
cases:40.86%
controls:12.44%
cases:33.29%
controls:2.84%
cases:20.61%
controls:0.17%
cases:42.64%
controls:2.89%
cases:47.03%
controls:13.46%
cases:54.69%
controls:24.77%
223
1100
471
5835
284
863
411
6077
231
197
463
6743
143
12
551
6928
287
200
386
6721
253
895
285
5754
175
1203
145
3654
darbepoetin alfa; parenteral
B03XA02 [21601134]
2.9e+00
2.8e+00
2.5e+00
—
2.9e+00
3.3e+00
2.2e+00
cases:3.31%
controls:0.19%
cases:2.45%
controls:0.16%
cases:1.01%
controls:0.09%
—
—
cases:1.34%
controls:0.07%
cases:4.46%
controls:0.17%
cases:4.06%
controls:0.47%
23
13
671
6922
17
11
678
6929
7
6
687
6934
—
9
5
664
6916
24
11
514
6638
13
23
307
4834
Lactate dehydrogenase [Enzymatic activity/volume] in Serum or Plasma by Lactate to pyruvate reaction
14804-9 [3022250]
1.9e+00
2.8e+00
3.5e+00
1.0e+50
3.7e+00
2.7e+00
1.9e+00
cases:20.61%
controls:3.73%
cases:25.76%
controls:2.16%
cases:11.82%
controls:0.39%
cases:2.31%
controls:0.00%
cases:13.37%
controls:0.39%
cases:22.49%
controls:1.97%
cases:28.75%
controls:5.46%
143
259
551
6676
179
150
516
6790
82
27
612
6913
16
0
678
6940
90
27
583
6894
121
131
417
6518
92
265
228
4592
Immunoglobulin light chains.free panel - Serum
57778-3 [40760888]
1.7e+00
3.1e+00
3.9e+00
—
3.4e+00
2.8e+00
1.6e+00
cases:4.61%
controls:0.84%
cases:5.90%
controls:0.29%
cases:3.31%
controls:0.07%
—
—
cases:2.53%
controls:0.09%
cases:4.83%
controls:0.32%
cases:4.06%
controls:0.84%
32
58
662
6877
41
20
654
6920
23
5
671
6935
—
17
6
656
6915
26
21
512
6628
13
41
307
4816
Metamyelocytes/Leukocytes in Blood
28541-1 [3002179]
1.7e+00
2.2e+00
4.0e+00
1.0e+50
4.0e+00
2.5e+00
1.8e+00
cases:9.51%
controls:1.85%
cases:13.24%
controls:1.59%
cases:11.24%
controls:0.23%
cases:3.17%
controls:0.00%
cases:16.79%
controls:0.36%
cases:18.22%
controls:1.76%
cases:19.06%
controls:3.79%
66
128
628
6807
92
110
603
6830
78
16
616
6924
22
0
672
6940
113
25
560
6896
98
117
440
6532
61
184
259
4673
Promyelocytes/Leukocytes in Blood
26524-9 [3021440]
1.8e+00
2.2e+00
4.1e+00
1.0e+50
3.9e+00
2.4e+00
1.8e+00
cases:10.66%
controls:1.99%
cases:13.67%
controls:1.66%
cases:11.53%
controls:0.22%
cases:3.46%
controls:0.00%
cases:15.75%
controls:0.36%
cases:16.91%
controls:1.73%
cases:19.06%
controls:3.77%
74
138
620
6797
95
115
600
6825
80
15
614
6925
24
0
670
6940
106
25
567
6896
91
115
447
6534
61
183
259
4674
Bacteria identified in Blood by Culture
600-7 [3023368]
1.2e+00
2.4e+00
4.4e+00
—
4.5e+00
2.3e+00
1.4e+00
cases:24.06%
controls:8.36%
cases:30.50%
controls:3.70%
cases:35.88%
controls:0.66%
—
—
cases:32.10%
controls:0.51%
cases:29.00%
controls:4.05%
cases:35.31%
controls:12.39%
167
580
527
6355
212
257
483
6683
249
46
445
6894
—
216
35
457
6886
156
269
382
6380
113
602
207
4255
Extensive body CT
JN4BD [2001310899]
1.5e+00
2.9e+00
3.4e+00
1.0e+50
2.2e+00
3.5e+00
2.9e+00
cases:10.52%
controls:2.65%
cases:12.23%
controls:0.79%
cases:2.88%
controls:0.10%
cases:5.33%
controls:0.00%
cases:0.89%
controls:0.10%
cases:10.78%
controls:0.38%
cases:10.94%
controls:0.70%
73
184
621
6751
85
55
610
6885
20
7
674
6933
37
0
657
6940
6
7
667
6914
58
25
480
6624
35
34
285
4823
CD3 cells [#/volume] in Blood
8122-4 [3011412]
3.2e+00
3.8e+00
—
—
1.0e+50
5.3e+00
3.9e+00
cases:5.19%
controls:0.23%
cases:5.47%
controls:0.13%
—
—
—
—
cases:6.39%
controls:0.00%
cases:13.20%
controls:0.08%
cases:10.63%
controls:0.25%
36
16
658
6919
38
9
657
6931
—
—
43
0
630
6921
71
5
467
6644
34
12
286
4845
Abnormal findings on diagnostic imaging of lung
R91 [45548995]
1.5e+00
2.5e+00
3.8e+00
1.0e+50
3.9e+00
2.9e+00
1.5e+00
cases:7.78%
controls:1.87%
cases:7.77%
controls:0.66%
cases:5.91%
controls:0.14%
cases:3.31%
controls:0.00%
cases:6.09%
controls:0.13%
cases:9.48%
controls:0.60%
cases:7.50%
controls:1.75%
54
130
640
6805
54
46
641
6894
41
10
653
6930
23
0
671
6940
41
9
632
6912
51
40
487
6609
24
85
296
4772
pH of Blood
11558-4 [3010421]
1.4e+00
2.1e+00
3.7e+00
1.0e+50
4.2e+00
2.8e+00
1.6e+00
cases:4.03%
controls:0.98%
cases:3.31%
controls:0.43%
cases:3.46%
controls:0.09%
cases:2.45%
controls:0.00%
cases:5.35%
controls:0.09%
cases:4.65%
controls:0.30%
cases:5.00%
controls:1.03%
28
68
666
6867
23
30
672
6910
24
6
670
6934
17
0
677
6940
36
6
637
6915
25
20
513
6629
16
50
304
4807
Pneumocystis jirovecii DNA [Presence] in Specimen by NAA with probe detection
6521-9 [3009595]
2.8e+00
4.2e+00
—
1.0e+50
—
4.5e+00
4.2e+00
cases:4.03%
controls:0.26%
cases:5.61%
controls:0.09%
—
—
cases:5.76%
controls:0.00%
—
—
cases:10.22%
controls:0.12%
cases:14.38%
controls:0.25%
28
18
666
6917
39
6
656
6934
—
40
0
654
6940
—
55
8
483
6641
46
12
274
4845
Mycobacterium tuberculosis DNA [Presence] in Specimen by NAA with probe detection
13956-8 [3014162]
1.9e+00
3.1e+00
5.0e+00
1.0e+50
—
3.3e+00
2.3e+00
cases:7.49%
controls:1.18%
cases:6.76%
controls:0.33%
cases:9.65%
controls:0.07%
cases:3.75%
controls:0.00%
—
—
cases:8.74%
controls:0.36%
cases:11.56%
controls:1.30%
52
82
642
6853
47
23
648
6917
67
5
627
6935
26
0
668
6940
—
47
24
491
6625
37
63
283
4794
Thorax X-ray examination
GD1AA [2001303617]
1.4e+00
2.4e+00
4.4e+00
—
3.3e+00
2.6e+00
1.5e+00
cases:39.34%
controls:14.28%
cases:40.43%
controls:5.94%
cases:29.11%
controls:0.49%
—
—
cases:15.45%
controls:0.66%
cases:42.01%
controls:5.32%
cases:42.50%
controls:14.04%
273
990
421
5945
281
412
414
6528
202
34
492
6906
—
104
46
569
6875
226
354
312
6295
136
682
184
4175
HIV 1 and 2 tests - Meaningful Use set
75622-1 [46235355]
1.6e+00
2.5e+00
3.6e+00
—
4.1e+00
2.5e+00
1.2e+00
cases:15.27%
controls:3.50%
cases:14.24%
controls:1.38%
cases:6.05%
controls:0.17%
—
—
cases:11.00%
controls:0.20%
cases:12.64%
controls:1.17%
cases:13.75%
controls:4.59%
106
243
588
6692
99
96
596
6844
42
12
652
6928
—
74
14
599
6907
68
78
470
6571
44
223
276
4634
cycloSPORINE [Mass/volume] in Blood
3520-4 [3010375]
2.3e+00
2.2e+00
2.9e+00
—
3.0e+00
2.5e+00
2.6e+00
cases:2.59%
controls:0.27%
cases:2.30%
controls:0.26%
cases:1.59%
controls:0.09%
—
—
cases:1.78%
controls:0.09%
cases:3.16%
controls:0.27%
cases:4.38%
controls:0.35%
18
19
676
6916
16
18
679
6922
11
6
683
6934
—
12
6
661
6915
17
18
521
6631
14
17
306
4840
Blasts/Leukocytes in Blood
26446-5 [3025159]
1.6e+00
2.1e+00
3.8e+00
1.0e+50
3.8e+00
2.4e+00
1.6e+00
cases:8.65%
controls:1.79%
cases:12.37%
controls:1.66%
cases:11.10%
controls:0.27%
cases:3.46%
controls:0.00%
cases:15.16%
controls:0.40%
cases:16.54%
controls:1.74%
cases:17.81%
controls:4.04%
60
124
634
6811
86
115
609
6825
77
19
617
6921
24
0
670
6940
102
28
571
6893
89
116
449
6533
57
196
263
4661
Bacteria [#/volume] in Urine by Automated count
51480-2 [3031040]
5.3e-01
1.3e+00
3.1e+00
5.7e+00
2.6e+00
1.4e+00
6.0e-01
cases:38.47%
controls:26.89%
cases:37.27%
controls:13.65%
cases:31.99%
controls:2.06%
cases:18.16%
controls:0.07%
cases:23.33%
controls:2.15%
cases:37.17%
controls:13.04%
cases:45.63%
controls:31.54%
267
1865
427
5070
259
947
436
5993
222
143
472
6797
126
5
568
6935
157
149
516
6772
200
867
338
5782
146
1532
174
3325
rituximab
L01FA01 [955167]
2.2e+00
3.1e+00
—
—
2.9e+00
3.3e+00
3.7e+00
cases:3.75%
controls:0.42%
cases:4.46%
controls:0.22%
—
—
—
—
cases:1.34%
controls:0.07%
cases:3.72%
controls:0.14%
cases:5.31%
controls:0.14%
26
29
668
6906
31
15
664
6925
—
—
9
5
664
6916
20
9
518
6640
17
7
303
4850
Magnesium [Moles/volume] in Serum or Plasma
2601-3 [3012095]
1.5e+00
2.3e+00
3.6e+00
—
4.1e+00
2.4e+00
1.3e+00
cases:19.16%
controls:5.13%
cases:19.42%
controls:2.39%
cases:9.65%
controls:0.29%
—
—
cases:17.38%
controls:0.36%
cases:19.89%
controls:2.18%
cases:20.31%
controls:6.26%
133
356
561
6579
135
166
560
6774
67
20
627
6920
—
117
25
556
6896
107
145
431
6504
65
304
255
4553
Gas panel - Arterial blood
24336-0 [3019060]
1.2e+00
2.2e+00
4.2e+00
—
4.5e+00
1.9e+00
1.2e+00
cases:7.64%
controls:2.44%
cases:6.47%
controls:0.73%
cases:5.33%
controls:0.09%
—
—
cases:9.36%
controls:0.12%
cases:5.58%
controls:0.92%
cases:7.50%
controls:2.37%
53
169
641
6766
45
51
650
6889
37
6
657
6934
—
63
8
610
6913
30
61
508
6588
24
115
296
4742
Oxygen [Partial pressure] in Arterial blood
2703-7 [3027801]
1.1e+00
2.1e+00
4.2e+00
—
4.6e+00
1.9e+00
1.2e+00
cases:10.23%
controls:3.55%
cases:10.22%
controls:1.34%
cases:8.79%
controls:0.14%
—
—
cases:13.52%
controls:0.16%
cases:9.29%
controls:1.56%
cases:14.38%
controls:4.88%
71
246
623
6689
71
93
624
6847
61
10
633
6930
—
91
11
582
6910
50
104
488
6545
46
237
274
4620
Carbon dioxide [Partial pressure] in Arterial blood
2019-8 [3027946]
1.1e+00
2.1e+00
4.2e+00
—
4.6e+00
1.9e+00
1.2e+00
cases:10.23%
controls:3.55%
cases:10.22%
controls:1.34%
cases:8.79%
controls:0.14%
—
—
cases:13.52%
controls:0.16%
cases:9.29%
controls:1.56%
cases:14.38%
controls:4.90%
71
246
623
6689
71
93
624
6847
61
10
633
6930
—
91
11
582
6910
50
104
488
6545
46
238
274
4619
Kappa light chains.free [Mass/volume] in Serum
36916-5 [3034860]
1.7e+00
2.8e+00
3.8e+00
—
3.1e+00
2.4e+00
1.3e+00
cases:5.19%
controls:1.04%
cases:6.76%
controls:0.46%
cases:3.60%
controls:0.09%
—
—
cases:3.42%
controls:0.16%
cases:5.76%
controls:0.54%
cases:5.31%
controls:1.44%
36
72
658
6863
47
32
648
6908
25
6
669
6934
—
23
11
650
6910
31
36
507
6613
17
70
303
4787
Lambda light chains.free [Mass/volume] in Serum or Plasma
33944-0 [3047169]
1.6e+00
2.8e+00
3.8e+00
—
3.1e+00
2.4e+00
1.3e+00
cases:5.19%
controls:1.05%
cases:6.76%
controls:0.46%
cases:3.60%
controls:0.09%
—
—
cases:3.27%
controls:0.16%
cases:5.76%
controls:0.54%
cases:5.31%
controls:1.44%
36
73
658
6862
47
32
648
6908
25
6
669
6934
—
22
11
651
6910
31
36
507
6613
17
70
303
4787
Bacteria identified in Isolate by Culture
43409-2 [3042936]
1.2e+00
2.0e+00
3.5e+00
1.0e+50
5.3e+00
1.8e+00
1.2e+00
cases:13.40%
controls:4.51%
cases:11.22%
controls:1.71%
cases:8.93%
controls:0.30%
cases:2.59%
controls:0.00%
cases:26.45%
controls:0.19%
cases:10.59%
controls:1.83%
cases:16.56%
controls:5.54%
93
313
601
6622
78
119
617
6821
62
21
632
6919
18
0
676
6940
178
13
495
6908
57
122
481
6527
53
269
267
4588
prednisolone
A07EA01 [21600653]
1.2e+00
2.4e+00
3.1e+00
—
4.0e+00
2.5e+00
1.6e+00
cases:36.89%
controls:14.49%
cases:44.32%
controls:6.71%
cases:21.76%
controls:1.22%
—
—
cases:38.19%
controls:1.14%
cases:45.72%
controls:6.63%
cases:43.13%
controls:13.44%
256
1005
438
5930
308
466
387
6474
151
85
543
6855
—
257
79
416
6842
246
441
292
6208
138
653
182
4204
prednisolone; oral, parenteral
H02AB06 [21602734]
1.2e+00
2.4e+00
3.1e+00
—
4.0e+00
2.5e+00
1.6e+00
cases:36.46%
controls:14.45%
cases:44.32%
controls:6.67%
cases:21.76%
controls:1.22%
—
—
cases:38.19%
controls:1.14%
cases:45.72%
controls:6.62%
cases:43.13%
controls:13.38%
253
1002
441
5933
308
463
387
6477
151
85
543
6855
—
257
79
416
6842
246
440
292
6209
138
650
182
4207
Erythrocyte sedimentation rate [Velocity] in Red Blood Cells by Westergren method
4537-7 [3013707]
7.0e-01
1.5e+00
2.7e+00
4.5e+00
2.9e+00
1.5e+00
9.2e-01
cases:48.70%
controls:31.94%
cases:47.34%
controls:16.21%
cases:25.50%
controls:2.29%
cases:5.91%
controls:0.07%
cases:28.97%
controls:2.15%
cases:47.21%
controls:16.11%
cases:59.38%
controls:36.81%
338
2215
356
4720
329
1125
366
5815
177
159
517
6781
41
5
653
6935
195
149
478
6772
254
1071
284
5578
190
1788
130
3069
pH of Arterial blood
2744-1 [3019977]
1.1e+00
2.1e+00
4.2e+00
—
4.5e+00
1.8e+00
1.1e+00
cases:9.94%
controls:3.60%
cases:9.93%
controls:1.38%
cases:8.65%
controls:0.14%
—
—
cases:13.22%
controls:0.17%
cases:8.92%
controls:1.56%
cases:13.75%
controls:4.98%
69
250
625
6685
69
96
626
6844
60
10
634
6930
—
89
12
584
6909
48
104
490
6545
44
242
276
4615
Pulmonary Disease
29 [38004472]
1.1e+00
1.9e+00
3.4e+00
—
3.8e+00
2.8e+00
1.7e+00
cases:31.99%
controls:13.27%
cases:32.52%
controls:6.69%
cases:26.37%
controls:1.21%
—
—
cases:39.23%
controls:1.37%
cases:54.46%
controls:6.72%
cases:43.13%
controls:12.58%
222
920
472
6015
226
464
469
6476
183
84
511
6856
—
264
95
409
6826
293
447
245
6202
138
611
182
4246
CBC W Ordered Manual Differential panel - Blood
57782-5 [40760892]
1.3e+00
2.1e+00
3.5e+00
—
3.7e+00
2.3e+00
1.7e+00
cases:22.62%
controls:7.05%
cases:26.76%
controls:4.15%
cases:19.02%
controls:0.72%
—
—
cases:26.89%
controls:0.94%
cases:30.86%
controls:4.23%
cases:34.06%
controls:8.59%
157
489
537
6446
186
288
509
6652
132
50
562
6890
—
181
65
492
6856
166
281
372
6368
109
417
211
4440
Hepatitis B virus core Ab [Presence] in Serum
16933-4 [3021879]
1.9e+00
2.9e+00
3.2e+00
—
2.7e+00
2.5e+00
1.5e+00
cases:12.10%
controls:1.93%
cases:10.36%
controls:0.63%
cases:2.02%
controls:0.09%
—
—
cases:1.49%
controls:0.10%
cases:6.13%
controls:0.56%
cases:8.75%
controls:2.16%
84
134
610
6801
72
44
623
6896
14
6
680
6934
—
10
7
663
6914
33
37
505
6612
28
105
292
4752
Base excess in Arterial blood by calculation
1925-7 [3003396]
1.1e+00
2.0e+00
4.1e+00
—
4.4e+00
1.8e+00
1.1e+00
cases:10.23%
controls:3.60%
cases:9.50%
controls:1.34%
cases:8.21%
controls:0.14%
—
—
cases:12.63%
controls:0.17%
cases:8.55%
controls:1.55%
cases:13.44%
controls:4.86%
71
250
623
6685
66
93
629
6847
57
10
637
6930
—
85
12
588
6909
46
103
492
6546
43
236
277
4621
pegfilgrastim; parenteral
L03AA13 [21603856]
1.8e+00
3.3e+00
4.3e+00
—
—
3.4e+00
1.7e+00
cases:3.89%
controls:0.68%
cases:7.77%
controls:0.30%
cases:4.90%
controls:0.07%
—
—
—
—
cases:5.39%
controls:0.20%
cases:2.50%
controls:0.47%
27
47
667
6888
54
21
641
6919
34
5
660
6935
—
—
29
13
509
6636
8
23
312
4834
Reticulocytes [#/volume] in Blood
14196-0 [3023520]
1.6e+00
2.3e+00
3.2e+00
1.0e+50
3.9e+00
2.2e+00
1.2e+00
cases:12.25%
controls:2.65%
cases:12.52%
controls:1.40%
cases:4.32%
controls:0.19%
cases:1.30%
controls:0.00%
cases:6.54%
controls:0.14%
cases:11.15%
controls:1.37%
cases:12.50%
controls:4.14%
85
184
609
6751
87
97
608
6843
30
13
664
6927
9
0
685
6940
44
10
629
6911
60
91
478
6558
40
201
280
4656
Cortisol [Moles/volume] in Serum or Plasma
14675-3 [3036481]
1.3e+00
2.0e+00
2.9e+00
—
4.2e+00
2.4e+00
1.6e+00
cases:8.36%
controls:2.39%
cases:6.19%
controls:0.91%
cases:2.74%
controls:0.16%
—
—
cases:6.54%
controls:0.10%
cases:10.78%
controls:1.07%
cases:13.75%
controls:3.15%
58
166
636
6769
43
63
652
6877
19
11
675
6929
—
44
7
629
6914
58
71
480
6578
44
153
276
4704
Hemoglobin [Mass/volume] in Arterial blood
30313-1 [3002173]
1.0e+00
2.0e+00
4.3e+00
—
4.2e+00
1.6e+00
1.0e+00
cases:7.78%
controls:2.94%
cases:8.06%
controls:1.12%
cases:7.20%
controls:0.10%
—
—
cases:9.66%
controls:0.16%
cases:6.88%
controls:1.43%
cases:10.94%
controls:4.16%
54
204
640
6731
56
78
639
6862
50
7
644
6933
—
65
11
608
6910
37
95
501
6554
35
202
285
4655
Emergency Medicine
93 [38004510]
6.0e-01
1.3e+00
3.0e+00
5.7e+00
2.3e+00
9.3e-01
4.6e-01
cases:36.17%
controls:23.76%
cases:35.25%
controls:12.72%
cases:29.83%
controls:2.00%
cases:22.62%
controls:0.10%
cases:13.97%
controls:1.65%
cases:28.81%
controls:13.75%
cases:45.31%
controls:34.34%
251
1648
443
5287
245
883
450
6057
207
139
487
6801
157
7
537
6933
94
114
579
6807
155
914
383
5735
145
1668
175
3189
valaciclovir; oral
J05AB11 [21603137]
1.5e+00
2.2e+00
3.3e+00
—
2.9e+00
2.7e+00
1.8e+00
cases:10.37%
controls:2.60%
cases:7.91%
controls:0.98%
cases:2.31%
controls:0.09%
—
—
cases:3.27%
controls:0.19%
cases:10.78%
controls:0.83%
cases:13.75%
controls:2.61%
72
180
622
6755
55
68
640
6872
16
6
678
6934
—
22
13
651
6908
58
55
480
6594
44
127
276
4730
Erythrocyte [DistWidth] in Red Blood Cells
30385-9 [3002385]
5.4e-01
1.2e+00
2.8e+00
5.0e+00
2.9e+00
1.3e+00
6.7e-01
cases:54.03%
controls:40.66%
cases:63.02%
controls:34.87%
cases:58.07%
controls:7.98%
cases:46.54%
controls:0.61%
cases:60.48%
controls:7.72%
cases:66.36%
controls:35.57%
cases:70.63%
controls:55.28%
375
2820
319
4115
438
2420
257
4520
403
554
291
6386
323
42
371
6898
407
534
266
6387
357
2365
181
4284
226
2685
94
2172
Proteinase 3 Ab [Units/volume] in Serum
6968-2 [3009445]
1.6e+00
3.2e+00
—
1.0e+50
4.4e+00
3.1e+00
2.0e+00
cases:6.63%
controls:1.36%
cases:6.91%
controls:0.30%
—
—
cases:0.72%
controls:0.00%
cases:7.43%
controls:0.10%
cases:5.58%
controls:0.27%
cases:7.50%
controls:1.11%
46
94
648
6841
48
21
647
6919
—
5
0
689
6940
50
7
623
6914
30
18
508
6631
24
54
296
4803
CD4 cells/Lymphocytes in Specimen
80223-1 [21494815]
2.4e+00
3.2e+00
—
—
—
5.0e+00
3.7e+00
cases:3.60%
controls:0.35%
cases:3.60%
controls:0.16%
—
—
—
—
—
—
cases:11.90%
controls:0.09%
cases:11.88%
controls:0.33%
25
24
669
6911
25
11
670
6929
—
—
—
64
6
474
6643
38
16
282
4841
Body CT examination
JN4AD [2001310897]
1.7e+00
2.7e+00
3.6e+00
—
2.6e+00
2.2e+00
1.4e+00
cases:8.07%
controls:1.61%
cases:12.95%
controls:0.95%
cases:5.62%
controls:0.16%
—
—
cases:3.12%
controls:0.25%
cases:10.22%
controls:1.23%
cases:12.50%
controls:3.50%
56
112
638
6823
90
66
605
6874
39
11
655
6929
—
21
17
652
6904
55
82
483
6567
40
170
280
4687
Tacrolimus [Mass/volume] in Blood
11253-2 [3026250]
3.2e+00
2.4e+00
3.0e+00
—
—
2.6e+00
2.8e+00
cases:2.74%
controls:0.12%
cases:1.58%
controls:0.14%
cases:1.44%
controls:0.07%
—
—
—
—
cases:1.86%
controls:0.14%
cases:4.69%
controls:0.29%
19
8
675
6927
11
10
684
6930
10
5
684
6935
—
—
10
9
528
6640
15
14
305
4843
Nuclear Ab [Titer] in Serum
29953-7 [3037522]
1.3e+00
2.3e+00
3.3e+00
—
4.2e+00
1.7e+00
1.1e+00
cases:12.10%
controls:3.66%
cases:10.50%
controls:1.11%
cases:4.03%
controls:0.16%
—
—
cases:5.65%
controls:0.09%
cases:5.95%
controls:1.14%
cases:11.56%
controls:4.08%
84
254
610
6681
73
77
622
6863
28
11
666
6929
—
38
6
635
6915
32
76
506
6573
37
198
283
4659
Bicarbonate [Moles/volume] in Serum or Plasma
1963-8 [3016293]
1.4e+00
1.5e+00
3.4e+00
1.0e+50
4.1e+00
2.2e+00
1.3e+00
cases:6.20%
controls:1.64%
cases:3.74%
controls:0.84%
cases:3.89%
controls:0.13%
cases:3.31%
controls:0.00%
cases:7.43%
controls:0.13%
cases:6.51%
controls:0.75%
cases:8.44%
controls:2.49%
43
114
651
6821
26
58
669
6882
27
9
667
6931
23
0
671
6940
50
9
623
6912
35
50
503
6599
27
121
293
4736
Oxygen saturation in Arterial blood
2708-6 [3016502]
1.1e+00
1.9e+00
4.0e+00
—
4.1e+00
1.7e+00
1.1e+00
cases:9.08%
controls:3.13%
cases:7.77%
controls:1.20%
cases:5.91%
controls:0.12%
—
—
cases:9.21%
controls:0.17%
cases:7.62%
controls:1.47%
cases:11.88%
controls:4.45%
63
217
631
6718
54
83
641
6857
41
8
653
6932
—
62
12
611
6909
41
98
497
6551
38
216
282
4641
Reticulocytes/Erythrocytes in Blood
4679-7 [3027945]
1.5e+00
2.4e+00
3.1e+00
1.0e+50
3.4e+00
2.2e+00
1.2e+00
cases:15.85%
controls:3.86%
cases:16.69%
controls:1.84%
cases:6.05%
controls:0.29%
cases:2.02%
controls:0.00%
cases:7.28%
controls:0.26%
cases:14.68%
controls:1.82%
cases:15.94%
controls:5.17%
110
268
584
6667
116
128
579
6812
42
20
652
6920
14
0
680
6940
49
18
624
6903
79
121
459
6528
51
251
269
4606
prednisone; oral
H02AB07 [21602735]
1.4e+00
2.2e+00
2.9e+00
—
3.3e+00
2.4e+00
1.6e+00
cases:6.63%
controls:1.76%
cases:4.60%
controls:0.52%
cases:1.87%
controls:0.10%
—
—
cases:2.38%
controls:0.09%
cases:4.46%
controls:0.44%
cases:5.00%
controls:1.01%
46
122
648
6813
32
36
663
6904
13
7
681
6933
—
16
6
657
6915
24
29
514
6620
16
49
304
4808
prednisone
A07EA03 [21600655]
1.4e+00
2.2e+00
2.9e+00
—
3.3e+00
2.4e+00
1.6e+00
cases:6.63%
controls:1.76%
cases:4.60%
controls:0.52%
cases:1.87%
controls:0.10%
—
—
cases:2.38%
controls:0.09%
cases:4.46%
controls:0.44%
cases:5.00%
controls:1.01%
46
122
648
6813
32
36
663
6904
13
7
681
6933
—
16
6
657
6915
24
29
514
6620
16
49
304
4808
Sodium [Moles/volume] in Serum or Plasma
2951-2 [3019550]
3.2e-01
1.1e+00
2.8e+00
5.3e+00
3.1e+00
1.0e+00
4.5e-02
cases:65.71%
controls:58.17%
cases:71.94%
controls:46.59%
cases:63.26%
controls:9.42%
cases:56.20%
controls:0.62%
cases:70.88%
controls:9.49%
cases:71.93%
controls:47.48%
cases:72.81%
controls:71.92%
456
4034
238
2901
500
3233
195
3707
439
654
255
6286
390
43
304
6897
477
657
196
6264
387
3157
151
3492
233
3493
87
1364
ondansetron; oral, parenteral, rectal
A04AA01 [21600493]
2.1e+00
2.9e+00
2.3e+00
—
3.0e+00
2.0e+00
1.4e+00
cases:7.93%
controls:1.07%
cases:8.49%
controls:0.50%
cases:1.30%
controls:0.13%
—
—
cases:1.93%
controls:0.10%
cases:4.65%
controls:0.66%
cases:4.69%
controls:1.15%
55
74
639
6861
59
35
636
6905
9
9
685
6931
—
13
7
660
6914
25
44
513
6605
15
56
305
4801
Potassium [Moles/volume] in Serum or Plasma
2823-3 [3023103]
3.1e-01
1.1e+00
2.8e+00
5.3e+00
3.1e+00
1.1e+00
3.3e-02
cases:65.85%
controls:58.56%
cases:72.09%
controls:47.16%
cases:63.69%
controls:9.64%
cases:55.62%
controls:0.62%
cases:71.03%
controls:9.65%
cases:72.68%
controls:47.93%
cases:72.81%
controls:72.16%
457
4061
237
2874
501
3273
194
3667
442
669
252
6271
386
43
308
6897
478
668
195
6253
391
3187
147
3462
233
3505
87
1352
clindamycin; oral, parenteral
J01FF01 [21602985]
9.3e-01
1.4e+00
2.9e+00
—
5.5e+00
1.6e+00
1.3e+00
cases:8.65%
controls:3.59%
cases:4.17%
controls:1.11%
cases:2.59%
controls:0.14%
—
—
cases:24.37%
controls:0.13%
cases:4.65%
controls:0.96%
cases:10.31%
controls:2.96%
60
249
634
6686
29
77
666
6863
18
10
676
6930
—
164
9
509
6912
25
64
513
6585
33
144
287
4713
Protein [Mass/volume] in Serum or Plasma
2885-2 [3020630]
1.6e+00
2.4e+00
2.9e+00
—
3.1e+00
2.2e+00
1.3e+00
cases:11.53%
controls:2.51%
cases:10.22%
controls:0.98%
cases:4.18%
controls:0.23%
—
—
cases:5.35%
controls:0.26%
cases:8.92%
controls:1.08%
cases:12.19%
controls:3.52%
80
174
614
6761
71
68
624
6872
29
16
665
6924
—
36
18
637
6903
48
72
490
6577
39
171
281
4686
Calcium.ionized [Moles/volume] adjusted to pH 7.4 in Blood
47598-8 [3048816]
1.4e+00
2.1e+00
3.2e+00
—
3.4e+00
2.3e+00
1.3e+00
cases:10.09%
controls:2.60%
cases:10.79%
controls:1.46%
cases:6.05%
controls:0.27%
—
—
cases:7.73%
controls:0.29%
cases:12.83%
controls:1.47%
cases:11.56%
controls:3.58%
70
180
624
6755
75
101
620
6839
42
19
652
6921
—
52
20
621
6901
69
98
469
6551
37
174
283
4683
mycophenolic acid; oral, parenteral
L04AA06 [21603896]
2.7e+00
2.6e+00
2.6e+00
—
—
2.9e+00
2.8e+00
cases:6.48%
controls:0.48%
cases:5.32%
controls:0.40%
cases:1.15%
controls:0.09%
—
—
—
—
cases:6.13%
controls:0.38%
cases:9.06%
controls:0.58%
45
33
649
6902
37
28
658
6912
8
6
686
6934
—
—
33
25
505
6624
29
28
291
4829
Protein electrophoresis panel - Serum or Plasma
24351-9 [3004588]
1.7e+00
2.6e+00
2.8e+00
—
2.9e+00
2.0e+00
1.4e+00
cases:10.52%
controls:2.06%
cases:10.07%
controls:0.82%
cases:2.88%
controls:0.19%
—
—
cases:4.01%
controls:0.23%
cases:6.69%
controls:0.92%
cases:10.63%
controls:2.72%
73
143
621
6792
70
57
625
6883
20
13
674
6927
—
27
16
646
6905
36
61
502
6588
34
132
286
4725
Bronchial lavation
TGC00 [2001303585]
2.3e+00
3.4e+00
1.0e+50
1.0e+50
1.0e+50
4.2e+00
3.5e+00
cases:3.89%
controls:0.40%
cases:5.04%
controls:0.17%
cases:6.77%
controls:0.00%
cases:21.61%
controls:0.00%
cases:7.73%
controls:0.00%
cases:5.76%
controls:0.09%
cases:6.56%
controls:0.21%
27
28
667
6907
35
12
660
6928
47
0
647
6940
150
0
544
6940
52
0
621
6921
31
6
507
6643
21
10
299
4847
Other specified interstitial pulmonary diseases
J84.8 [45548126]
2.5e+00
3.4e+00
—
1.0e+50
—
3.9e+00
3.5e+00
cases:2.16%
controls:0.17%
cases:3.45%
controls:0.12%
—
—
cases:3.31%
controls:0.00%
—
—
cases:5.76%
controls:0.12%
cases:5.94%
controls:0.19%
15
12
679
6923
24
8
671
6932
—
23
0
671
6940
—
31
8
507
6641
19
9
301
4848
Creatinine [Moles/volume] in Serum or Plasma
14682-9 [3020564]
2.9e-01
1.1e+00
2.8e+00
5.1e+00
3.0e+00
1.1e+00
3.0e-01
cases:68.30%
controls:61.76%
cases:76.69%
controls:52.68%
cases:69.16%
controls:11.64%
cases:56.05%
controls:0.76%
cases:72.36%
controls:11.75%
cases:77.32%
controls:53.42%
cases:80.94%
controls:75.95%
474
4283
220
2652
533
3656
162
3284
480
808
214
6132
389
53
305
6887
487
813
186
6108
416
3552
122
3097
259
3689
61
1168
IgA [Mass/volume] in Serum or Plasma
2458-8 [3007164]
1.0e+00
2.2e+00
3.2e+00
—
3.9e+00
2.2e+00
9.1e-01
cases:13.98%
controls:5.41%
cases:11.94%
controls:1.50%
cases:4.32%
controls:0.19%
—
—
cases:8.32%
controls:0.19%
cases:13.57%
controls:1.77%
cases:14.06%
controls:6.20%
97
375
597
6560
83
104
612
6836
30
13
664
6927
—
56
13
617
6908
73
118
465
6531
45
301
275
4556
Microorganisms panel - Urine sediment
58435-9 [40761536]
1.1e+00
2.0e+00
3.2e+00
1.0e+50
3.4e+00
2.3e+00
1.3e+00
cases:8.36%
controls:3.03%
cases:8.78%
controls:1.25%
cases:6.92%
controls:0.29%
cases:2.59%
controls:0.00%
cases:6.39%
controls:0.22%
cases:9.85%
controls:1.10%
cases:9.38%
controls:2.86%
58
210
636
6725
61
87
634
6853
48
20
646
6920
18
0
676
6940
43
15
630
6906
53
73
485
6576
30
139
290
4718
Bordetella parapertussis DNA [Presence] in Specimen by NAA with probe detection
29723-4 [3037875]
2.7e+00
3.6e+00
1.0e+50
1.0e+50
1.0e+50
4.1e+00
3.0e+00
cases:2.31%
controls:0.16%
cases:3.02%
controls:0.09%
cases:5.48%
controls:0.00%
cases:3.89%
controls:0.00%
cases:10.85%
controls:0.00%
cases:4.28%
controls:0.08%
cases:3.44%
controls:0.19%
16
11
678
6924
21
6
674
6934
38
0
656
6940
27
0
667
6940
73
0
600
6921
23
5
515
6644
11
9
309
4848
Secondary malignant neoplasm of other specified sites
C79.8 [45547524]
2.4e+00
2.8e+00
3.4e+00
—
2.4e+00
2.3e+00
—
cases:3.17%
controls:0.30%
cases:5.47%
controls:0.35%
cases:4.61%
controls:0.16%
—
—
cases:2.38%
controls:0.23%
cases:4.65%
controls:0.47%
—
—
22
21
672
6914
38
24
657
6916
32
11
662
6929
—
16
16
657
6905
25
31
513
6618
—
pH of Venous blood
2746-6 [3012544]
1.2e+00
1.9e+00
3.7e+00
1.0e+50
3.5e+00
2.0e+00
1.1e+00
cases:9.22%
controls:2.94%
cases:8.92%
controls:1.46%
cases:7.35%
controls:0.20%
cases:4.90%
controls:0.00%
cases:8.77%
controls:0.30%
cases:10.97%
controls:1.71%
cases:15.00%
controls:5.56%
64
204
630
6731
62
101
633
6839
51
14
643
6926
34
0
660
6940
59
21
614
6900
59
114
479
6535
48
270
272
4587
Metastasis
OMOP4998856 [36769180]
2.4e+00
2.8e+00
3.4e+00
—
2.4e+00
2.3e+00
—
cases:3.17%
controls:0.30%
cases:5.47%
controls:0.35%
cases:4.61%
controls:0.16%
—
—
cases:2.38%
controls:0.23%
cases:4.65%
controls:0.48%
—
—
22
21
672
6914
38
24
657
6916
32
11
662
6929
—
16
16
657
6905
25
32
513
6617
—
Methicillin resistant Staphylococcus aureus [Presence] in Specimen by Organism specific culture
13317-3 [3019902]
1.3e+00
1.8e+00
3.5e+00
—
3.6e+00
2.2e+00
9.0e-01
cases:11.82%
controls:3.58%
cases:10.22%
controls:1.84%
cases:7.20%
controls:0.24%
—
—
cases:7.43%
controls:0.22%
cases:10.78%
controls:1.29%
cases:9.06%
controls:3.91%
82
248
612
6687
71
128
624
6812
50
17
644
6923
—
50
15
623
6906
58
86
480
6563
29
190
291
4667
Streptococcus pneumoniae DNA [Presence] in Specimen by NAA with probe detection
49672-9 [3032699]
2.6e+00
3.7e+00
1.0e+50
1.0e+50
1.0e+50
3.9e+00
3.0e+00
cases:2.31%
controls:0.17%
cases:3.31%
controls:0.09%
cases:6.20%
controls:0.00%
cases:3.89%
controls:0.00%
cases:11.74%
controls:0.00%
cases:4.46%
controls:0.09%
cases:4.06%
controls:0.21%
16
12
678
6923
23
6
672
6934
43
0
651
6940
27
0
667
6940
79
0
594
6921
24
6
514
6643
13
10
307
4847
filgrastim; parenteral
L03AA02 [21603851]
2.9e+00
3.5e+00
—
—
—
3.9e+00
2.8e+00
cases:6.20%
controls:0.35%
cases:7.77%
controls:0.24%
—
—
—
—
—
—
cases:5.58%
controls:0.12%
cases:5.00%
controls:0.31%
43
24
651
6911
54
17
641
6923
—
—
—
30
8
508
6641
16
15
304
4842
Base excess in Venous blood by calculation
1927-3 [3002032]
1.2e+00
1.9e+00
3.5e+00
1.0e+50
3.5e+00
1.9e+00
1.1e+00
cases:8.93%
controls:2.81%
cases:8.78%
controls:1.40%
cases:6.77%
controls:0.22%
cases:4.90%
controls:0.00%
cases:8.62%
controls:0.27%
cases:10.41%
controls:1.71%
cases:14.38%
controls:5.35%
62
195
632
6740
61
97
634
6843
47
15
647
6925
34
0
660
6940
58
19
615
6902
56
114
482
6535
46
260
274
4597
FEV1 percent change
69983-5 [42868472]
1.2e+00
2.2e+00
2.6e+00
—
2.7e+00
2.4e+00
2.1e+00
cases:9.94%
controls:3.26%
cases:6.91%
controls:0.81%
cases:1.01%
controls:0.07%
—
—
cases:1.04%
controls:0.07%
cases:7.62%
controls:0.77%
cases:13.13%
controls:1.89%
69
226
625
6709
48
56
647
6884
7
5
687
6935
—
7
5
666
6916
41
51
497
6598
42
92
278
4765
Forced vital capacity [Volume] Respiratory system --post bronchodilation
19875-4 [3001668]
1.2e+00
2.2e+00
2.6e+00
—
2.7e+00
2.4e+00
2.1e+00
cases:9.94%
controls:3.26%
cases:6.91%
controls:0.81%
cases:1.01%
controls:0.07%
—
—
cases:1.04%
controls:0.07%
cases:7.62%
controls:0.77%
cases:13.13%
controls:1.89%
69
226
625
6709
48
56
647
6884
7
5
687
6935
—
7
5
666
6916
41
51
497
6598
42
92
278
4765
FVC percent change Respiratory system
69982-7 [42868471]
1.2e+00
2.2e+00
2.6e+00
—
2.7e+00
2.4e+00
2.1e+00
cases:9.94%
controls:3.26%
cases:6.91%
controls:0.81%
cases:1.01%
controls:0.07%
—
—
cases:1.04%
controls:0.07%
cases:7.62%
controls:0.77%
cases:13.13%
controls:1.89%
69
226
625
6709
48
56
647
6884
7
5
687
6935
—
7
5
666
6916
41
51
497
6598
42
92
278
4765
FEV1/FVC --post bronchodilation
69970-2 [42868459]
1.2e+00
2.2e+00
2.6e+00
—
2.7e+00
2.4e+00
2.1e+00
cases:9.94%
controls:3.26%
cases:6.91%
controls:0.81%
cases:1.01%
controls:0.07%
—
—
cases:1.04%
controls:0.07%
cases:7.62%
controls:0.77%
cases:13.13%
controls:1.89%
69
226
625
6709
48
56
647
6884
7
5
687
6935
—
7
5
666
6916
41
51
497
6598
42
92
278
4765
FEV1 --post bronchodilation
20155-8 [3023550]
1.2e+00
2.2e+00
2.6e+00
—
2.7e+00
2.4e+00
2.1e+00
cases:9.94%
controls:3.26%
cases:6.91%
controls:0.81%
cases:1.01%
controls:0.07%
—
—
cases:1.04%
controls:0.07%
cases:7.62%
controls:0.77%
cases:13.13%
controls:1.89%
69
226
625
6709
48
56
647
6884
7
5
687
6935
—
7
5
666
6916
41
51
497
6598
42
92
278
4765
Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma
1742-6 [3006923]
3.5e-01
1.3e+00
2.8e+00
4.4e+00
3.0e+00
1.2e+00
3.9e-01
cases:66.28%
controls:58.20%
cases:74.96%
controls:45.06%
cases:58.79%
controls:7.88%
cases:23.20%
controls:0.36%
cases:65.38%
controls:8.35%
cases:74.54%
controls:45.98%
cases:79.69%
controls:72.66%
460
4036
234
2899
521
3127
174
3813
408
547
286
6393
161
25
533
6915
440
578
233
6343
401
3057
137
3592
255
3529
65
1328
FEV1
20150-9 [3024653]
1.2e+00
2.2e+00
2.5e+00
—
2.9e+00
2.4e+00
2.0e+00
cases:11.53%
controls:3.71%
cases:8.92%
controls:1.07%
cases:1.59%
controls:0.13%
—
—
cases:1.49%
controls:0.09%
cases:9.48%
controls:0.98%
cases:14.38%
controls:2.29%
80
257
614
6678
62
74
633
6866
11
9
683
6931
—
10
6
663
6915
51
65
487
6584
46
111
274
4746
Forced vital capacity [Volume] Respiratory system
19870-5 [3020158]
1.2e+00
2.2e+00
2.5e+00
—
2.9e+00
2.4e+00
2.0e+00
cases:11.53%
controls:3.71%
cases:8.92%
controls:1.07%
cases:1.59%
controls:0.13%
—
—
cases:1.49%
controls:0.09%
cases:9.48%
controls:0.98%
cases:14.38%
controls:2.29%
80
257
614
6678
62
74
633
6866
11
9
683
6931
—
10
6
663
6915
51
65
487
6584
46
111
274
4746
FEV1/FVC
19926-5 [3011505]
1.2e+00
2.2e+00
2.5e+00
—
2.9e+00
2.4e+00
2.0e+00
cases:11.53%
controls:3.71%
cases:8.92%
controls:1.07%
cases:1.59%
controls:0.13%
—
—
cases:1.49%
controls:0.09%
cases:9.48%
controls:0.98%
cases:14.38%
controls:2.29%
80
257
614
6678
62
74
633
6866
11
9
683
6931
—
10
6
663
6915
51
65
487
6584
46
111
274
4746
Phosphate [Moles/volume] in Serum or Plasma
14879-1 [3003458]
1.4e+00
2.0e+00
2.8e+00
—
3.4e+00
1.9e+00
1.6e+00
cases:17.58%
controls:4.79%
cases:16.55%
controls:2.61%
cases:8.50%
controls:0.55%
—
—
cases:15.45%
controls:0.64%
cases:17.66%
controls:3.07%
cases:22.50%
controls:5.76%
122
332
572
6603
115
181
580
6759
59
38
635
6902
—
104
44
569
6877
95
204
443
6445
72
280
248
4577
Carbon dioxide [Partial pressure] in Venous blood
2021-4 [3021447]
1.2e+00
1.8e+00
3.6e+00
1.0e+50
3.5e+00
1.9e+00
1.1e+00
cases:8.79%
controls:2.78%
cases:8.49%
controls:1.44%
cases:7.20%
controls:0.22%
cases:5.04%
controls:0.00%
cases:8.62%
controls:0.29%
cases:10.41%
controls:1.73%
cases:14.69%
controls:5.60%
61
193
633
6742
59
100
636
6840
50
15
644
6925
35
0
659
6940
58
20
615
6901
56
115
482
6534
47
272
273
4585
Other seropositive rheumatoid arthritis
M05.8 [45538634]
1.8e+00
2.1e+00
2.5e+00
—
2.6e+00
2.0e+00
2.0e+00
cases:9.08%
controls:1.61%
cases:9.21%
controls:1.22%
cases:4.18%
controls:0.35%
—
—
cases:4.31%
controls:0.35%
cases:8.74%
controls:1.25%
cases:9.69%
controls:1.46%
63
112
631
6823
64
85
631
6855
29
24
665
6916
—
29
24
644
6897
47
83
491
6566
31
71
289
4786
MCH [Entitic mass]
28539-5 [3035941]
2.6e-01
1.0e+00
2.8e+00
5.2e+00
2.9e+00
1.0e+00
1.6e-01
cases:69.60%
controls:63.85%
cases:77.41%
controls:55.50%
cases:71.61%
controls:12.97%
cases:59.51%
controls:0.81%
cases:72.66%
controls:12.61%
cases:77.88%
controls:55.63%
cases:81.25%
controls:78.71%
483
4428
211
2507
538
3852
157
3088
497
900
197
6040
413
56
281
6884
489
873
184
6048
419
3699
119
2950
260
3823
60
1034
Platelets [#/volume] in Blood
26515-7 [3007461]
2.6e-01
1.0e+00
2.8e+00
5.2e+00
2.9e+00
1.0e+00
1.6e-01
cases:69.60%
controls:63.94%
cases:77.41%
controls:55.48%
cases:71.61%
controls:12.98%
cases:59.51%
controls:0.81%
cases:72.66%
controls:12.63%
cases:77.88%
controls:55.63%
cases:81.25%
controls:78.61%
483
4434
211
2501
538
3850
157
3090
497
901
197
6039
413
56
281
6884
489
874
184
6047
419
3699
119
2950
260
3818
60
1039
MCV [Entitic mean volume] in Red Blood Cells
30428-7 [3024731]
2.5e-01
1.0e+00
2.8e+00
5.2e+00
2.9e+00
1.0e+00
1.6e-01
cases:69.60%
controls:63.95%
cases:77.41%
controls:55.55%
cases:71.61%
controls:12.98%
cases:59.51%
controls:0.81%
cases:72.66%
controls:12.61%
cases:77.88%
controls:55.66%
cases:81.25%
controls:78.73%
483
4435
211
2500
538
3855
157
3085
497
901
197
6039
413
56
281
6884
489
873
184
6048
419
3701
119
2948
260
3824
60
1033
Erythrocytes [#/volume] in Blood
26453-1 [3026361]
2.6e-01
1.0e+00
2.8e+00
5.2e+00
2.9e+00
1.0e+00
1.6e-01
cases:69.60%
controls:63.94%
cases:77.41%
controls:55.55%
cases:71.61%
controls:12.97%
cases:59.51%
controls:0.81%
cases:72.66%
controls:12.61%
cases:77.88%
controls:55.71%
cases:81.25%
controls:78.75%
483
4434
211
2501
538
3855
157
3085
497
900
197
6040
413
56
281
6884
489
873
184
6048
419
3704
119
2945
260
3825
60
1032
Leukocytes [#/volume] in Blood
26464-8 [3010813]
2.5e-01
1.0e+00
2.8e+00
5.2e+00
2.9e+00
1.0e+00
1.5e-01
cases:69.60%
controls:64.02%
cases:77.41%
controls:55.56%
cases:71.61%
controls:13.00%
cases:59.51%
controls:0.81%
cases:72.66%
controls:12.63%
cases:77.88%
controls:55.68%
cases:81.25%
controls:78.79%
483
4440
211
2495
538
3856
157
3084
497
902
197
6038
413
56
281
6884
489
874
184
6047
419
3702
119
2947
260
3827
60
1030
Hemoglobin [Mass/volume] in Blood
718-7 [3000963]
2.5e-01
1.0e+00
2.8e+00
5.2e+00
2.9e+00
1.0e+00
1.5e-01
cases:69.60%
controls:63.98%
cases:77.55%
controls:55.59%
cases:71.61%
controls:13.04%
cases:59.51%
controls:0.81%
cases:72.66%
controls:12.66%
cases:77.88%
controls:55.72%
cases:81.25%
controls:78.79%
483
4437
211
2498
539
3858
156
3082
497
905
197
6035
413
56
281
6884
489
876
184
6045
419
3705
119
2944
260
3827
60
1030
Respiratory virus DNA+RNA [Identifier] in Specimen by NAA with probe detection
50548-7 [3030692]
2.4e+00
3.3e+00
—
1.0e+50
1.0e+50
4.1e+00
3.1e+00
cases:4.32%
controls:0.39%
cases:4.89%
controls:0.19%
—
—
cases:6.77%
controls:0.00%
cases:20.21%
controls:0.00%
cases:7.81%
controls:0.14%
cases:7.50%
controls:0.37%
30
27
664
6908
34
13
661
6927
—
47
0
647
6940
136
0
537
6921
42
9
496
6640
24
18
296
4839
Hematocrit [Volume Fraction] of Blood by calculation
20570-8 [3009542]
2.5e-01
1.0e+00
2.8e+00
5.2e+00
2.9e+00
1.0e+00
1.6e-01
cases:69.60%
controls:63.98%
cases:77.41%
controls:55.53%
cases:71.61%
controls:13.00%
cases:59.51%
controls:0.81%
cases:72.66%
controls:12.69%
cases:77.88%
controls:55.69%
cases:81.25%
controls:78.75%
483
4437
211
2498
538
3854
157
3086
497
902
197
6038
413
56
281
6884
489
878
184
6043
419
3703
119
2946
260
3825
60
1032
pH of Serum or Plasma
2753-2 [3018418]
1.2e+00
1.9e+00
3.2e+00
—
3.3e+00
2.1e+00
1.2e+00
cases:28.67%
controls:10.54%
cases:30.07%
controls:5.95%
cases:16.71%
controls:0.85%
—
—
cases:23.63%
controls:1.10%
cases:36.06%
controls:6.20%
cases:36.88%
controls:15.36%
199
731
495
6204
209
413
486
6527
116
59
578
6881
—
159
76
514
6845
194
412
344
6237
118
746
202
4111
Human bocavirus DNA [Presence] in Specimen by NAA with probe detection
62424-7 [40765161]
2.5e+00
3.5e+00
—
1.0e+50
1.0e+50
3.9e+00
3.0e+00
cases:6.05%
controls:0.50%
cases:6.47%
controls:0.22%
—
—
cases:7.49%
controls:0.00%
cases:23.92%
controls:0.00%
cases:8.36%
controls:0.18%
cases:8.75%
controls:0.47%
42
35
652
6900
45
15
650
6925
—
52
0
642
6940
161
0
512
6921
45
12
493
6637
28
23
292
4834
Epstein Barr virus DNA [Units/volume] (viral load) in Serum or Plasma by NAA with probe detection
43730-1 [3043849]
2.9e+00
3.5e+00
—
1.0e+50
—
3.5e+00
3.0e+00
cases:7.35%
controls:0.42%
cases:6.33%
controls:0.20%
—
—
cases:1.15%
controls:0.00%
—
—
cases:7.25%
controls:0.24%
cases:11.56%
controls:0.66%
51
29
643
6906
44
14
651
6926
—
8
0
686
6940
—
39
16
499
6633
37
32
283
4825
Extracorporeal dialysis
Z49.1 [45537649]
2.3e+00
2.0e+00
2.0e+00
—
2.0e+00
2.4e+00
2.3e+00
cases:2.02%
controls:0.22%
cases:1.73%
controls:0.24%
cases:1.15%
controls:0.16%
—
—
cases:1.04%
controls:0.14%
cases:2.60%
controls:0.24%
cases:3.13%
controls:0.33%
14
15
680
6920
12
17
683
6923
8
11
686
6929
—
7
10
666
6911
14
16
524
6633
10
16
310
4841
Bicarbonate [Moles/volume] standard in Venous blood
19232-8 [3007628]
1.2e+00
1.7e+00
3.1e+00
—
3.4e+00
2.1e+00
1.3e+00
cases:4.32%
controls:1.34%
cases:4.17%
controls:0.76%
cases:2.74%
controls:0.13%
—
—
cases:3.71%
controls:0.13%
cases:6.32%
controls:0.83%
cases:9.69%
controls:2.86%
30
93
664
6842
29
53
666
6887
19
9
675
6931
—
25
9
648
6912
34
55
504
6594
31
139
289
4718
Fractional oxyhemoglobin in Arterial blood
2714-4 [3014007]
7.9e-01
1.7e+00
3.5e+00
—
4.1e+00
1.5e+00
1.2e+00
cases:4.03%
controls:1.87%
cases:4.03%
controls:0.78%
cases:2.74%
controls:0.09%
—
—
cases:4.31%
controls:0.07%
cases:3.90%
controls:0.89%
cases:8.13%
controls:2.68%
28
130
666
6805
28
54
667
6886
19
6
675
6934
—
29
5
644
6916
21
59
517
6590
26
130
294
4727
Gas panel - Venous blood
24339-4 [3000991]
1.1e+00
1.6e+00
3.3e+00
—
3.4e+00
2.0e+00
1.3e+00
cases:6.48%
controls:2.32%
cases:6.33%
controls:1.28%
cases:4.32%
controls:0.17%
—
—
cases:6.39%
controls:0.22%
cases:8.55%
controls:1.20%
cases:12.50%
controls:3.85%
45
161
649
6774
44
89
651
6851
30
12
664
6928
—
43
15
630
6906
46
80
492
6569
40
187
280
4670
methylprednisolone; oral, parenteral
H02AB04 [21602732]
1.6e+00
2.6e+00
—
—
3.3e+00
2.8e+00
2.6e+00
cases:6.92%
controls:1.51%
cases:6.33%
controls:0.52%
—
—
—
—
cases:2.23%
controls:0.09%
cases:7.06%
controls:0.48%
cases:11.56%
controls:1.01%
48
105
646
6830
44
36
651
6904
—
—
15
6
658
6915
38
32
500
6617
37
49
283
4808
Internal Medicine
11 [38004456]
9.7e-01
2.1e+00
3.4e+00
—
2.9e+00
2.0e+00
1.3e+00
cases:45.24%
controls:23.89%
cases:45.32%
controls:8.86%
cases:29.83%
controls:1.40%
—
—
cases:18.13%
controls:1.21%
cases:39.22%
controls:8.30%
cases:47.81%
controls:19.66%
314
1657
380
5278
315
615
380
6325
207
97
487
6843
—
122
84
551
6837
211
552
327
6097
153
955
167
3902
Parainfluenza virus RNA [Presence] in Specimen by NAA with probe detection
61365-3 [40764126]
2.4e+00
3.6e+00
—
1.0e+50
1.0e+50
3.9e+00
2.8e+00
cases:2.45%
controls:0.22%
cases:3.45%
controls:0.10%
—
—
cases:4.32%
controls:0.00%
cases:10.85%
controls:0.00%
cases:4.28%
controls:0.09%
cases:3.75%
controls:0.25%
17
15
677
6920
24
7
671
6933
—
30
0
664
6940
73
0
600
6921
23
6
515
6643
12
12
308
4845
Bone marrow biopsy
XW000 [2001310618]
2.7e+00
4.2e+00
—
1.0e+50
—
3.4e+00
2.3e+00
cases:9.65%
controls:0.71%
cases:9.93%
controls:0.16%
—
—
cases:1.01%
controls:0.00%
—
—
cases:4.46%
controls:0.15%
cases:5.94%
controls:0.64%
67
49
627
6886
69
11
626
6929
—
7
0
687
6940
—
24
10
514
6639
19
31
301
4826
Human coronavirus RNA [Presence] in Specimen by NAA with probe detection
41001-9 [3042596]
2.5e+00
3.5e+00
—
1.0e+50
1.0e+50
3.4e+00
3.2e+00
cases:4.03%
controls:0.33%
cases:5.18%
controls:0.16%
—
—
cases:5.33%
controls:0.00%
cases:17.38%
controls:0.00%
cases:6.51%
controls:0.23%
cases:7.19%
controls:0.33%
28
23
666
6912
36
11
659
6929
—
37
0
657
6940
117
0
556
6921
35
15
503
6634
23
16
297
4841
Urea [Moles/volume] in Serum or Plasma
22664-7 [3020779]
1.3e+00
1.8e+00
2.7e+00
—
3.4e+00
1.9e+00
1.5e+00
cases:11.96%
controls:3.40%
cases:10.22%
controls:1.80%
cases:6.48%
controls:0.46%
—
—
cases:11.44%
controls:0.42%
cases:12.27%
controls:2.08%
cases:15.00%
controls:3.95%
83
236
611
6699
71
125
624
6815
45
32
649
6908
—
77
29
596
6892
66
138
472
6511
48
192
272
4665
aPTT in Platelet poor plasma by Coagulation assay
14979-9 [3018677]
1.0e+00
1.9e+00
3.4e+00
1.0e+50
3.5e+00
1.8e+00
9.8e-01
cases:13.40%
controls:5.25%
cases:11.37%
controls:1.90%
cases:3.60%
controls:0.13%
cases:1.44%
controls:0.00%
cases:5.65%
controls:0.17%
cases:10.41%
controls:1.80%
cases:14.06%
controls:5.76%
93
364
601
6571
79
132
616
6808
25
9
669
6931
10
0
684
6940
38
12
635
6909
56
120
482
6529
45
280
275
4577
Osmolality of Urine
2695-5 [3026782]
9.5e-01
1.6e+00
3.5e+00
1.0e+50
3.4e+00
2.0e+00
1.2e+00
cases:17.58%
controls:7.60%
cases:13.81%
controls:3.10%
cases:11.96%
controls:0.42%
cases:6.34%
controls:0.00%
cases:11.89%
controls:0.46%
cases:17.10%
controls:2.65%
cases:20.31%
controls:7.12%
122
527
572
6408
96
215
599
6725
83
29
611
6911
44
0
650
6940
80
32
593
6889
92
176
446
6473
65
346
255
4511
Hepatitis C virus Ab [Presence] in Serum
16128-1 [3017143]
1.7e+00
2.6e+00
2.7e+00
—
2.4e+00
2.0e+00
1.2e+00
cases:14.84%
controls:2.94%
cases:11.94%
controls:1.02%
cases:2.45%
controls:0.17%
—
—
cases:1.93%
controls:0.17%
cases:7.06%
controls:1.02%
cases:10.31%
controls:3.34%
103
204
591
6731
83
71
612
6869
17
12
677
6928
—
13
12
660
6909
38
68
500
6581
33
162
287
4695
calcium carbonate; oral
A12AA04 [21600863]
2.0e+00
2.7e+00
2.5e+00
—
—
3.1e+00
2.3e+00
cases:2.45%
controls:0.35%
cases:2.73%
controls:0.19%
cases:0.86%
controls:0.07%
—
—
—
—
cases:4.65%
controls:0.23%
cases:5.31%
controls:0.54%
17
24
677
6911
19
13
676
6927
6
5
688
6935
—
—
25
15
513
6634
17
26
303
4831
calcium carbonate
A02AC01 [21600065]
2.0e+00
2.7e+00
2.5e+00
—
—
3.1e+00
2.3e+00
cases:2.45%
controls:0.35%
cases:2.73%
controls:0.19%
cases:0.86%
controls:0.07%
—
—
—
—
cases:4.65%
controls:0.23%
cases:5.31%
controls:0.54%
17
24
677
6911
19
13
676
6927
6
5
688
6935
—
—
25
15
513
6634
17
26
303
4831
ciclosporin; oral, parenteral
L04AD01 [21603924]
2.4e+00
2.5e+00
1.7e+00
—
2.3e+00
2.6e+00
2.7e+00
cases:4.90%
controls:0.46%
cases:4.60%
controls:0.39%
cases:0.86%
controls:0.16%
—
—
cases:1.04%
controls:0.10%
cases:4.83%
controls:0.38%
cases:6.25%
controls:0.45%
34
32
660
6903
32
27
663
6913
6
11
688
6929
—
7
7
666
6914
26
25
512
6624
20
22
300
4835
Demanding antibody therapy of methastized malignancy
WD415 [2001310689]
2.7e+00
3.7e+00
—
—
—
3.8e+00
2.3e+00
cases:3.89%
controls:0.26%
cases:4.03%
controls:0.10%
—
—
—
—
—
—
cases:4.46%
controls:0.11%
cases:1.56%
controls:0.16%
27
18
667
6917
28
7
667
6933
—
—
—
24
7
514
6642
5
8
315
4849
Legionella pneumophila DNA [Presence] in Specimen by NAA with probe detection
21363-7 [3020565]
2.6e+00
3.7e+00
1.0e+50
1.0e+50
—
3.8e+00
2.4e+00
cases:4.76%
controls:0.37%
cases:7.77%
controls:0.20%
cases:11.82%
controls:0.00%
cases:7.78%
controls:0.00%
—
—
cases:7.99%
controls:0.20%
cases:6.88%
controls:0.66%
33
26
661
6909
54
14
641
6926
82
0
612
6940
54
0
640
6940
—
43
13
495
6636
22
32
298
4825
Hepatitis B virus surface Ag [Presence] in Serum
5195-3 [3019284]
1.7e+00
2.5e+00
2.5e+00
—
2.8e+00
2.1e+00
1.0e+00
cases:14.84%
controls:3.06%
cases:13.24%
controls:1.21%
cases:2.31%
controls:0.20%
—
—
cases:2.67%
controls:0.17%
cases:7.99%
controls:1.10%
cases:10.31%
controls:4.04%
103
212
591
6723
92
84
603
6856
16
14
678
6926
—
18
12
655
6909
43
73
495
6576
33
196
287
4661
Oxygen [Partial pressure] in Blood
11556-8 [3027315]
1.5e+00
2.1e+00
—
1.0e+50
4.3e+00
2.8e+00
1.8e+00
cases:4.03%
controls:0.89%
cases:2.45%
controls:0.32%
—
—
cases:2.31%
controls:0.00%
cases:5.05%
controls:0.07%
cases:3.53%
controls:0.23%
cases:2.81%
controls:0.47%
28
62
666
6873
17
22
678
6918
—
16
0
678
6940
34
5
639
6916
19
15
519
6634
9
23
311
4834
Base excess in Blood by calculation
11555-0 [3012501]
1.5e+00
2.1e+00
—
1.0e+50
4.3e+00
2.8e+00
1.8e+00
cases:3.89%
controls:0.88%
cases:2.45%
controls:0.32%
—
—
cases:2.31%
controls:0.00%
cases:5.05%
controls:0.07%
cases:3.53%
controls:0.23%
cases:2.81%
controls:0.47%
27
61
667
6874
17
22
678
6918
—
16
0
678
6940
34
5
639
6916
19
15
519
6634
9
23
311
4834
Human metapneumovirus RNA [Presence] in Specimen by NAA with probe detection
38917-1 [3042194]
2.5e+00
3.5e+00
—
1.0e+50
—
3.7e+00
2.8e+00
cases:7.93%
controls:0.74%
cases:9.78%
controls:0.32%
—
—
cases:9.80%
controls:0.00%
—
—
cases:11.52%
controls:0.32%
cases:11.88%
controls:0.84%
55
51
639
6884
68
22
627
6918
—
68
0
626
6940
—
62
21
476
6628
38
41
282
4816
Carbon dioxide [Partial pressure] in Blood
11557-6 [3013290]
1.5e+00
2.1e+00
—
1.0e+50
4.3e+00
2.8e+00
1.8e+00
cases:3.89%
controls:0.89%
cases:2.45%
controls:0.32%
—
—
cases:2.31%
controls:0.00%
cases:5.05%
controls:0.07%
cases:3.53%
controls:0.23%
cases:2.81%
controls:0.47%
27
62
667
6873
17
22
678
6918
—
16
0
678
6940
34
5
639
6916
19
15
519
6634
9
23
311
4834
Cystostatic therapy of methastized malignancy
WD105 [2001310678]
2.6e+00
2.5e+00
2.7e+00
—
1.7e+00
2.8e+00
1.8e+00
cases:6.48%
controls:0.49%
cases:6.19%
controls:0.56%
cases:3.17%
controls:0.22%
—
—
cases:1.04%
controls:0.19%
cases:6.51%
controls:0.41%
cases:3.13%
controls:0.54%
45
34
649
6901
43
39
652
6901
22
15
672
6925
—
7
13
666
6908
35
27
503
6622
10
26
310
4831
Enterovirus RNA [Presence] in Specimen by NAA with probe detection
29591-5 [3016881]
2.5e+00
3.4e+00
1.0e+50
1.0e+50
—
3.8e+00
2.8e+00
cases:3.03%
controls:0.26%
cases:3.02%
controls:0.10%
cases:3.89%
controls:0.00%
cases:2.45%
controls:0.00%
—
—
cases:3.72%
controls:0.09%
cases:4.69%
controls:0.31%
21
18
673
6917
21
7
674
6933
27
0
667
6940
17
0
677
6940
—
20
6
518
6643
15
15
305
4842
nystatin; oral
A07AA02 [21600604]
1.2e+00
2.7e+00
—
—
4.1e+00
3.0e+00
1.5e+00
cases:4.18%
controls:1.33%
cases:4.89%
controls:0.35%
—
—
—
—
cases:4.01%
controls:0.07%
cases:6.51%
controls:0.35%
cases:5.63%
controls:1.34%
29
92
665
6843
34
24
661
6916
—
—
27
5
646
6916
35
23
503
6626
18
65
302
4792
Drug-induced neutropenia
D70.82 [2000501376]
1.9e+00
3.9e+00
—
1.0e+50
—
3.8e+00
2.7e+00
cases:1.30%
controls:0.19%
cases:4.75%
controls:0.10%
—
—
cases:2.31%
controls:0.00%
—
—
cases:3.35%
controls:0.08%
cases:1.56%
controls:0.10%
9
13
685
6922
33
7
662
6933
—
16
0
678
6940
—
18
5
520
6644
5
5
315
4852
Nephrology
39 [38004479]
1.6e+00
1.9e+00
2.4e+00
—
2.3e+00
2.1e+00
2.0e+00
cases:7.64%
controls:1.59%
cases:8.63%
controls:1.35%
cases:5.33%
controls:0.52%
—
—
cases:4.31%
controls:0.45%
cases:10.04%
controls:1.34%
cases:14.06%
controls:2.10%
53
110
641
6825
60
94
635
6846
37
36
657
6904
—
29
31
644
6890
54
89
484
6560
45
102
275
4755
dexamethasone; oral, parenteral
H02AB02 [21602730]
1.3e+00
2.6e+00
3.5e+00
—
2.2e+00
2.0e+00
7.6e-01
cases:12.82%
controls:3.78%
cases:21.87%
controls:2.06%
cases:8.65%
controls:0.27%
—
—
cases:1.93%
controls:0.22%
cases:10.41%
controls:1.59%
cases:9.06%
controls:4.45%
89
262
605
6673
152
143
543
6797
60
19
634
6921
—
13
15
660
6906
56
106
482
6543
29
216
291
4641
Office Visit
OMOP4822458 [581477]
8.5e-01
1.8e+00
2.8e+00
—
3.8e+00
2.0e+00
1.2e+00
cases:19.31%
controls:9.27%
cases:12.09%
controls:2.29%
cases:4.76%
controls:0.30%
—
—
cases:9.06%
controls:0.23%
cases:11.90%
controls:1.80%
cases:11.56%
controls:3.79%
134
643
560
6292
84
159
611
6781
33
21
661
6919
—
61
16
612
6905
64
120
474
6529
37
184
283
4673
Extensive high resolution CT examination of lungs
GD1ED [2001303637]
1.7e+00
3.3e+00
—
1.0e+50
1.0e+50
4.0e+00
3.4e+00
cases:2.74%
controls:0.50%
cases:2.30%
controls:0.09%
—
—
cases:4.32%
controls:0.00%
cases:0.74%
controls:0.00%
cases:3.90%
controls:0.08%
cases:3.44%
controls:0.12%
19
35
675
6900
16
6
679
6934
—
30
0
664
6940
5
0
668
6921
21
5
517
6644
11
6
309
4851
INR in Blood by Coagulation assay
34714-6 [3032080]
8.3e-01
1.4e+00
2.1e+00
3.8e+00
2.2e+00
1.2e+00
7.7e-01
cases:36.60%
controls:20.09%
cases:34.53%
controls:11.87%
cases:24.35%
controls:3.98%
cases:9.22%
controls:0.22%
cases:27.64%
controls:3.90%
cases:30.67%
controls:11.25%
cases:39.38%
controls:23.18%
254
1393
440
5542
240
824
455
6116
169
276
525
6664
64
15
630
6925
186
270
487
6651
165
748
373
5901
126
1126
194
3731
Rhinovirus RNA [Presence] in Specimen by NAA with probe detection
7993-9 [3025023]
2.4e+00
3.4e+00
1.0e+50
1.0e+50
1.0e+50
3.7e+00
2.8e+00
cases:2.88%
controls:0.26%
cases:2.88%
controls:0.10%
cases:3.89%
controls:0.00%
cases:2.45%
controls:0.00%
cases:10.25%
controls:0.00%
cases:3.53%
controls:0.09%
cases:4.69%
controls:0.29%
20
18
674
6917
20
7
675
6933
27
0
667
6940
17
0
677
6940
69
0
604
6921
19
6
519
6643
15
14
305
4843
Other interstitial pulmonary diseases with fibrosis
J84.1 [45557630]
2.6e+00
3.2e+00
—
1.0e+50
—
3.6e+00
2.9e+00
cases:4.03%
controls:0.32%
cases:5.04%
controls:0.22%
—
—
cases:5.33%
controls:0.00%
—
—
cases:6.69%
controls:0.20%
cases:5.94%
controls:0.33%
28
22
666
6913
35
15
660
6925
—
37
0
657
6940
—
36
13
502
6636
19
16
301
4841
Bordetella pertussis DNA [Presence] in Specimen by NAA with probe detection
23826-1 [3012477]
2.5e+00
3.7e+00
1.0e+50
1.0e+50
—
3.8e+00
2.3e+00
cases:4.90%
controls:0.42%
cases:7.77%
controls:0.20%
cases:11.82%
controls:0.00%
cases:8.50%
controls:0.00%
—
—
cases:8.36%
controls:0.21%
cases:8.13%
controls:0.86%
34
29
660
6906
54
14
641
6926
82
0
612
6940
59
0
635
6940
—
45
14
493
6635
26
42
294
4815
Rheumatology
66 [38004491]
1.5e+00
2.1e+00
2.1e+00
—
2.4e+00
2.2e+00
2.1e+00
cases:16.57%
controls:4.43%
cases:17.41%
controls:2.49%
cases:3.89%
controls:0.50%
—
—
cases:4.75%
controls:0.45%
cases:19.14%
controls:2.66%
cases:25.94%
controls:4.20%
115
307
579
6628
121
173
574
6767
27
35
667
6905
—
32
31
641
6890
103
177
435
6472
83
204
237
4653
Bicarbonate [Moles/volume] in Venous blood
14627-4 [3027273]
1.2e+00
2.0e+00
3.8e+00
1.0e+50
3.5e+00
1.8e+00
8.3e-01
cases:4.76%
controls:1.54%
cases:4.89%
controls:0.68%
cases:3.89%
controls:0.09%
cases:2.59%
controls:0.00%
cases:4.01%
controls:0.13%
cases:5.02%
controls:0.90%
cases:5.94%
controls:2.68%
33
107
661
6828
34
47
661
6893
27
6
667
6934
18
0
676
6940
27
9
646
6912
27
60
511
6589
19
130
301
4727
Interstitial pulmonary disease, unspecified
J84.9 [45543277]
2.4e+00
3.1e+00
—
1.0e+50
—
3.4e+00
3.2e+00
cases:4.61%
controls:0.42%
cases:5.61%
controls:0.26%
—
—
cases:4.18%
controls:0.00%
—
—
cases:8.18%
controls:0.29%
cases:7.19%
controls:0.31%
32
29
662
6906
39
18
656
6922
—
29
0
665
6940
—
44
19
494
6630
23
15
297
4842
Paranasal sinuses X-ray examination in one projection
DM1QA [2001301761]
2.6e+00
3.0e+00
1.0e+50
1.0e+50
1.0e+50
3.8e+00
2.8e+00
cases:4.61%
controls:0.36%
cases:2.88%
controls:0.14%
cases:2.02%
controls:0.00%
cases:2.31%
controls:0.00%
cases:0.89%
controls:0.00%
cases:3.72%
controls:0.09%
cases:4.69%
controls:0.29%
32
25
662
6910
20
10
675
6930
14
0
680
6940
16
0
678
6940
6
0
667
6921
20
6
518
6643
15
14
305
4843
Body temperature
8310-5 [3020891]
6.6e-01
1.7e+00
3.7e+00
1.0e+50
4.0e+00
1.7e+00
1.0e+00
cases:3.03%
controls:1.59%
cases:3.45%
controls:0.63%
cases:3.46%
controls:0.09%
cases:3.46%
controls:0.00%
cases:4.46%
controls:0.09%
cases:4.09%
controls:0.77%
cases:6.25%
controls:2.29%
21
110
673
6825
24
44
671
6896
24
6
670
6934
24
0
670
6940
30
6
643
6915
22
51
516
6598
20
111
300
4746
Beta 2 globulin [Mass/volume] in Serum or Plasma by Electrophoresis
32731-2 [3043747]
1.7e+00
2.2e+00
2.9e+00
—
2.5e+00
1.9e+00
9.9e-01
cases:5.76%
controls:1.07%
cases:4.89%
controls:0.58%
cases:1.73%
controls:0.10%
—
—
cases:2.53%
controls:0.20%
cases:3.53%
controls:0.57%
cases:5.00%
controls:1.91%
40
74
654
6861
34
40
661
6900
12
7
682
6933
—
17
14
656
6907
19
38
519
6611
16
93
304
4764
Paranasal sinuses X-ray examination without contrast
DM1AA [2001301740]
2.4e+00
3.4e+00
1.0e+50
1.0e+50
—
3.6e+00
2.7e+00
cases:3.31%
controls:0.30%
cases:2.59%
controls:0.09%
cases:1.44%
controls:0.00%
cases:1.59%
controls:0.00%
—
—
cases:2.60%
controls:0.08%
cases:3.13%
controls:0.21%
23
21
671
6914
18
6
677
6934
10
0
684
6940
11
0
683
6940
—
14
5
524
6644
10
10
310
4847
Beta 1 globulin [Mass/volume] in Serum or Plasma by Electrophoresis
32730-4 [3043723]
1.7e+00
2.2e+00
2.9e+00
—
2.5e+00
1.9e+00
9.9e-01
cases:5.76%
controls:1.07%
cases:4.89%
controls:0.59%
cases:1.73%
controls:0.10%
—
—
cases:2.53%
controls:0.20%
cases:3.53%
controls:0.57%
cases:5.00%
controls:1.91%
40
74
654
6861
34
41
661
6899
12
7
682
6933
—
17
14
656
6907
19
38
519
6611
16
93
304
4764
Alpha 2 globulin [Mass/volume] in Serum or Plasma by Electrophoresis
2868-8 [3005229]
1.7e+00
2.2e+00
2.9e+00
—
2.5e+00
1.9e+00
9.9e-01
cases:5.76%
controls:1.07%
cases:4.89%
controls:0.59%
cases:1.73%
controls:0.10%
—
—
cases:2.53%
controls:0.20%
cases:3.53%
controls:0.57%
cases:5.00%
controls:1.91%
40
74
654
6861
34
41
661
6899
12
7
682
6933
—
17
14
656
6907
19
38
519
6611
16
93
304
4764
metoclopramide; oral, parenteral, rectal
A03FA01 [21600484]
1.5e+00
2.9e+00
2.3e+00
—
2.6e+00
1.8e+00
1.0e+00
cases:16.43%
controls:4.11%
cases:23.17%
controls:1.70%
cases:3.75%
controls:0.37%
—
—
cases:2.67%
controls:0.20%
cases:8.55%
controls:1.52%
cases:9.69%
controls:3.79%
114
285
580
6650
161
118
534
6822
26
26
668
6914
—
18
14
655
6907
46
101
492
6548
31
184
289
4673
Adenovirus DNA [Identifier] in Specimen by NAA with probe detection
40976-3 [3040853]
2.5e+00
3.5e+00
—
1.0e+50
—
3.6e+00
2.6e+00
cases:7.78%
controls:0.69%
cases:9.50%
controls:0.33%
—
—
cases:9.94%
controls:0.00%
—
—
cases:11.34%
controls:0.35%
cases:12.19%
controls:1.05%
54
48
640
6887
66
23
629
6917
—
69
0
625
6940
—
61
23
477
6626
39
51
281
4806
Kidney transplant status
Z94.0 [45566477]
3.1e+00
2.9e+00
—
1.0e+50
—
3.1e+00
3.0e+00
cases:3.46%
controls:0.16%
cases:3.31%
controls:0.19%
—
—
cases:2.45%
controls:0.00%
—
—
cases:3.72%
controls:0.18%
cases:5.63%
controls:0.29%
24
11
670
6924
23
13
672
6927
—
17
0
677
6940
—
20
12
518
6637
18
14
302
4843
Chloride [Moles/volume] in Serum or Plasma
2075-0 [3014576]
7.2e-01
1.6e+00
3.5e+00
—
3.3e+00
1.9e+00
1.1e+00
cases:8.21%
controls:4.17%
cases:9.64%
controls:2.13%
cases:7.64%
controls:0.24%
—
—
cases:8.92%
controls:0.38%
cases:12.45%
controls:2.15%
cases:17.19%
controls:6.71%
57
289
637
6646
67
148
628
6792
53
17
641
6923
—
60
26
613
6895
67
143
471
6506
55
326
265
4531
Mycoplasma pneumoniae DNA [Presence] in Specimen by NAA with probe detection
29257-3 [3002482]
2.5e+00
3.4e+00
—
1.0e+50
—
3.6e+00
2.5e+00
cases:5.91%
controls:0.49%
cases:8.20%
controls:0.29%
—
—
cases:9.51%
controls:0.00%
—
—
cases:10.41%
controls:0.33%
cases:10.63%
controls:0.99%
41
34
653
6901
57
20
638
6920
—
66
0
628
6940
—
56
22
482
6627
34
48
286
4809
Bacteria identified in Sputum by Culture
6460-0 [3023419]
2.4e+00
3.0e+00
—
1.0e+50
1.0e+50
4.0e+00
2.6e+00
cases:3.60%
controls:0.35%
cases:3.88%
controls:0.20%
—
—
cases:0.72%
controls:0.00%
cases:9.96%
controls:0.00%
cases:5.39%
controls:0.11%
cases:7.81%
controls:0.60%
25
24
669
6911
27
14
668
6926
—
5
0
689
6940
67
0
606
6921
29
7
509
6642
25
29
295
4828
Bone marrow Pathology biopsy report
33721-2 [3045142]
2.4e+00
4.0e+00
1.0e+50
—
1.0e+50
3.5e+00
2.2e+00
cases:4.61%
controls:0.45%
cases:5.04%
controls:0.10%
cases:1.01%
controls:0.00%
—
—
cases:0.89%
controls:0.00%
cases:2.79%
controls:0.09%
cases:3.75%
controls:0.43%
32
31
662
6904
35
7
660
6933
7
0
687
6940
—
6
0
667
6921
15
6
523
6643
12
21
308
4836
Alpha 1 globulin [Mass/volume] in Serum or Plasma by Electrophoresis
2865-4 [3015322]
1.6e+00
2.1e+00
2.9e+00
—
2.6e+00
1.8e+00
1.0e+00
cases:4.90%
controls:1.01%
cases:4.32%
controls:0.58%
cases:1.73%
controls:0.10%
—
—
cases:2.53%
controls:0.19%
cases:3.16%
controls:0.56%
cases:4.69%
controls:1.71%
34
70
660
6865
30
40
665
6900
12
7
682
6933
—
17
13
656
6908
17
37
521
6612
15
83
305
4774
Chlamydophila pneumoniae DNA [Presence] in Specimen by NAA with probe detection
34645-2 [3031478]
2.4e+00
3.4e+00
—
1.0e+50
1.0e+50
3.5e+00
2.6e+00
cases:4.18%
controls:0.37%
cases:6.91%
controls:0.24%
—
—
cases:8.93%
controls:0.00%
cases:28.53%
controls:0.00%
cases:8.92%
controls:0.30%
cases:10.00%
controls:0.82%
29
26
665
6909
48
17
647
6923
—
62
0
632
6940
192
0
481
6921
48
20
490
6629
32
40
288
4817
Morphology [Interpretation] in Bone marrow Narrative
51628-6 [3042111]
2.5e+00
3.8e+00
—
—
—
3.4e+00
2.2e+00
cases:7.78%
controls:0.66%
cases:6.62%
controls:0.16%
—
—
—
—
—
—
cases:4.28%
controls:0.15%
cases:5.31%
controls:0.62%
54
46
640
6889
46
11
649
6929
—
—
—
23
10
515
6639
17
30
303
4827
Parainfluenza type 2 nucleic acid detection
222351000000102 [44790048]
2.4e+00
3.5e+00
—
1.0e+50
—
3.4e+00
2.6e+00
cases:3.89%
controls:0.37%
cases:5.47%
controls:0.17%
—
—
cases:4.76%
controls:0.00%
—
—
cases:6.13%
controls:0.21%
cases:6.56%
controls:0.51%
27
26
667
6909
38
12
657
6928
—
33
0
661
6940
—
33
14
505
6635
21
25
299
4832
Parainfluenza type 4 nucleic acid detection
810871000000102 [44806118]
2.4e+00
3.5e+00
—
1.0e+50
—
3.4e+00
2.6e+00
cases:3.89%
controls:0.37%
cases:5.47%
controls:0.17%
—
—
cases:4.76%
controls:0.00%
—
—
cases:6.13%
controls:0.21%
cases:6.56%
controls:0.51%
27
26
667
6909
38
12
657
6928
—
33
0
661
6940
—
33
14
505
6635
21
25
299
4832
Parainfluenza type 3 nucleic acid detection
222361000000104 [44790049]
2.4e+00
3.5e+00
—
1.0e+50
—
3.4e+00
2.6e+00
cases:3.89%
controls:0.37%
cases:5.47%
controls:0.17%
—
—
cases:4.76%
controls:0.00%
—
—
cases:6.13%
controls:0.21%
cases:6.56%
controls:0.51%
27
26
667
6909
38
12
657
6928
—
33
0
661
6940
—
33
14
505
6635
21
25
299
4832
Parainfluenza type 1 nucleic acid detection
222341000000100 [44790047]
2.4e+00
3.5e+00
—
1.0e+50
—
3.4e+00
2.6e+00
cases:3.89%
controls:0.37%
cases:5.47%
controls:0.17%
—
—
cases:4.76%
controls:0.00%
—
—
cases:6.13%
controls:0.21%
cases:6.56%
controls:0.51%
27
26
667
6909
38
12
657
6928
—
33
0
661
6940
—
33
14
505
6635
21
25
299
4832
Hemoglobin [Mass/volume] in Venous blood
30350-3 [3004119]
9.9e-01
1.7e+00
3.6e+00
1.0e+50
2.9e+00
1.8e+00
9.2e-01
cases:5.19%
controls:1.99%
cases:4.17%
controls:0.82%
cases:3.60%
controls:0.10%
cases:2.74%
controls:0.00%
cases:3.71%
controls:0.22%
cases:6.13%
controls:1.04%
cases:8.44%
controls:3.54%
36
138
658
6797
29
57
666
6883
25
7
669
6933
19
0
675
6940
25
15
648
6906
33
69
505
6580
27
172
293
4685
Emergency Room and Inpatient Visit
ERIP [262]
9.0e-01
1.9e+00
3.7e+00
—
3.1e+00
1.5e+00
6.9e-01
cases:20.17%
controls:9.32%
cases:26.33%
controls:4.90%
cases:22.05%
controls:0.71%
—
—
cases:14.71%
controls:0.78%
cases:23.05%
controls:6.05%
cases:32.19%
controls:19.21%
140
646
554
6289
183
340
512
6600
153
49
541
6891
—
99
54
574
6867
124
402
414
6247
103
933
217
3924
pH of Capillary blood
2745-8 [3009343]
1.4e+00
1.6e+00
2.6e+00
—
4.8e+00
1.4e+00
7.2e-01
cases:6.77%
controls:1.82%
cases:4.46%
controls:0.94%
cases:2.74%
controls:0.20%
—
—
cases:8.02%
controls:0.07%
cases:3.90%
controls:0.98%
cases:6.25%
controls:3.15%
47
126
647
6809
31
65
664
6875
19
14
675
6926
—
54
5
619
6916
21
65
517
6584
20
153
300
4704
Bacteria identified in Skin by Aerobe culture
620-5 [3007853]
1.1e+00
1.3e+00
3.0e+00
—
3.2e+00
1.9e+00
1.3e+00
cases:9.51%
controls:3.30%
cases:5.04%
controls:1.38%
cases:2.45%
controls:0.13%
—
—
cases:2.67%
controls:0.12%
cases:7.06%
controls:1.08%
cases:11.56%
controls:3.58%
66
229
628
6706
35
96
660
6844
17
9
677
6931
—
18
8
655
6913
38
72
500
6577
37
174
283
4683
Carbon dioxide [Partial pressure] in Capillary blood
2020-6 [3023024]
1.4e+00
1.5e+00
2.7e+00
—
4.8e+00
1.4e+00
7.4e-01
cases:6.77%
controls:1.82%
cases:4.46%
controls:1.01%
cases:2.88%
controls:0.20%
—
—
cases:8.32%
controls:0.07%
cases:3.90%
controls:1.02%
cases:6.56%
controls:3.23%
47
126
647
6809
31
70
664
6870
20
14
674
6926
—
56
5
617
6916
21
68
517
6581
21
157
299
4700
Outpatient Visit
OP [9202]
5.9e-01
1.3e+00
1.7e+00
3.8e+00
1.4e+00
1.6e+00
1.5e+00
cases:90.92%
controls:84.69%
cases:87.48%
controls:66.25%
cases:44.67%
controls:13.17%
cases:19.45%
controls:0.55%
cases:38.19%
controls:13.70%
cases:89.03%
controls:63.23%
cases:97.19%
controls:88.20%
631
5873
63
1062
608
4598
87
2342
310
914
384
6026
135
38
559
6902
257
948
416
5973
479
4204
59
2445
311
4284
9
573
Inpatient Hospital
21 [8717]
7.3e-01
1.9e+00
3.0e+00
1.0e+50
3.0e+00
1.9e+00
1.1e+00
cases:47.12%
controls:29.96%
cases:40.86%
controls:8.96%
cases:20.75%
controls:1.30%
cases:38.90%
controls:0.00%
cases:19.91%
controls:1.21%
cases:32.71%
controls:6.92%
cases:35.63%
controls:14.95%
327
2078
367
4857
284
622
411
6318
144
90
550
6850
270
0
424
6940
134
84
539
6837
176
460
362
6189
114
726
206
4131
Short blood count panel - Blood
55429-5 [40758558]
9.9e-01
1.8e+00
2.9e+00
—
3.1e+00
1.8e+00
1.0e+00
cases:21.76%
controls:9.34%
cases:24.60%
controls:4.94%
cases:18.30%
controls:1.18%
—
—
cases:19.76%
controls:1.11%
cases:25.09%
controls:5.13%
cases:28.13%
controls:12.21%
151
648
543
6287
171
343
524
6597
127
82
567
6858
—
133
77
540
6844
135
341
403
6308
90
593
230
4264
tacrolimus; oral, parenteral
L04AD02 [21603925]
3.1e+00
2.9e+00
2.3e+00
—
—
2.9e+00
2.8e+00
cases:2.59%
controls:0.12%
cases:2.45%
controls:0.14%
cases:0.72%
controls:0.07%
—
—
—
—
cases:2.79%
controls:0.15%
cases:3.75%
controls:0.25%
18
8
676
6927
17
10
678
6930
5
5
689
6935
—
—
15
10
523
6639
12
12
308
4845
Flexible bronchoscopy
UGC12 [2001303610]
1.9e+00
4.0e+00
—
1.0e+50
—
3.3e+00
2.5e+00
cases:7.35%
controls:1.12%
cases:7.91%
controls:0.16%
—
—
cases:20.75%
controls:0.00%
—
—
cases:6.32%
controls:0.26%
cases:7.50%
controls:0.68%
51
78
643
6857
55
11
640
6929
—
144
0
550
6940
—
34
17
504
6632
24
33
296
4824
CBC panel - Blood by Automated count
58410-2 [40761511]
2.7e-01
8.2e-01
2.3e+00
4.7e+00
2.7e+00
8.9e-01
4.0e-01
cases:61.10%
controls:54.49%
cases:56.83%
controls:36.82%
cases:44.24%
controls:7.20%
cases:28.82%
controls:0.37%
cases:51.11%
controls:6.65%
cases:56.88%
controls:35.13%
cases:68.75%
controls:59.69%
424
3779
270
3156
395
2555
300
4385
307
500
387
6440
200
26
494
6914
344
460
329
6461
306
2336
232
4313
220
2899
100
1958
Oxygen [Partial pressure] in Venous blood
2705-2 [3024354]
1.0e+00
1.6e+00
3.3e+00
1.0e+50
3.0e+00
1.8e+00
9.9e-01
cases:6.20%
controls:2.35%
cases:5.18%
controls:1.10%
cases:4.32%
controls:0.17%
cases:4.32%
controls:0.00%
cases:4.75%
controls:0.25%
cases:7.43%
controls:1.31%
cases:11.56%
controls:4.63%
43
163
651
6772
36
76
659
6864
30
12
664
6928
30
0
664
6940
32
17
641
6904
40
87
498
6562
37
225
283
4632
Oxygen [Partial pressure] adjusted to patient's actual temperature in Venous blood
19258-3 [3004529]
1.1e+00
1.8e+00
3.8e+00
1.0e+50
3.3e+00
1.7e+00
7.5e-01
cases:3.75%
controls:1.30%
cases:3.74%
controls:0.62%
cases:3.60%
controls:0.09%
cases:3.03%
controls:0.00%
cases:3.27%
controls:0.13%
cases:5.02%
controls:0.93%
cases:6.88%
controls:3.38%
26
90
668
6845
26
43
669
6897
25
6
669
6934
21
0
673
6940
22
9
651
6912
27
62
511
6587
22
164
298
4693
Carboxyhemoglobin/Hemoglobin.total in Arterial blood
2030-5 [3028653]
6.4e-01
1.6e+00
3.5e+00
—
3.7e+00
1.6e+00
1.2e+00
cases:3.46%
controls:1.86%
cases:3.74%
controls:0.78%
cases:2.88%
controls:0.09%
—
—
cases:4.01%
controls:0.10%
cases:4.28%
controls:0.89%
cases:8.13%
controls:2.68%
24
129
670
6806
26
54
669
6886
20
6
674
6934
—
27
7
646
6914
23
59
515
6590
26
130
294
4727
Mycobacterium sp identified in Specimen by Organism specific culture
543-9 [3005702]
1.9e+00
3.3e+00
—
1.0e+50
—
3.5e+00
3.0e+00
cases:6.05%
controls:0.94%
cases:5.47%
controls:0.22%
—
—
cases:1.59%
controls:0.00%
—
—
cases:6.69%
controls:0.23%
cases:9.38%
controls:0.54%
42
65
652
6870
38
15
657
6925
—
11
0
683
6940
—
36
15
502
6634
30
26
290
4831
Abdominal ultrasound examination
JN3AE [2001305555]
1.7e+00
2.6e+00
3.1e+00
1.0e+50
—
2.2e+00
2.0e+00
cases:10.37%
controls:2.06%
cases:6.47%
controls:0.52%
cases:1.87%
controls:0.09%
cases:1.87%
controls:0.00%
—
—
cases:4.09%
controls:0.47%
cases:9.69%
controls:1.46%
72
143
622
6792
45
36
650
6904
13
6
681
6934
13
0
681
6940
—
22
31
516
6618
31
71
289
4786
Epithelial cells [#/volume] in Urine
30383-4 [3000850]
9.0e-01
1.6e+00
3.2e+00
1.0e+50
2.8e+00
1.9e+00
1.1e+00
cases:17.00%
controls:7.66%
cases:15.25%
controls:3.49%
cases:11.96%
controls:0.55%
cases:5.91%
controls:0.00%
cases:8.62%
controls:0.58%
cases:18.03%
controls:3.16%
cases:23.13%
controls:8.71%
118
531
576
6404
106
242
589
6698
83
38
611
6902
41
0
653
6940
58
40
615
6881
97
210
441
6439
74
423
246
4434
Bacteria [Presence] in Urine
87829-8 [36304419]
8.5e-01
1.6e+00
3.2e+00
—
3.0e+00
1.8e+00
1.1e+00
cases:19.60%
controls:9.44%
cases:19.86%
controls:4.58%
cases:16.14%
controls:0.78%
—
—
cases:12.48%
controls:0.69%
cases:21.93%
controls:4.50%
cases:29.38%
controls:12.54%
136
655
558
6280
138
318
557
6622
112
54
582
6886
—
84
48
589
6873
118
299
420
6350
94
609
226
4248
Influenza virus A and B and SARS-CoV-2 (COVID-19) and Respiratory syncytial virus RNA panel - Respiratory system specimen by NAA with probe detection
95941-1 [36031861]
9.9e-01
1.9e+00
4.1e+00
1.0e+50
3.1e+00
1.5e+00
5.3e-01
cases:2.45%
controls:0.92%
cases:4.89%
controls:0.75%
cases:4.76%
controls:0.09%
cases:5.76%
controls:0.00%
cases:2.53%
controls:0.12%
cases:3.35%
controls:0.78%
cases:5.63%
controls:3.40%
17
64
677
6871
34
52
661
6888
33
6
661
6934
40
0
654
6940
17
8
656
6913
18
52
520
6597
18
165
302
4692
ANTIHYPERTENSIVE_DRUG - yes
ANTIHYPERTENSIVE_DRUG-1 [2002330215]
2.5e+00
2.7e+00
—
—
—
3.1e+00
3.2e+00
cases:4.03%
controls:0.33%
cases:3.88%
controls:0.27%
—
—
—
—
—
—
cases:4.65%
controls:0.21%
cases:6.56%
controls:0.29%
28
23
666
6912
27
19
668
6921
—
—
—
25
14
513
6635
21
14
299
4843
Blood transfusion
WW500 [2001310603]
2.4e+00
3.4e+00
—
1.0e+50
—
3.9e+00
1.9e+00
cases:4.47%
controls:0.43%
cases:6.91%
controls:0.26%
—
—
cases:4.18%
controls:0.00%
—
—
cases:7.43%
controls:0.17%
cases:3.13%
controls:0.47%
31
30
663
6905
48
18
647
6922
—
29
0
665
6940
—
40
11
498
6638
10
23
310
4834
Supplier / Service Provider
OMOP5117446 [33004]
-1.3e-02
8.6e-01
1.0e+00
—
3.9e+00
3.0e+00
2.7e+00
cases:30.69%
controls:30.97%
cases:18.85%
controls:8.96%
cases:2.88%
controls:1.07%
—
—
cases:4.16%
controls:0.09%
cases:16.54%
controls:0.98%
cases:26.25%
controls:2.29%
213
2148
481
4787
131
622
564
6318
20
74
674
6866
—
28
6
645
6915
89
65
449
6584
84
111
236
4746
Methemoglobin/Hemoglobin.total in Arterial blood
2615-3 [3006217]
6.4e-01
1.6e+00
3.5e+00
—
3.7e+00
1.6e+00
1.1e+00
cases:3.46%
controls:1.86%
cases:3.74%
controls:0.76%
cases:2.74%
controls:0.09%
—
—
cases:3.86%
controls:0.10%
cases:3.90%
controls:0.83%
cases:7.19%
controls:2.43%
24
129
670
6806
26
53
669
6887
19
6
675
6934
—
26
7
647
6914
21
55
517
6594
23
118
297
4739
Myeloperoxidase IgG Ab [Units/volume] in Serum
48404-8 [3049804]
9.9e-01
2.7e+00
—
—
3.6e+00
2.6e+00
1.5e+00
cases:2.59%
controls:0.98%
cases:3.17%
controls:0.22%
—
—
—
—
cases:2.67%
controls:0.07%
cases:2.23%
controls:0.17%
cases:3.44%
controls:0.76%
18
68
676
6867
22
15
673
6925
—
—
18
5
655
6916
12
11
526
6638
11
37
309
4820
Urinalysis microscopic panel [#/volume] - Urine by Automated count
50554-5 [3029287]
8.2e-01
1.6e+00
3.3e+00
—
3.0e+00
1.7e+00
9.5e-01
cases:26.37%
controls:13.60%
cases:25.90%
controls:6.30%
cases:20.46%
controls:0.91%
—
—
cases:15.75%
controls:0.95%
cases:28.25%
controls:6.42%
cases:35.63%
controls:17.67%
183
943
511
5992
180
437
515
6503
142
63
552
6877
—
106
66
567
6855
152
427
386
6222
114
858
206
3999
Lactate [Moles/volume] in Serum or Plasma
2524-7 [3014111]
8.4e-01
1.6e+00
2.8e+00
—
3.3e+00
1.8e+00
1.0e+00
cases:5.76%
controls:2.57%
cases:5.04%
controls:1.08%
cases:3.17%
controls:0.20%
—
—
cases:5.05%
controls:0.19%
cases:6.32%
controls:1.05%
cases:10.00%
controls:3.79%
40
178
654
6757
35
75
660
6865
22
14
672
6926
—
34
13
639
6908
34
70
504
6579
32
184
288
4673
Other chronic renal failure
N18.8 [45534123]
1.5e+00
1.5e+00
2.7e+00
—
2.1e+00
2.0e+00
1.7e+00
cases:2.45%
controls:0.58%
cases:1.44%
controls:0.33%
cases:1.30%
controls:0.09%
—
—
cases:1.04%
controls:0.13%
cases:2.04%
controls:0.29%
cases:2.50%
controls:0.47%
17
40
677
6895
10
23
685
6917
9
6
685
6934
—
7
9
666
6912
11
19
527
6630
8
23
312
4834
Albumin [Mass/volume] in Serum or Plasma
1751-7 [3024561]
1.0e+00
1.8e+00
2.7e+00
—
3.0e+00
1.8e+00
1.1e+00
cases:35.30%
controls:16.47%
cases:37.12%
controls:9.11%
cases:18.88%
controls:1.53%
—
—
cases:24.37%
controls:1.55%
cases:37.73%
controls:9.29%
cases:45.63%
controls:21.62%
245
1142
449
5793
258
632
437
6308
131
106
563
6834
—
164
107
509
6814
203
618
335
6031
146
1050
174
3807
CICLOSPORIN - yes
CICLOSPORIN-1 [2002330221]
2.7e+00
2.9e+00
—
—
—
2.9e+00
2.9e+00
cases:1.73%
controls:0.12%
cases:1.58%
controls:0.09%
—
—
—
—
—
—
cases:1.30%
controls:0.08%
cases:2.19%
controls:0.12%
12
8
682
6927
11
6
684
6934
—
—
—
7
5
531
6644
7
6
313
4851
Casts [#/volume] in Urine by Automated count
51483-6 [3030467]
8.3e-01
1.6e+00
3.2e+00
—
3.0e+00
1.7e+00
1.1e+00
cases:20.03%
controls:9.88%
cases:21.01%
controls:5.04%
cases:16.43%
controls:0.79%
—
—
cases:12.78%
controls:0.74%
cases:22.49%
controls:5.13%
cases:31.56%
controls:13.63%
139
685
555
6250
146
350
549
6590
114
55
580
6885
—
86
51
587
6870
121
341
417
6308
101
662
219
4195
Calcium [Moles/volume] in Serum or Plasma
2000-8 [3015377]
9.7e-01
1.7e+00
2.9e+00
—
3.0e+00
1.7e+00
1.0e+00
cases:25.07%
controls:11.22%
cases:23.45%
controls:5.10%
cases:12.54%
controls:0.82%
—
—
cases:13.82%
controls:0.78%
cases:24.16%
controls:5.49%
cases:30.63%
controls:13.90%
174
778
520
6157
163
354
532
6586
87
57
607
6883
—
93
54
580
6867
130
365
408
6284
98
675
222
4182
Kappa light chains/Lambda light chains [Mass Ratio] in Serum
15189-4 [3007778]
1.7e+00
2.8e+00
—
—
2.9e+00
2.5e+00
1.4e+00
cases:5.19%
controls:0.99%
cases:5.76%
controls:0.37%
—
—
—
—
cases:2.38%
controls:0.13%
cases:5.20%
controls:0.47%
cases:5.00%
controls:1.30%
36
69
658
6866
40
26
655
6914
—
—
16
9
657
6912
28
31
510
6618
16
63
304
4794
azathioprine; oral, parenteral
L04AX01 [21603927]
2.1e+00
2.3e+00
2.2e+00
—
1.2e+00
2.1e+00
2.5e+00
cases:5.33%
controls:0.68%
cases:5.32%
controls:0.55%
cases:1.87%
controls:0.20%
—
—
cases:0.74%
controls:0.22%
cases:4.09%
controls:0.54%
cases:7.50%
controls:0.66%
37
47
657
6888
37
38
658
6902
13
14
681
6926
—
5
15
668
6906
22
36
516
6613
24
32
296
4825
Urate [Moles/volume] in Serum or Plasma
14933-6 [3026493]
1.0e+00
1.9e+00
2.8e+00
—
2.7e+00
1.7e+00
1.1e+00
cases:24.35%
controls:10.34%
cases:23.60%
controls:4.25%
cases:7.64%
controls:0.52%
—
—
cases:7.13%
controls:0.51%
cases:19.14%
controls:4.35%
cases:27.19%
controls:10.87%
169
717
525
6218
164
295
531
6645
53
36
641
6904
—
48
35
625
6886
103
289
435
6360
87
528
233
4329
Gamma globulin [Mass/volume] in Serum or Plasma by Electrophoresis
2874-6 [3023465]
1.7e+00
2.3e+00
2.7e+00
—
2.6e+00
1.8e+00
9.7e-01
cases:5.19%
controls:1.04%
cases:4.32%
controls:0.43%
cases:1.30%
controls:0.09%
—
—
cases:2.08%
controls:0.16%
cases:2.97%
controls:0.50%
cases:4.06%
controls:1.59%
36
72
658
6863
30
30
665
6910
9
6
685
6934
—
14
11
659
6910
16
33
522
6616
13
77
307
4780
Outpatient Hospital
22 [8756]
6.8e-01
1.8e+00
2.8e+00
—
2.9e+00
1.8e+00
1.1e+00
cases:41.79%
controls:26.72%
cases:30.65%
controls:6.97%
cases:14.27%
controls:0.97%
—
—
cases:11.00%
controls:0.69%
cases:24.16%
controls:4.95%
cases:27.50%
controls:10.81%
290
1853
404
5082
213
484
482
6456
99
67
595
6873
—
74
48
599
6873
130
329
408
6320
88
525
232
4332
tinzaparin; parenteral
B01AB10 [21600981]
1.3e+00
1.8e+00
2.7e+00
—
2.1e+00
2.2e+00
9.1e-01
cases:5.48%
controls:1.63%
cases:5.18%
controls:0.88%
cases:3.03%
controls:0.22%
—
—
cases:1.34%
controls:0.16%
cases:6.88%
controls:0.78%
cases:6.56%
controls:2.76%
38
113
656
6822
36
61
659
6879
21
15
673
6925
—
9
11
664
6910
37
52
501
6597
21
134
299
4723
Transferrin [Mass/volume] in Serum or Plasma
3034-6 [3004789]
1.3e+00
1.8e+00
2.4e+00
—
2.5e+00
1.8e+00
1.2e+00
cases:13.69%
controls:4.30%
cases:13.81%
controls:2.46%
cases:4.03%
controls:0.37%
—
—
cases:5.05%
controls:0.43%
cases:15.24%
controls:2.81%
cases:21.88%
controls:8.11%
95
298
599
6637
96
171
599
6769
28
26
666
6914
—
34
30
639
6891
82
187
456
6462
70
394
250
4463
Iron/Transferrin [Ratio] in Serum or Plasma
60517-0 [40763571]
1.3e+00
1.8e+00
2.5e+00
—
2.4e+00
1.8e+00
1.2e+00
cases:13.26%
controls:4.18%
cases:13.24%
controls:2.38%
cases:3.89%
controls:0.35%
—
—
cases:4.46%
controls:0.40%
cases:14.13%
controls:2.66%
cases:21.88%
controls:7.60%
92
290
602
6645
92
165
603
6775
27
24
667
6916
—
30
28
643
6893
76
177
462
6472
70
369
250
4488
IgG subclass 4 [Mass/volume] in Serum
2469-5 [3024980]
1.7e+00
3.2e+00
—
—
—
3.3e+00
2.7e+00
cases:2.74%
controls:0.49%
cases:1.73%
controls:0.07%
—
—
—
—
—
—
cases:3.72%
controls:0.14%
cases:5.63%
controls:0.39%
19
34
675
6901
12
5
683
6935
—
—
—
20
9
518
6640
18
19
302
4838
Erythrocytes [#/volume] in Urine
30391-7 [3002582]
8.2e-01
1.6e+00
3.2e+00
—
2.8e+00
1.7e+00
8.8e-01
cases:22.33%
controls:11.23%
cases:22.59%
controls:5.79%
cases:18.16%
controls:0.91%
—
—
cases:13.97%
controls:0.95%
cases:26.02%
controls:5.91%
cases:31.88%
controls:16.24%
155
779
539
6156
157
402
538
6538
126
63
568
6877
—
94
66
579
6855
140
393
398
6256
102
789
218
4068
Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI)/1.73 sq M
62238-1 [40764999]
7.3e-02
7.0e-01
2.4e+00
4.7e+00
2.4e+00
7.9e-01
3.4e-01
cases:46.11%
controls:44.30%
cases:56.12%
controls:38.90%
cases:50.58%
controls:8.69%
cases:39.34%
controls:0.61%
cases:52.01%
controls:8.64%
cases:60.22%
controls:40.68%
cases:70.31%
controls:62.88%
320
3072
374
3863
390
2700
305
4240
351
603
343
6337
273
42
421
6898
350
598
323
6323
324
2705
214
3944
225
3054
95
1803
Myeloperoxidase Ab [Units/volume] in Serum
6969-0 [3023150]
2.1e+00
3.4e+00
—
—
—
3.4e+00
2.1e+00
cases:3.60%
controls:0.46%
cases:3.31%
controls:0.12%
—
—
—
—
—
—
cases:3.16%
controls:0.11%
cases:3.75%
controls:0.49%
25
32
669
6903
23
8
672
6932
—
—
—
17
7
521
6642
12
24
308
4833
Laboratory Visit
OMOP4822461 [32036]
1.3e-01
6.9e-01
2.4e+00
4.8e+00
2.4e+00
6.5e-01
-1.4e-02
cases:71.90%
controls:69.16%
cases:78.71%
controls:64.88%
cases:74.93%
controls:21.57%
cases:64.27%
controls:1.44%
cases:74.44%
controls:21.14%
cases:79.00%
controls:66.28%
cases:82.19%
controls:82.40%
499
4796
195
2139
547
4503
148
2437
520
1497
174
5443
446
100
248
6840
501
1463
172
5458
425
4407
113
2242
263
4002
57
855
Streptococcus pneumoniae Ag [Presence] in Urine
24027-5 [3011363]
3.1e+00
2.9e+00
1.0e+50
1.0e+50
1.0e+50
2.9e+00
2.1e+00
cases:2.74%
controls:0.13%
cases:1.73%
controls:0.10%
cases:2.88%
controls:0.00%
cases:1.15%
controls:0.00%
cases:3.86%
controls:0.00%
cases:1.30%
controls:0.08%
cases:3.13%
controls:0.39%
19
9
675
6926
12
7
683
6933
20
0
674
6940
8
0
686
6940
26
0
647
6921
7
5
531
6644
10
19
310
4838
Treatment plan or consultation
WZC00 [2001310885]
1.0e+00
2.0e+00
2.6e+00
—
2.4e+00
2.0e+00
8.2e-01
cases:21.18%
controls:8.72%
cases:20.43%
controls:3.33%
cases:4.76%
controls:0.36%
—
—
cases:3.86%
controls:0.36%
cases:17.84%
controls:2.92%
cases:18.13%
controls:8.89%
147
605
547
6330
142
231
553
6709
33
25
661
6915
—
26
25
647
6896
96
194
442
6455
58
432
262
4425
Mycobacterium sp identified in Specimen
40699-1 [3042631]
1.9e+00
2.9e+00
1.0e+50
1.0e+50
—
3.4e+00
2.6e+00
cases:3.89%
controls:0.58%
cases:3.74%
controls:0.22%
cases:4.32%
controls:0.00%
cases:1.15%
controls:0.00%
—
—
cases:4.65%
controls:0.17%
cases:5.63%
controls:0.43%
27
40
667
6895
26
15
669
6925
30
0
664
6940
8
0
686
6940
—
25
11
513
6638
18
21
302
4836
Cathetrisation of vein
TPH04 [2001309597]
8.0e-01
1.9e+00
2.5e+00
1.0e+50
2.4e+00
1.9e+00
1.3e+00
cases:10.95%
controls:5.25%
cases:10.65%
controls:1.70%
cases:2.74%
controls:0.23%
cases:4.18%
controls:0.00%
cases:2.23%
controls:0.20%
cases:9.67%
controls:1.61%
cases:16.56%
controls:5.15%
76
364
618
6571
74
118
621
6822
19
16
675
6924
29
0
665
6940
15
14
658
6907
52
107
486
6542
53
250
267
4607
CD3-CD16+CD56+ (Natural killer) cells/cells in Blood
8112-5 [3027831]
3.1e+00
3.8e+00
—
—
1.0e+50
—
3.9e+00
cases:3.75%
controls:0.17%
cases:3.88%
controls:0.09%
—
—
—
—
cases:5.05%
controls:0.00%
—
—
cases:8.13%
controls:0.19%
26
12
668
6923
27
6
668
6934
—
—
34
0
639
6921
—
26
9
294
4848
denosumab; parenteral
M05BX04 [21604169]
1.5e+00
1.6e+00
2.4e+00
—
1.8e+00
2.0e+00
1.5e+00
cases:5.48%
controls:1.24%
cases:5.90%
controls:1.28%
cases:2.59%
controls:0.23%
—
—
cases:1.49%
controls:0.26%
cases:8.74%
controls:1.25%
cases:7.81%
controls:1.89%
38
86
656
6849
41
89
654
6851
18
16
676
6924
—
10
18
663
6903
47
83
491
6566
25
92
295
4765
Fibrin D-dimer FEU [Mass/volume] in Platelet poor plasma
48065-7 [3051714]
7.2e-01
1.6e+00
2.9e+00
1.0e+50
3.0e+00
1.7e+00
8.9e-01
cases:12.39%
controls:6.43%
cases:10.07%
controls:2.26%
cases:4.90%
controls:0.29%
cases:3.03%
controls:0.00%
cases:4.61%
controls:0.23%
cases:10.78%
controls:2.20%
cases:16.25%
controls:7.37%
86
446
608
6489
70
157
625
6783
34
20
660
6920
21
0
673
6940
31
16
642
6905
58
146
480
6503
52
358
268
4499
Dyspnoea
R06.0 [45558449]
1.0e+00
1.5e+00
3.1e+00
1.0e+50
2.7e+00
1.5e+00
9.8e-01
cases:13.83%
controls:5.45%
cases:9.21%
controls:2.26%
cases:4.76%
controls:0.22%
cases:4.90%
controls:0.00%
cases:2.67%
controls:0.19%
cases:8.55%
controls:2.11%
cases:15.31%
controls:6.36%
96
378
598
6557
64
157
631
6783
33
15
661
6925
34
0
660
6940
18
13
655
6908
46
140
492
6509
49
309
271
4548
MCHC [Entitic Mass/volume] in Red Blood Cells
28540-3 [3003338]
1.5e-01
6.8e-01
2.3e+00
4.8e+00
2.3e+00
6.5e-01
5.8e-02
cases:49.42%
controls:45.80%
cases:53.67%
controls:36.92%
cases:47.84%
controls:8.21%
cases:39.91%
controls:0.53%
cases:46.36%
controls:8.18%
cases:52.60%
controls:36.73%
cases:57.19%
controls:55.75%
343
3176
351
3759
373
2562
322
4378
332
570
362
6370
277
37
417
6903
312
566
361
6355
283
2442
255
4207
183
2708
137
2149
Abdominal CT examination
JN3AD [2001305554]
8.6e-01
2.0e+00
2.9e+00
—
2.7e+00
1.2e+00
1.1e+00
cases:4.32%
controls:1.87%
cases:4.89%
controls:0.71%
cases:1.30%
controls:0.07%
—
—
cases:1.34%
controls:0.09%
cases:3.16%
controls:1.01%
cases:10.63%
controls:3.95%
30
130
664
6805
34
49
661
6891
9
5
685
6935
—
9
6
664
6915
17
67
521
6582
34
192
286
4665
Mycobacterium sp identified in Sputum by Organism specific culture
539-7 [3027544]
2.1e+00
2.7e+00
—
—
—
3.6e+00
2.3e+00
cases:2.16%
controls:0.27%
cases:1.29%
controls:0.09%
—
—
—
—
—
—
cases:2.60%
controls:0.08%
cases:4.06%
controls:0.41%
15
19
679
6916
9
6
686
6934
—
—
—
14
5
524
6644
13
20
307
4837
Iron [Moles/volume] in Serum or Plasma
14798-3 [3022948]
1.2e+00
1.8e+00
2.4e+00
—
2.4e+00
1.8e+00
1.1e+00
cases:14.12%
controls:4.93%
cases:13.96%
controls:2.61%
cases:4.18%
controls:0.39%
—
—
cases:5.05%
controls:0.48%
cases:15.61%
controls:3.08%
cases:22.81%
controls:8.77%
98
342
596
6593
97
181
598
6759
29
27
665
6913
—
34
33
639
6888
84
205
454
6444
73
426
247
4431
Cytomegalovirus IgG Ab [Units/volume] in Serum or Plasma
7852-7 [3010130]
2.3e+00
3.1e+00
—
1.0e+50
—
3.1e+00
2.1e+00
cases:5.76%
controls:0.61%
cases:2.73%
controls:0.13%
—
—
cases:0.72%
controls:0.00%
—
—
cases:2.97%
controls:0.14%
cases:3.75%
controls:0.47%
40
42
654
6893
19
9
676
6931
—
5
0
689
6940
—
16
9
522
6640
12
23
308
4834
Leukocytes [#/volume] in Urine
30405-5 [3018095]
7.5e-01
1.5e+00
3.0e+00
—
2.7e+00
1.6e+00
9.1e-01
cases:22.91%
controls:12.27%
cases:24.75%
controls:6.60%
cases:18.59%
controls:1.08%
—
—
cases:14.56%
controls:1.14%
cases:28.62%
controls:7.23%
cases:37.19%
controls:19.27%
159
851
535
6084
172
458
523
6482
129
75
565
6865
—
98
79
575
6842
154
481
384
6168
119
936
201
3921
granisetron; oral, parenteral, transdermal
A04AA02 [21600494]
1.7e+00
2.8e+00
3.5e+00
—
—
2.5e+00
1.2e+00
cases:5.33%
controls:0.99%
cases:8.63%
controls:0.56%
cases:2.88%
controls:0.09%
—
—
—
—
cases:4.65%
controls:0.41%
cases:1.88%
controls:0.58%
37
69
657
6866
60
39
635
6901
20
6
674
6934
—
—
25
27
513
6622
6
28
314
4829
Cytomegalovirus IgG Ab [Titer] in Serum or Plasma
22246-3 [3017918]
2.2e+00
3.3e+00
—
1.0e+50
—
3.1e+00
1.9e+00
cases:6.34%
controls:0.72%
cases:3.02%
controls:0.12%
—
—
cases:0.72%
controls:0.00%
—
—
cases:3.16%
controls:0.15%
cases:3.44%
controls:0.51%
44
50
650
6885
21
8
674
6932
—
5
0
689
6940
—
17
10
521
6639
11
25
309
4832
Oxygen capacity [Volume Fraction] in Arterial blood
59275-8 [40762366]
9.9e-01
2.1e+00
—
—
4.6e+00
1.7e+00
1.1e+00
cases:4.76%
controls:1.82%
cases:5.18%
controls:0.66%
—
—
—
—
cases:6.69%
controls:0.07%
cases:4.65%
controls:0.86%
cases:6.88%
controls:2.45%
33
126
661
6809
36
46
659
6894
—
—
45
5
628
6916
25
57
513
6592
22
119
298
4738
Natriuretic peptide B [Mass/volume] in Serum or Plasma
30934-4 [3011960]
8.9e-01
1.5e+00
3.2e+00
—
3.5e+00
1.5e+00
4.6e-01
cases:8.36%
controls:3.62%
cases:5.90%
controls:1.43%
cases:4.76%
controls:0.20%
—
—
cases:5.35%
controls:0.17%
cases:5.20%
controls:1.26%
cases:4.38%
controls:2.80%
58
251
636
6684
41
99
654
6841
33
14
661
6926
—
36
12
637
6909
28
84
510
6565
14
136
306
4721
Lymphocyte T-cell and B-cell and Natural killer subsets panel - Blood
80721-4 [21493690]
3.0e+00
3.7e+00
—
—
1.0e+50
—
3.8e+00
cases:3.75%
controls:0.19%
cases:4.32%
controls:0.12%
—
—
—
—
cases:6.39%
controls:0.00%
—
—
cases:8.44%
controls:0.21%
26
13
668
6922
30
8
665
6932
—
—
43
0
630
6921
—
27
10
293
4847
Cytomegalovirus IgM Ab [Units/volume] in Serum or Plasma
7853-5 [3015635]
2.2e+00
3.1e+00
—
1.0e+50
—
3.1e+00
2.1e+00
cases:6.20%
controls:0.74%
cases:2.88%
controls:0.13%
—
—
cases:0.72%
controls:0.00%
—
—
cases:2.97%
controls:0.14%
cases:3.75%
controls:0.49%
43
51
651
6884
20
9
675
6931
—
5
0
689
6940
—
16
9
522
6640
12
24
308
4833
Glucose [Moles/volume] in Serum or Plasma
14749-6 [3013826]
7.3e-01
1.6e+00
3.0e+00
—
2.9e+00
1.4e+00
8.3e-01
cases:38.76%
controls:23.32%
cases:37.70%
controls:11.37%
cases:25.79%
controls:1.63%
—
—
cases:23.03%
controls:1.60%
cases:34.39%
controls:11.25%
cases:48.13%
controls:28.80%
269
1617
425
5318
262
789
433
6151
179
113
515
6827
—
155
111
518
6810
185
748
353
5901
154
1399
166
3458
Inpatient Visit
IP [9201]
7.7e-01
1.6e+00
2.8e+00
—
3.2e+00
1.6e+00
5.0e-01
cases:21.04%
controls:11.02%
cases:19.42%
controls:4.86%
cases:8.21%
controls:0.53%
—
—
cases:12.78%
controls:0.59%
cases:21.38%
controls:4.99%
cases:24.69%
controls:16.59%
146
764
548
6171
135
337
560
6603
57
37
637
6903
—
86
41
587
6880
115
332
423
6317
79
806
241
4051
levofloxacin; inhalant, oral, parenteral
J01MA12 [21603019]
1.4e+00
2.1e+00
3.8e+00
—
—
2.1e+00
1.0e+00
cases:10.81%
controls:2.96%
cases:9.35%
controls:1.22%
cases:6.05%
controls:0.14%
—
—
—
—
cases:7.62%
controls:0.99%
cases:9.69%
controls:3.62%
75
205
619
6730
65
85
630
6855
42
10
652
6930
—
—
41
66
497
6583
31
176
289
4681
Prealbumin [Mass/volume] in Serum or Plasma
14338-8 [3013742]
9.5e-01
1.7e+00
2.1e+00
—
3.1e+00
1.8e+00
7.8e-01
cases:6.92%
controls:2.78%
cases:5.90%
controls:1.11%
cases:1.44%
controls:0.17%
—
—
cases:2.82%
controls:0.13%
cases:6.32%
controls:1.16%
cases:7.19%
controls:3.42%
48
193
646
6742
41
77
654
6863
10
12
684
6928
—
19
9
654
6912
34
77
504
6572
23
166
297
4691
Follicular lymphoma grade II
C82.1 [45532946]
2.1e+00
2.5e+00
—
1.0e+50
—
2.5e+00
3.3e+00
cases:1.59%
controls:0.20%
cases:1.87%
controls:0.16%
—
—
cases:1.59%
controls:0.00%
—
—
cases:2.60%
controls:0.21%
cases:4.38%
controls:0.16%
11
14
683
6921
13
11
682
6929
—
11
0
683
6940
—
14
14
524
6635
14
8
306
4849
Anaemia, unspecified
D64.9 [45600610]
6.9e-01
2.4e+00
3.0e+00
1.0e+50
3.2e+00
1.8e+00
8.3e-02
cases:3.46%
controls:1.77%
cases:5.47%
controls:0.53%
cases:2.02%
controls:0.10%
cases:2.02%
controls:0.00%
cases:2.38%
controls:0.10%
cases:4.83%
controls:0.83%
cases:2.50%
controls:2.31%
24
123
670
6812
38
37
657
6903
14
7
680
6933
14
0
680
6940
16
7
657
6914
26
55
512
6594
8
112
312
4745
CD3 cells/Lymphocytes in Blood
90304-7 [1175426]
3.1e+00
3.6e+00
—
—
1.0e+50
—
3.7e+00
cases:3.75%
controls:0.17%
cases:4.03%
controls:0.12%
—
—
—
—
cases:5.05%
controls:0.00%
—
—
cases:8.13%
controls:0.23%
26
12
668
6923
28
8
667
6932
—
—
34
0
639
6921
—
26
11
294
4846
CD3+CD4+ (T4 helper) cells [#/volume] in Blood
24467-3 [3028167]
2.6e+00
3.5e+00
—
—
1.0e+50
—
4.2e+00
cases:3.17%
controls:0.23%
cases:3.31%
controls:0.10%
—
—
—
—
cases:6.24%
controls:0.00%
—
—
cases:9.69%
controls:0.16%
22
16
672
6919
23
7
672
6933
—
—
42
0
631
6921
—
31
8
289
4849
Microscopic observation [Identifier] in Buccal smear by Cyto stain
18501-7 [3018559]
1.9e+00
3.8e+00
—
—
—
2.3e+00
2.4e+00
cases:3.17%
controls:0.49%
cases:3.60%
controls:0.09%
—
—
—
—
—
—
cases:1.49%
controls:0.15%
cases:2.81%
controls:0.27%
22
34
672
6901
25
6
670
6934
—
—
—
8
10
530
6639
9
13
311
4844
Granulocytes [#/volume] in Blood
30394-1 [3035715]
1.8e+00
2.7e+00
1.0e+50
—
—
3.3e+00
2.5e+00
cases:4.18%
controls:0.74%
cases:3.17%
controls:0.22%
cases:1.73%
controls:0.00%
—
—
—
—
cases:3.53%
controls:0.14%
cases:2.50%
controls:0.21%
29
51
665
6884
22
15
673
6925
12
0
682
6940
—
—
19
9
519
6640
8
10
312
4847
Erythrocytes [Presence] in Urine by Automated
53292-9 [3041096]
6.1e-01
1.5e+00
3.0e+00
—
2.8e+00
1.6e+00
7.7e-01
cases:15.85%
controls:9.30%
cases:16.69%
controls:4.16%
cases:12.82%
controls:0.72%
—
—
cases:11.14%
controls:0.77%
cases:18.40%
controls:4.36%
cases:23.13%
controls:12.27%
110
645
584
6290
116
289
579
6651
89
50
605
6890
—
75
53
598
6868
99
290
439
6359
74
596
246
4261
CD19 cells [#/volume] in Blood
8116-6 [3010503]
2.9e+00
3.4e+00
—
—
1.0e+50
—
4.1e+00
cases:3.46%
controls:0.20%
cases:3.60%
controls:0.13%
—
—
—
—
cases:4.90%
controls:0.00%
—
—
cases:8.75%
controls:0.16%
24
14
670
6921
25
9
670
6931
—
—
33
0
640
6921
—
28
8
292
4849
Epstein Barr virus nuclear IgG Ab [Units/volume] in Serum
31374-2 [3007080]
2.4e+00
3.1e+00
—
—
—
2.6e+00
2.2e+00
cases:5.04%
controls:0.48%
cases:2.73%
controls:0.13%
—
—
—
—
—
—
cases:2.23%
controls:0.17%
cases:2.81%
controls:0.33%
35
33
659
6902
19
9
676
6931
—
—
—
12
11
526
6638
9
16
311
4841
Hypertension secondary to other renal disorders
I15.1 [45557535]
2.6e+00
2.3e+00
—
—
—
3.0e+00
2.3e+00
cases:1.73%
controls:0.13%
cases:1.15%
controls:0.12%
—
—
—
—
—
—
cases:1.86%
controls:0.09%
cases:2.19%
controls:0.23%
12
9
682
6926
8
8
687
6932
—
—
—
10
6
528
6643
7
11
313
4846
Epstein Barr virus capsid IgM Ab [Units/volume] in Serum by Immunoassay
5159-9 [3007844]
2.2e+00
3.2e+00
—
—
—
2.8e+00
1.9e+00
cases:5.04%
controls:0.56%
cases:2.88%
controls:0.12%
—
—
—
—
—
—
cases:2.60%
controls:0.17%
cases:2.50%
controls:0.37%
35
39
659
6896
20
8
675
6932
—
—
—
14
11
524
6638
8
18
312
4839
Physiotherapy
R4110 [2001310233]
8.4e-01
1.3e+00
2.7e+00
—
2.9e+00
1.6e+00
9.2e-01
cases:15.56%
controls:7.40%
cases:9.78%
controls:2.91%
cases:3.46%
controls:0.24%
—
—
cases:5.05%
controls:0.29%
cases:9.48%
controls:2.17%
cases:13.75%
controls:5.99%
108
513
586
6422
68
202
627
6738
24
17
670
6923
—
34
20
639
6901
51
144
487
6505
44
291
276
4566
Neutrophils [#/volume] in Blood
26499-4 [3017732]
5.2e-01
1.5e+00
3.1e+00
1.0e+50
3.1e+00
1.6e+00
9.1e-01
cases:3.03%
controls:1.82%
cases:5.18%
controls:1.25%
cases:4.18%
controls:0.20%
cases:2.02%
controls:0.00%
cases:4.75%
controls:0.22%
cases:7.25%
controls:1.55%
cases:11.88%
controls:5.13%
21
126
673
6809
36
87
659
6853
29
14
665
6926
14
0
680
6940
32
15
641
6906
39
103
499
6546
38
249
282
4608
CD3+CD4+ (T4 helper) cells/cells in Blood
8123-2 [3014037]
2.7e+00
3.9e+00
—
—
—
—
3.5e+00
cases:3.03%
controls:0.22%
cases:3.60%
controls:0.07%
—
—
—
—
—
—
—
—
cases:9.06%
controls:0.29%
21
15
673
6920
25
5
670
6935
—
—
—
—
29
14
291
4843
Prothrombin time (PT) actual/Normal
5894-1 [3033658]
6.4e-01
1.5e+00
2.7e+00
—
3.1e+00
1.5e+00
6.8e-01
cases:16.57%
controls:9.44%
cases:16.26%
controls:4.22%
cases:8.65%
controls:0.62%
—
—
cases:13.08%
controls:0.65%
cases:16.17%
controls:4.24%
cases:19.38%
controls:10.83%
115
655
579
6280
113
293
582
6647
60
43
634
6897
—
88
45
585
6876
87
282
451
6367
62
526
258
4331
oxycodone; oral, parenteral
N02AA05 [21604260]
1.2e+00
2.0e+00
2.1e+00
—
1.9e+00
2.0e+00
9.6e-01
cases:7.78%
controls:2.60%
cases:10.07%
controls:1.50%
cases:5.62%
controls:0.69%
—
—
cases:4.01%
controls:0.62%
cases:12.45%
controls:1.96%
cases:11.88%
controls:4.90%
54
180
640
6755
70
104
625
6836
39
48
655
6892
—
27
43
646
6878
67
130
471
6519
38
238
282
4619
EKG study
11524-6 [3013512]
2.0e-01
6.3e-01
2.5e+00
4.3e+00
2.0e+00
6.0e-01
2.9e-01
cases:16.14%
controls:13.66%
cases:13.38%
controls:7.62%
cases:9.80%
controls:0.85%
cases:4.90%
controls:0.07%
cases:6.54%
controls:0.90%
cases:13.57%
controls:7.90%
cases:24.06%
controls:19.15%
112
947
582
5988
93
529
602
6411
68
59
626
6881
34
5
660
6935
44
62
629
6859
73
525
465
6124
77
930
243
3927
Bicarbonate [Moles/volume] in Arterial blood
1960-4 [3008152]
1.2e+00
2.3e+00
—
—
4.1e+00
1.4e+00
1.1e+00
cases:6.92%
controls:2.26%
cases:7.19%
controls:0.75%
—
—
—
—
cases:8.02%
controls:0.14%
cases:4.28%
controls:1.07%
cases:7.81%
controls:2.86%
48
157
646
6778
50
52
645
6888
—
—
54
10
619
6911
23
71
515
6578
25
139
295
4718
amoxicillin and beta-lactamase inhibitor; oral, parenteral
J01CR02 [21602863]
9.1e-01
1.5e+00
3.0e+00
—
1.8e+00
1.5e+00
1.2e+00
cases:19.74%
controls:8.97%
cases:12.23%
controls:2.90%
cases:7.06%
controls:0.36%
—
—
cases:1.78%
controls:0.29%
cases:10.97%
controls:2.68%
cases:22.81%
controls:8.03%
137
622
557
6313
85
201
610
6739
49
25
645
6915
—
12
20
661
6901
59
178
479
6471
73
390
247
4467
Immunohistochemistry procedure
117617002 [4035726]
1.4e+00
2.7e+00
2.2e+00
—
—
2.2e+00
1.4e+00
cases:10.09%
controls:2.58%
cases:12.52%
controls:0.92%
cases:1.44%
controls:0.16%
—
—
—
—
cases:5.02%
controls:0.56%
cases:8.75%
controls:2.39%
70
179
624
6756
87
64
608
6876
10
11
684
6929
—
—
27
37
511
6612
28
116
292
4741
aciclovir; oral, parenteral
J05AB01 [21603131]
1.0e+00
1.7e+00
2.1e+00
—
2.1e+00
1.9e+00
1.1e+00
cases:8.65%
controls:3.36%
cases:6.04%
controls:1.11%
cases:1.87%
controls:0.23%
—
—
cases:2.23%
controls:0.27%
cases:7.62%
controls:1.25%
cases:9.06%
controls:3.19%
60
233
634
6702
42
77
653
6863
13
16
681
6924
—
15
19
658
6902
41
83
497
6566
29
155
291
4702
Epstein Barr virus Ab [Presence] in Serum
49178-7 [3048929]
2.1e+00
3.2e+00
—
—
—
2.9e+00
1.8e+00
cases:5.62%
controls:0.74%
cases:3.31%
controls:0.14%
—
—
—
—
—
—
cases:2.79%
controls:0.15%
cases:3.13%
controls:0.56%
39
51
655
6884
23
10
672
6930
—
—
—
15
10
523
6639
10
27
310
4830
Granulocytes/Leukocytes in Blood
30395-8 [3035933]
1.9e+00
2.6e+00
1.0e+50
—
—
3.2e+00
2.3e+00
cases:5.48%
controls:0.89%
cases:3.45%
controls:0.26%
cases:2.02%
controls:0.00%
—
—
—
—
cases:3.53%
controls:0.15%
cases:2.50%
controls:0.27%
38
62
656
6873
24
18
671
6922
14
0
680
6940
—
—
19
10
519
6639
8
13
312
4844
Thorax X-ray examination outside radiological department
GD1UA [2001303652]
1.1e+00
2.0e+00
3.9e+00
—
—
1.9e+00
9.0e-01
cases:9.08%
controls:3.19%
cases:9.06%
controls:1.31%
cases:4.90%
controls:0.10%
—
—
—
—
cases:6.51%
controls:0.99%
cases:7.81%
controls:3.34%
63
221
631
6714
63
91
632
6849
34
7
660
6933
—
—
35
66
503
6583
25
162
295
4695
Protein.monoclonal band 1 [Mass/volume] in Serum or Plasma by Electrophoresis
51435-6 [3029713]
1.5e+00
2.0e+00
2.2e+00
—
2.5e+00
1.7e+00
9.1e-01
cases:4.03%
controls:0.92%
cases:4.03%
controls:0.56%
cases:0.86%
controls:0.10%
—
—
cases:1.78%
controls:0.14%
cases:2.60%
controls:0.50%
cases:3.75%
controls:1.54%
28
64
666
6871
28
39
667
6901
6
7
688
6933
—
12
10
661
6911
14
33
524
6616
12
75
308
4782
moxifloxacin; oral, parenteral
J01MA14 [21603021]
1.9e+00
2.8e+00
—
—
—
3.0e+00
2.1e+00
cases:6.05%
controls:0.97%
cases:5.18%
controls:0.32%
—
—
—
—
—
—
cases:4.09%
controls:0.21%
cases:7.81%
controls:0.99%
42
67
652
6868
36
22
659
6918
—
—
—
22
14
516
6635
25
48
295
4809
Leukaemia and other malignant diseases of the blood and bone marrow, and malignant diseases of the lymphatic tissue
117 [2001600117]
3.1e+00
4.4e+00
—
—
—
2.4e+00
1.0e+00
cases:12.54%
controls:0.65%
cases:13.09%
controls:0.19%
—
—
—
—
—
—
cases:1.12%
controls:0.11%
cases:1.56%
controls:0.56%
87
45
607
6890
91
13
604
6927
—
—
—
6
7
532
6642
5
27
315
4830
Troponin I.cardiac [Mass/volume] in Serum or Plasma
10839-9 [3021337]
6.8e-01
1.5e+00
3.5e+00
—
3.0e+00
1.1e+00
3.7e-01
cases:13.26%
controls:7.18%
cases:12.95%
controls:3.24%
cases:8.50%
controls:0.29%
—
—
cases:9.21%
controls:0.49%
cases:10.59%
controls:3.62%
cases:13.13%
controls:9.45%
92
498
602
6437
90
225
605
6715
59
20
635
6920
—
62
34
611
6887
57
241
481
6408
42
459
278
4398
Chronic kidney disease, unspecified
N18.9 [45553438]
1.2e+00
1.4e+00
2.5e+00
—
2.0e+00
1.5e+00
1.1e+00
cases:4.61%
controls:1.41%
cases:3.60%
controls:0.88%
cases:2.31%
controls:0.19%
—
—
cases:1.63%
controls:0.23%
cases:4.65%
controls:1.04%
cases:6.25%
controls:2.16%
32
98
662
6837
25
61
670
6879
16
13
678
6927
—
11
16
662
6905
25
69
513
6580
20
105
300
4752
Methemoglobin/Hemoglobin.total in Venous blood
2617-9 [3024889]
7.8e-01
1.4e+00
3.1e+00
1.0e+50
2.6e+00
1.5e+00
1.1e+00
cases:3.17%
controls:1.49%
cases:2.30%
controls:0.61%
cases:2.16%
controls:0.10%
cases:2.02%
controls:0.00%
cases:1.78%
controls:0.13%
cases:3.72%
controls:0.83%
cases:8.13%
controls:2.82%
22
103
672
6832
16
42
679
6898
15
7
679
6933
14
0
680
6940
12
9
661
6912
20
55
518
6594
26
137
294
4720
CD19 cells/cells in Blood
8117-4 [3016228]
2.6e+00
2.9e+00
—
—
1.0e+50
—
4.2e+00
cases:1.87%
controls:0.14%
cases:1.87%
controls:0.10%
—
—
—
—
cases:3.57%
controls:0.00%
—
—
cases:6.25%
controls:0.10%
13
10
681
6925
13
7
682
6933
—
—
24
0
649
6921
—
20
5
300
4852
Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma
1920-8 [3013721]
7.7e-01
1.3e+00
2.7e+00
—
3.0e+00
1.4e+00
5.5e-01
cases:21.33%
controls:11.18%
cases:15.97%
controls:5.03%
cases:8.93%
controls:0.68%
—
—
cases:12.48%
controls:0.69%
cases:17.66%
controls:5.05%
cases:21.56%
controls:13.65%
148
775
546
6160
111
349
584
6591
62
47
632
6893
—
84
48
589
6873
95
336
443
6313
69
663
251
4194
Epithelial cells.squamous [#/volume] in Urine by Automated count
51486-9 [3029879]
6.0e-01
1.3e+00
2.9e+00
—
2.8e+00
1.3e+00
7.5e-01
cases:8.50%
controls:4.86%
cases:8.92%
controls:2.58%
cases:6.77%
controls:0.39%
—
—
cases:5.50%
controls:0.36%
cases:10.41%
controls:3.01%
cases:16.56%
controls:8.61%
59
337
635
6598
62
179
633
6761
47
27
647
6913
—
37
25
636
6896
56
200
482
6449
53
418
267
4439
Bilirubin.conjugated [Moles/volume] in Serum or Plasma
29760-6 [3005772]
1.1e+00
1.8e+00
2.4e+00
—
2.9e+00
1.6e+00
7.2e-01
cases:9.37%
controls:3.42%
cases:7.91%
controls:1.47%
cases:2.74%
controls:0.26%
—
—
cases:3.86%
controls:0.23%
cases:7.43%
controls:1.59%
cases:8.13%
controls:4.14%
65
237
629
6698
55
102
640
6838
19
18
675
6922
—
26
16
647
6905
40
106
498
6543
26
201
294
4656
Natriuretic peptide.B prohormone N-Terminal [Mass/volume] in Serum or Plasma
33762-6 [3029187]
7.3e-01
1.4e+00
2.6e+00
—
3.1e+00
1.2e+00
5.7e-01
cases:20.03%
controls:10.81%
cases:19.57%
controls:5.72%
cases:9.22%
controls:0.75%
—
—
cases:15.60%
controls:0.79%
cases:18.77%
controls:6.36%
cases:26.25%
controls:16.76%
139
750
555
6185
136
397
559
6543
64
52
630
6888
—
105
55
568
6866
101
423
437
6226
84
814
236
4043
Epithelial cells.non-squamous [#/volume] in Urine by Automated count
51485-1 [3030306]
5.4e-01
1.3e+00
2.9e+00
—
2.7e+00
1.3e+00
8.5e-01
cases:7.93%
controls:4.76%
cases:9.93%
controls:2.84%
cases:6.92%
controls:0.42%
—
—
cases:5.94%
controls:0.42%
cases:11.15%
controls:3.34%
cases:19.69%
controls:9.47%
55
330
639
6605
69
197
626
6743
48
29
646
6911
—
40
29
633
6892
60
222
478
6427
63
460
257
4397
Supine thorax X-ray examination
GD1QA [2001303648]
8.1e-01
1.4e+00
2.8e+00
1.0e+50
3.2e+00
1.4e+00
2.5e-01
cases:6.34%
controls:2.91%
cases:5.04%
controls:1.35%
cases:3.31%
controls:0.20%
cases:5.19%
controls:0.00%
cases:2.82%
controls:0.12%
cases:5.76%
controls:1.52%
cases:6.88%
controls:5.44%
44
202
650
6733
35
94
660
6846
23
14
671
6926
36
0
658
6940
19
8
654
6913
31
101
507
6548
22
264
298
4593

LabWAS

↥
OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
208
98
29.76
290.34
2.5
1.4
—
—
—
0
0
208
98
29.76
290.34
2.5
1.4
—
—
—
0
0
208
98
29.76
290.34
2.5
1.4
—
—
—
0
0
208
98
29.76
290.34
2.5
1.4
—
—
—
0
0
173
57
39.97
272.23
3.0
1.9
1039.75
1230.14
e6/l
0.46
167
50
147
41
45.10
241.52
3.8
2.4
35.79
42.86
%
1.52
94
25
346
554
11.36
231.41
7.3
2.8
8.31
10.93
g/l
10.40
341
513
396
850
9.41
201.92
2.4
1.5
—
—
—
0
0
251
332
11.22
191.74
3.1
2.0
0.95
2.21
ug/l
0.76
239
300
588
2041
12.67
185.74
12.5
4.6
—
—
—
0
0
417
1046
8.37
179.70
2.6
2.1
—
—
—
0
0
96
19
58.39
169.30
2.1
1.7
34.27
33.26
%
0.08
96
19
144
110
16.22
156.61
3.1
2.7
—
—
—
0
0
106
44
28.20
152.27
3.5
2.0
218.96
208.16
e6/l
0.10
101
38
353
865
7.21
151.27
2.1
1.8
—
—
—
0
0
148
126
14.62
150.94
2.6
2.5
—
—
—
0
0
252
444
8.30
148.53
3.4
1.7
1.02
1.43
g/l
2.14
224
412
290
644
6.97
135.47
11.2
4.8
1.12
0.90
%
0.85
225
211
359
978
6.47
134.98
15.0
6.0
1.07
1.03
mmol/l
1.36
353
909
196
295
8.83
131.56
2.9
1.5
8.60
12.07
iu/ml
—
14
8
94
42
25.69
130.95
3.4
1.9
512.01
642.62
e6/l
0.25
84
34
231
427
7.58
128.66
1.8
1.5
—
—
—
0
0
137
133
12.56
127.88
2.3
1.6
—
—
—
0
0
390
1204
6.05
125.79
8.4
3.5
0.80
0.82
mmol/l
1.44
380
1131
635
3103
12.11
119.93
24.6
6.6
8.90
9.09
%
0.66
627
2913
636
3147
12.01
117.39
24.6
6.5
24.15
26.71
%
4.51
629
2987
537
2285
6.77
116.55
22.3
6.2
—
—
—
0
0
628
3106
10.81
114.66
24.2
6.5
2.09
2.89
%
19.61
620
2917
128
137
11.21
111.25
1.6
1.4
—
—
—
0
0
622
3102
9.92
110.70
24.6
6.5
0.57
0.67
%
4.57
616
2908
122
124
11.70
109.88
1.6
1.4
124.03
151.75
au/ml
1.08
39
39
644
3348
12.36
108.89
22.3
6.3
0.64
0.60
e9/l
2.09
611
2856
645
3362
12.50
108.64
22.3
6.4
0.04
0.04
e9/l
5.23
613
2875
70
23
33.70
108.01
1.2
1.5
—
—
—
0
0
646
3402
12.46
106.66
22.7
6.4
2.06
1.90
e9/l
0.29
623
2986
264
660
5.81
105.53
2.3
1.6
—
—
—
0
0
647
3455
12.33
103.88
24.7
6.5
0.15
0.20
e9/l
16.09
624
3005
279
763
5.41
99.89
2.0
1.6
—
—
—
0
0
307
916
5.18
98.83
12.6
8.4
10.63
11.93
kpa
5.30
295
888
307
916
5.18
98.83
12.6
8.4
4.78
5.12
kpa
8.26
296
884
247
614
5.67
98.64
11.5
4.7
0.66
0.61
%
0.21
182
195
299
889
5.12
96.30
6.2
2.7
2.00
1.82
%
1.61
288
809
303
911
5.10
96.25
12.6
8.5
7.44
7.42
ph
6.65
191
524
243
609
5.58
95.86
12.1
4.9
0.16
0.14
%
0.20
178
177
300
902
5.07
95.12
12.3
8.5
1.23
1.00
mmol/l
0.48
252
749
100
95
12.11
93.85
1.7
1.3
—
—
—
0
0
178
347
6.54
91.85
2.5
2.0
1.56
1.48
g/l
0.37
150
308
118
148
9.38
90.50
6.6
4.0
—
—
—
0
0
653
3744
11.87
90.24
42.4
10.1
4.30
4.15
e9/l
0.85
628
3264
256
702
5.17
90.23
5.9
2.8
71.78
70.78
e9/l
0.14
194
532
638
3586
9.67
89.80
22.8
7.1
10.10
11.67
umol/l
4.35
632
3435
585
3066
6.49
88.61
15.5
5.4
32.68
35.30
g/l
19.80
570
2887
475
2120
4.85
88.27
14.1
4.3
7.40
7.40
ph
1.89
406
1535
128
183
8.33
88.08
1.4
1.3
—
—
—
0
0
84
67
14.11
87.80
1.6
1.1
—
—
—
0
0
110
131
9.77
87.74
1.4
1.3
264.12
267.75
u/ml
0.03
77
72
232
620
5.10
83.66
12.4
5.1
0.61
0.17
%
0.58
165
163
257
777
4.64
78.87
9.4
3.8
7.40
7.38
ph
3.92
188
447
353
1350
4.25
78.76
4.8
3.1
514.56
538.06
mosm/kgh2o
1.50
344
1184
613
3518
6.91
78.29
26.5
7.8
1.20
1.21
mmol/l
3.50
540
3040
247
742
4.60
76.10
9.4
3.8
1.88
1.94
mmol/l
0.08
221
638
229
649
4.76
76.02
3.2
2.2
371.58
382.06
nmol/l
0.21
224
608
313
1125
4.22
75.58
4.3
2.6
2.10
2.27
g/l
5.70
300
1044
577
3206
5.52
75.13
21.9
6.9
1.20
1.21
mmol/l
4.25
566
2947
324
1204
4.14
74.43
4.3
2.7
11.51
12.72
umol/l
2.65
315
1122
258
830
4.34
72.07
12.9
8.7
94.48
95.37
%
1.18
250
807
295
1056
4.10
70.85
4.4
2.6
22.28
22.59
%
0.15
288
990
217
623
4.60
70.29
1.8
1.4
—
—
—
0
0
90
115
8.83
67.46
8.9
4.0
1.41
1.33
%
0.06
85
105
131
256
6.06
66.28
1.6
1.3
—
—
—
0
0
254
869
4.02
64.11
1.7
1.3
320.59
483.02
titre
1.61
68
212
239
784
4.11
64.02
14.7
9.0
113.42
121.16
g/l
5.88
234
768
69
66
11.49
63.96
1.6
1.4
0.43
0.47
g/l
0.21
42
49
69
66
11.49
63.96
1.6
1.4
6.09
8.01
g/l
1.05
43
50
69
66
11.49
63.96
1.6
1.4
1.90
2.72
g/l
2.21
46
49
68
65
11.48
63.04
1.2
1.2
—
—
—
0
0
46
21
23.37
62.76
2.7
1.5
—
—
—
0
0
337
1413
3.67
62.45
17.7
5.2
—
—
—
0
0
68
67
11.13
61.74
2.4
2.4
24.09
60.70
iu/ml
—
11
7
105
179
6.72
60.78
2.5
1.7
—
—
—
0
0
362
1613
3.57
60.53
4.9
2.7
3.91
4.95
e6/l
1.01
354
1475
563
3332
4.50
60.52
18.5
15.3
1.21
1.27
inr
1.81
506
2755
67
68
10.79
59.57
1.6
1.4
—
—
—
0
0
185
529
4.39
59.31
6.7
2.7
—
—
—
0
0
386
1818
3.50
58.52
9.3
2.9
348.81
352.21
umol/l
0.25
368
1581
84
117
8.02
58.41
1.5
1.8
0.49
0.85
g/l
0.93
53
93
41
17
25.55
57.95
1.5
1.2
—
—
—
0
0
445
2305
3.55
57.49
6.6
3.5
52.69
84.49
e6/l
0.36
394
1792
402
2007
3.35
54.13
6.5
3.4
0.26
0.50
e6/l
2.89
348
1493
301
1270
3.40
53.51
3.2
1.5
2.30
2.62
g/l
1.14
240
752
609
3998
4.99
52.26
15.6
5.5
6.90
6.78
mmol/l
0.59
600
3820
64
73
9.55
52.16
1.5
1.2
—
—
—
0
0
463
2563
3.38
51.48
8.1
4.2
52.82
94.99
e6/l
1.08
399
1853
116
255
5.25
51.03
9.6
3.9
64.92
73.98
mg/l
0.14
94
217
199
664
3.79
50.68
15.7
8.9
—
—
—
0
0
115
254
5.22
50.29
9.6
3.9
58.69
60.51
mg/l
0.04
94
219
494
2891
3.40
49.02
41.3
12.2
0.01
0.00
e9/l
0.58
439
2375
431
2370
3.13
46.82
10.3
3.8
2.32
2.35
mmol/l
5.02
414
2134
163
499
3.95
46.71
6.3
3.7
7.43
7.42
ph
1.15
150
417
422
2298
3.10
46.56
4.9
3.2
2198.08
1297.61
ng/l
2.62
395
1980
315
1459
3.10
46.42
2.5
1.7
1.90
1.46
mg/l
0.61
279
1146
163
507
3.89
45.58
12.6
7.7
24.34
24.54
mmol/l
0.26
156
487
399
2125
3.04
45.48
4.0
2.8
63.48
61.79
u/l
0.11
383
1970
104
234
5.04
44.30
9.0
3.6
4.15
2.66
ratio
0.30
61
136
81
146
6.14
43.99
7.0
3.1
57.49
58.46
%
0.19
81
146
60
79
8.21
43.52
1.4
1.2
—
—
—
0
0
55
71
8.32
40.51
1.3
1.1
—
—
—
0
0
207
804
3.23
40.50
2.2
1.7
—
—
—
0
0
88
185
5.30
40.43
4.1
2.3
119.23
128.76
g/l
2.52
70
144
73
130
6.15
40.05
8.9
4.8
2.63
2.40
mmol/l
0.28
60
91
603
4262
3.97
38.79
8.5
4.8
1578.10
1204.69
e6/l
—
10
65
343
1797
2.78
38.42
3.0
2.3
3.20
2.94
mg/l
1.23
325
1529
113
305
4.22
38.10
1.6
1.3
—
—
—
0
0
373
2047
2.76
38.01
4.4
3.3
—
—
—
0
0
105
273
4.35
37.17
2.3
1.8
8.33
8.11
iu/ml
0.03
25
65
65
112
6.29
36.81
6.1
6.2
12.01
11.62
mg/l
0.25
60
104
361
2012
2.64
34.72
25.4
6.3
—
—
—
0
0
87
210
4.59
33.76
2.0
1.4
0.24
0.23
g/l
0.41
82
200
512
3426
2.83
33.32
7.1
4.0
0.00
0.00
estimate
-0.00
165
720
177
704
3.03
32.48
2.7
2.4
0.22
0.21
g/l
1.27
162
657
154
567
3.20
32.28
4.5
3.2
182.12
198.22
ng/l
0.22
144
524
189
782
2.94
32.28
6.7
3.0
7.17
8.61
umol/l
0.55
170
704
513
3469
2.79
32.08
7.2
4.1
16.02
2.56
estimate
0.61
167
735
515
3491
2.79
32.02
7.2
4.1
0.00
0.46
estimate
0.52
156
677
601
4436
3.49
31.76
9.9
4.7
—
2.23
—
0
7
124
404
3.51
31.63
2.1
1.2
222.92
283.31
u/ml
0.25
108
373
374
2193
2.51
31.30
8.0
3.4
36.14
33.73
u/l
0.32
366
2062
191
816
2.84
30.55
5.5
3.2
4.82
4.72
e9/l
0.09
184
704
60
115
5.61
30.36
1.1
1.1
—
—
—
0
0
431
2748
2.48
29.31
5.8
3.7
6.31
6.21
ph
1.03
241
1518
30
27
11.56
28.62
1.2
1.2
—
—
—
0
0
56
109
5.50
27.84
1.1
1.1
—
—
—
0
0
307
1713
2.41
27.75
10.4
4.3
88.47
87.87
%
0.16
297
1692
143
548
3.02
27.66
6.8
4.2
110.85
85.83
ng/l
2.10
130
489
460
3078
2.44
27.22
6.9
3.0
—
—
estimate
—
0
0
260
1356
2.46
27.22
6.5
4.2
180.84
327.48
ng/l
1.07
238
1130
436
2870
2.37
26.47
5.3
3.0
339.89
147.93
ug/l
3.41
421
2640
43
69
6.57
26.00
4.7
2.4
—
—
—
0
0
61
137
4.78
25.73
1.4
1.3
67.63
59.33
mmol/l
0.77
56
118
360
2203
2.30
25.70
6.4
2.6
—
—
—
0
0
72
190
4.11
24.72
4.2
3.2
3.34
1.70
index
1.17
38
109
242
1272
2.38
24.41
5.2
3.1
1.00
0.93
e6/l
0.10
154
705
62
148
4.50
24.25
1.5
1.2
—
—
—
0
0
35
49
7.47
23.93
2.7
2.0
—
—
—
0
0
225
1158
2.39
23.70
5.7
3.3
1.41
1.83
e6/l
0.60
139
590
128
523
2.77
21.67
7.1
3.8
—
—
—
0
0
29
11
27.42
21.49
1.2
1.7
—
—
—
0
0
97
344
3.11
21.19
1.8
1.7
—
—
—
0
0
110
423
2.90
20.82
7.2
2.7
1.19
1.18
%
0.02
110
423
48
107
4.74
20.39
4.9
2.2
32.77
32.76
pg
0.01
48
107
332
2113
2.09
19.85
2.1
1.7
17.75
20.34
nmol/l
2.82
303
1763
250
1432
2.16
19.71
5.1
3.2
2.47
2.46
mmol/l
0.82
234
1285
419
2917
2.08
19.50
3.9
2.5
76.92
78.36
nmol/l
0.55
406
2580
393
2676
2.07
19.39
6.6
4.1
32.63
75.36
ng/l
1.16
348
2059
37
70
5.52
18.91
1.2
1.2
—
—
—
0
0
53
136
4.13
18.84
1.2
1.2
—
—
—
0
0
140
638
2.49
18.83
3.9
2.6
38.89
35.64
u/l
0.37
126
534
30
49
6.35
17.78
1.6
1.2
3.34
0.23
u/ml
0.61
17
27
24
31
7.98
17.51
1.4
1.5
61.47
64.87
mg/l
0.06
19
24
33
61
5.63
17.28
1.2
1.2
—
—
—
0
0
48
122
4.15
17.27
1.8
1.2
—
—
—
0
0
76
267
3.07
16.78
5.5
3.8
1.53
1.35
mmol/l
0.68
71
261
197
1091
2.12
16.47
1.3
1.3
39.45
12.81
u/ml
1.70
54
413
279
1763
1.97
16.12
5.5
3.2
0.13
0.05
—
8
39
23
11
21.56
16.06
1.0
1.1
—
—
—
0
0
51
146
3.69
15.56
1.8
1.2
113.60
10.40
e6/l
0.45
40
108
67
230
3.12
15.37
13.3
8.8
1.33
1.30
mmol/l
0.11
61
204
29
53
5.66
15.36
1.5
1.2
90.00
104.00
titre
—
6
10
283
1823
1.93
15.24
6.8
3.5
0.04
0.05
estimate
0.09
141
569
23
13
18.25
15.23
4.9
2.5
2.87
2.54
%
0.08
23
13
321
2163
1.89
15.00
3.7
2.2
103.24
245.94
u/l
3.57
310
2057
23
34
6.96
14.94
1.9
1.5
—
—
—
0
0
35
78
4.67
14.86
3.9
2.8
1.11
1.26
g/24h
0.09
25
46
366
2584
1.87
14.67
7.3
4.1
0.01
0.01
estimate
0.09
149
598
359
2521
1.87
14.61
2.6
2.2
—
—
—
0
0
200
1167
2.00
14.22
1.3
1.3
68.16
33.93
iu/ml
1.97
81
354
150
787
2.15
14.20
5.5
4.4
16.78
30.60
ug/l
0.40
123
664
34
77
4.59
14.16
1.1
1.1
—
—
—
0
0
34
78
4.53
13.94
1.6
1.1
—
—
—
0
0
28
55
5.26
13.73
2.6
2.9
15.13
16.71
%
1.54
28
55
34
79
4.47
13.72
1.6
1.1
—
—
—
0
0
199
1178
1.96
13.47
1.8
1.7
1205.02
1203.95
nmol/l
0.00
168
890
44
126
3.66
13.41
1.3
1.3
213.72
181.09
miu/ml
—
5
49
46
137
3.52
13.23
6.1
3.0
13.77
8.91
pmol/l
1.24
46
137
21
16
13.49
12.49
1.0
1.0
—
—
—
0
0
22
19
11.91
12.38
2.0
2.0
—
—
—
0
0
288
1961
1.80
12.34
7.2
4.2
0.00
0.01
estimate
0.78
140
664
51
170
3.16
12.28
2.5
3.2
30.91
34.40
umol/l
0.63
45
151
23
42
5.63
12.18
1.0
1.0
—
—
—
0
0
262
1749
1.80
11.90
1.7
1.4
—
—
—
0
0
21
36
5.98
11.85
1.0
1.1
—
—
—
0
0
20
16
12.83
11.68
1.2
1.1
—
—
—
0
0
16
7
23.35
11.61
1.9
1.0
—
—
—
0
0
16
7
23.35
11.61
1.9
1.0
—
—
—
0
0
16
7
23.35
11.61
1.9
1.0
—
—
—
0
0
50
174
3.02
11.20
1.4
1.2
—
—
—
0
0
79
349
2.42
11.13
7.0
3.8
—
—
—
0
0
669
6053
3.31
10.98
77.4
17.9
27.92
25.78
mg/l
1.54
663
5058
33
89
3.84
10.97
1.4
1.2
6.21
7.29
u/ml
0.12
14
41
21
39
5.52
10.93
1.3
1.2
5.62
6.76
u/l
0.35
16
32
21
22
9.80
10.81
3.4
2.0
0.60
0.59
mmol/l
0.19
21
22
22
26
8.70
10.60
1.1
1.1
—
—
—
0
0
22
26
8.70
10.60
1.1
1.1
—
—
—
0
0
22
26
8.70
10.60
1.1
1.1
—
—
—
0
0
26
60
4.46
10.59
1.4
1.2
—
—
—
0
0
19
18
10.81
10.32
4.5
4.9
—
—
—
0
0
116
619
2.05
10.29
2.3
2.5
7.67
6.68
ug/l
0.24
103
556
401
3104
1.68
10.13
2.5
2.2
91.50
95.34
pmol/l
1.00
267
1601
15
9
17.00
9.90
1.2
1.0
—
—
—
0
0
15
9
17.00
9.90
1.5
1.2
—
—
—
0
0
26
64
4.18
9.77
2.5
2.3
—
—
—
0
0
33
97
3.52
9.71
1.6
1.3
2536.23
1581.19
e6/l
0.59
26
63
22
31
7.29
9.56
2.2
2.1
62.27
65.73
ug/l
0.06
22
31
30
84
3.69
9.47
1.6
1.3
—
—
—
0
0
20
41
4.99
9.36
4.8
3.4
0.75
0.85
index
0.34
20
41
49
187
2.74
9.30
1.7
1.2
7.40
2.59
u/ml
—
6
21
111
609
1.98
9.06
3.7
2.5
0.40
0.45
e6/l
0.12
111
586
24
60
4.11
8.85
1.5
1.1
—
—
—
0
0
16
15
10.89
8.82
1.4
1.5
—
—
—
0
0
27
74
3.75
8.80
1.6
1.4
19.14
29.61
ng/l
1.19
27
74
12
6
20.31
8.49
2.7
3.5
—
—
—
0
0
18
24
7.67
8.20
2.5
2.2
—
—
—
0
0
16
19
8.59
7.84
1.3
1.1
0.47
4.37
mmol/l
0.52
11
11
12
8
15.23
7.73
1.2
1.0
—
—
—
0
0
12
8
15.23
7.73
1.2
1.0
—
—
—
0
0
17
23
7.55
7.71
3.4
1.6
2.10
1.84
umol/l
0.44
17
17
62
291
2.24
7.60
1.6
1.3
—
—
—
0
0
13
11
12.01
7.60
1.8
1.3
—
—
—
0
0
21
54
3.98
7.48
1.1
1.1
128.00
101.57
pmol/l
0.64
21
54
481
4054
1.59
7.40
5.8
3.5
82.02
54.54
u/l
4.41
464
3770
63
305
2.17
7.17
4.1
3.9
461.30
4841.53
u/ml
0.74
57
264
55
254
2.26
7.02
5.9
3.9
297.66
230.79
mg/l
0.24
47
113
26
83
3.21
6.77
1.7
1.3
60712.53
42921.40
e6/l
0.13
17
43
26
83
3.21
6.77
1.5
1.2
—
116.66
—
0
5
104
614
1.81
6.73
2.7
1.5
—
—
—
0
0
20
54
3.78
6.68
2.2
2.8
9.14
8.07
mmol/l
0.35
20
54
21
61
3.52
6.33
1.9
1.3
42.13
30.68
%
0.60
15
41
13
17
7.77
6.14
4.0
2.6
—
—
—
0
0
35
140
2.58
6.12
1.8
1.5
—
—
—
0
0
140
925
1.64
6.02
1.4
1.3
—
—
—
0
0
123
788
1.68
5.95
1.4
1.3
—
—
—
0
0
25
85
3.01
5.89
4.9
2.9
4.23
4.05
mmol/l
0.82
25
85
45
210
2.22
5.63
1.3
1.4
242.11
276.56
ug/g
0.54
28
127
24
84
2.92
5.40
5.0
3.0
1.18
1.19
mmol/l
0.47
24
84
14
25
5.69
5.39
1.4
1.4
2.14
3.82
mmol/l
1.61
14
20
24
85
2.89
5.29
5.0
2.9
106.17
105.20
mmol/l
0.42
24
85
99
633
1.66
4.80
2.9
2.1
0.12
0.02
estimate
0.35
26
121
193
1437
1.47
4.77
1.6
1.8
124706341.68
26113450.15
pmol/l
0.57
170
1168
35
161
2.24
4.57
1.8
1.4
12.56
8.05
u/l
0.74
24
122
9
11
8.27
4.57
7.0
3.0
17.40
26.18
mg/mmol
—
9
11
666
6314
2.10
4.55
75.2
21.7
138.44
139.68
mmol/l
26.68
666
6200
21
77
2.78
4.38
1.3
1.2
—
—
—
0
0
7
6
11.77
4.28
1.3
1.2
—
—
—
0
0
111
756
1.56
4.15
3.6
2.5
236.15
127.25
ug/g
1.39
95
598
23
92
2.55
4.08
4.9
2.0
5562.65
5850.12
u/l
0.01
11
30
201
1548
1.42
4.06
7.0
4.3
1.02
1.02
kg/l
0.33
166
1054
58
335
1.80
4.06
2.6
3.6
3.91
4.50
pmol/l
3.94
51
289
7
7
10.08
4.01
1.3
1.1
—
—
u/ml
—
0
0
39
198
2.03
4.00
1.5
1.2
117.14
82.67
titre
—
7
15
10
18
5.62
3.98
1.1
1.4
26.00
26.78
s
—
10
18
32
151
2.17
3.96
2.6
3.2
0.85
0.88
nmol/l
0.09
24
121
15
48
3.17
3.95
1.4
1.1
—
—
—
0
0
59
347
1.76
3.89
2.2
2.4
—
—
—
0
0
8
11
7.34
3.86
1.1
1.1
—
—
—
0
0
20
77
2.64
3.83
16.7
2.0
8.04
10.56
%
2.14
20
77
20
78
2.61
3.74
2.3
1.5
51.38
62.04
%
0.50
13
50
13
34
3.88
3.70
2.2
1.5
44.68
61.12
%
0.86
13
26
8
12
6.73
3.68
11.9
10.3
5.76
5.40
mmol/l
—
8
12
9
16
5.68
3.66
2.7
1.9
—
—
—
0
0
15
51
2.98
3.59
1.4
1.2
—
—
—
0
0
10
21
4.81
3.56
1.2
1.1
—
23.60
u/ml
—
0
5
33
166
2.04
3.50
6.2
5.0
—
—
—
0
0
15
52
2.93
3.48
2.5
1.8
0.90
2.00
u/field
—
10
28
9
18
5.05
3.38
1.0
1.2
—
—
—
0
0
15
53
2.87
3.37
1.6
1.2
—
—
—
0
0
37
198
1.92
3.31
2.5
1.5
7607.62
13074.80
e6/l
0.73
26
139
39
214
1.87
3.25
1.4
1.2
—
555.00
—
0
6
11
29
3.84
3.19
2.4
1.5
5.09
1.07
%
0.62
11
23
518
4737
1.36
3.14
5.0
4.2
14.91
14.95
pmol/l
0.12
491
4286
650
6199
1.67
3.14
53.0
16.2
—
—
—
0
0
12
35
3.47
3.12
1.0
1.1
0.68
0.49
ratio
—
7
20
20
86
2.36
3.10
2.3
1.4
—
—
—
0
0
30
153
2.00
3.09
1.9
1.5
39.75
26.80
iu/l
0.84
23
125
12
37
3.28
2.94
1.4
1.1
—
—
—
0
0
120
893
1.41
2.88
1.5
1.3
—
—
—
0
0
12
43
2.82
2.65
1.0
1.1
296.29
372.50
nmol/l
—
7
36
7
15
4.70
2.60
6.7
8.7
5.26
5.35
kpa
—
7
15
19
88
2.19
2.53
2.7
1.7
—
—
—
0
0
44
274
1.65
2.44
4.5
3.4
49.75
111.24
u/ml
0.66
44
265
11
38
2.92
2.42
2.4
1.2
133.00
144.06
nmol/l
0.28
11
38
6
12
5.03
2.40
1.0
1.0
—
—
—
0
0
16
71
2.28
2.36
1.6
1.2
7379.91
288349.98
e6/l
1.34
11
51
9
28
3.24
2.31
1.2
1.1
—
—
—
0
0
18
86
2.12
2.24
1.2
1.1
—
—
—
0
0
283
2466
1.25
2.15
5.3
3.8
—
0.70
—
0
10
26
146
1.81
2.09
1.3
1.4
—
—
—
0
0
5
10
5.03
2.07
1.0
1.0
16.68
16.26
g/l
—
5
10
7
175
0.39
2.06
2.0
1.6
—
—
—
0
0
26
148
1.79
2.01
1.3
1.6
221.00
302.53
mu/l
1.28
21
136
26
150
1.76
1.93
1.3
1.9
115.44
4.35
iu/l
—
8
52
672
6543
1.65
1.93
97.7
27.2
93.00
91.49
fl
11.73
672
6470
27
158
1.74
1.91
5.1
3.7
419.48
1934.43
u/ml
0.47
27
148
672
6545
1.65
1.90
100.7
27.8
36.92
40.38
%
56.32
672
6469
672
6545
1.65
1.90
97.6
27.2
30.64
30.44
pg
1.88
672
6472
49
335
1.50
1.88
2.9
2.2
0.00
0.01
estimate
0.50
18
99
10
40
2.52
1.67
1.2
1.3
—
—
—
0
0
595
6164
0.77
1.65
6.3
6.3
2.52
2.62
mmol/l
2.13
549
5663
10
41
2.46
1.65
1.1
1.1
—
7.49
—
0
10
40
271
1.50
1.62
1.1
1.1
—
35.17
—
0
6
16
84
1.93
1.60
1.4
1.2
—
—
—
0
0
136
1617
0.80
1.51
2.3
3.4
0.67
0.75
ug/l
0.54
90
1104
13
65
2.02
1.49
1.5
1.2
—
—
—
0
0
276
2475
1.19
1.45
6.1
4.3
14.35
8.96
mg/mmol
1.30
208
1558
50
366
1.39
1.39
1.2
1.2
35.50
146.71
u/ml
5.72
15
137
5
122
0.41
1.38
1.0
1.6
—
—
—
0
0
278
2504
1.18
1.37
5.7
3.5
6.61
7.72
mmol/l
4.30
256
2105
56
423
1.35
1.30
1.5
1.4
—
—
—
0
0
66
513
1.32
1.27
3.4
2.4
6.15
6.07
ph
0.32
57
349
268
2429
1.17
1.20
5.7
3.5
74.13
47.97
mg/l
1.15
207
1586
8
38
2.12
1.18
1.3
1.2
4.01
6.01
ug/l
—
8
32
164
1430
1.19
1.16
1.3
1.3
0.71
1.27
u/ml
1.80
41
374
13
72
1.82
1.15
1.2
1.2
1.38
1.78
nmol/l
0.47
13
64
42
310
1.38
1.15
2.1
2.9
—
—
—
0
0
11
59
1.88
1.08
1.7
1.8
—
—
—
0
0
589
6060
0.82
1.07
5.8
5.5
4.42
4.51
mmol/l
1.36
549
5589
20
130
1.55
1.03
6.5
3.9
35.47
26.14
mg/l
0.44
15
88
13
75
1.75
1.03
3.1
3.0
3.27
5.66
nmol/l
0.56
13
75
7
34
2.07
1.03
1.3
1.4
—
—
—
0
0
10
53
1.90
1.01
1.0
1.2
—
2.23
—
0
6
197
2182
0.86
0.97
3.9
3.5
—
—
—
0
0
587
6026
0.84
0.92
5.6
5.4
1.37
1.44
mmol/l
3.73
545
5520
13
78
1.68
0.92
1.1
1.3
0.17
0.19
nmol/l
—
6
58
26
192
1.37
0.76
1.0
1.1
—
—
—
0
0
5
24
2.09
0.74
2.8
2.0
—
—
—
0
0
9
56
1.61
0.72
1.0
1.0
—
—
—
0
0
12
182
0.65
0.71
1.0
1.2
—
—
—
0
0
9
144
0.62
0.70
1.1
1.2
1.64
1.51
g/l
—
9
144
5
28
1.79
0.66
3.0
2.0
—
—
—
0
0
588
6004
0.87
0.65
6.3
5.6
6.09
6.04
mmol/l
0.31
549
5457
20
266
0.74
0.60
1.1
1.1
—
—
—
0
0
6
36
1.67
0.56
1.7
1.6
121.42
154.69
pmol/l
—
6
36
24
185
1.31
0.56
2.3
2.6
167.35
112.99
ug/min
0.36
17
101
6
37
1.63
0.55
5.7
1.5
24.68
22.58
umol/l
—
6
32
34
277
1.24
0.53
1.2
1.5
0.53
0.34
mg/l
0.57
17
129
10
66
1.52
0.52
1.1
1.2
—
—
—
0
0
58
500
1.17
0.52
1.2
1.2
—
—
—
0
0
14
191
0.73
0.51
21.4
11.2
—
—
—
0
0
9
65
1.39
0.50
9.4
1.5
—
—
—
0
0
12
167
0.71
0.49
2.1
1.9
178.75
223.59
pmol/l
0.73
12
157
16
212
0.75
0.49
1.9
1.9
46.69
40.57
nmol/l
0.36
16
203
260
2738
0.92
0.48
2.2
2.0
1.57
1.32
mmol/l
4.43
228
2252
7
46
1.53
0.48
1.0
3.3
8.56
7.21
mmol/l
—
7
26
11
76
1.45
0.48
1.2
1.3
—
—
—
0
0
11
77
1.44
0.45
1.1
1.3
—
—
nmol/l
—
0
0
7
51
1.38
0.44
3.9
1.7
—
—
—
0
0
5
33
1.52
0.41
1.4
1.1
261.80
190.29
mmol/24h
—
5
33
5
35
1.43
0.39
4.6
2.3
33.36
39.82
g/l
—
5
35
580
5884
0.92
0.35
8.0
7.1
39.98
39.88
mmol/mol
0.10
553
5468
575
5671
1.08
0.30
6.2
5.3
2.19
1.99
mu/l
0.81
540
5175
5
39
1.28
0.23
1.0
1.0
—
—
—
0
0
16
135
1.19
0.21
5.8
1.4
—
—
—
0
0
0
13
0.00
0.21
0.0
2.2
—
20.01
—
0
13
0
13
0.00
0.21
0.0
1.1
—
39.69
—
0
13
0
14
0.00
0.20
0.0
2.2
—
2.97
—
0
6
16
136
1.18
0.20
5.8
1.4
—
—
—
0
0
16
136
1.18
0.20
5.8
1.4
—
—
—
0
0
16
136
1.18
0.20
5.8
1.4
—
—
—
0
0
6
51
1.18
0.19
1.2
1.4
0.89
1.28
promille
—
6
42
571
5764
0.95
0.19
5.2
4.6
1.44
1.30
mmol/l
4.42
528
5236
281
2743
1.04
0.19
4.9
5.9
3.70
2.54
ug/l
0.65
255
2453
66
619
1.07
0.18
2.7
2.5
11.23
13.21
nmol/l
0.97
58
557
14
156
0.90
0.10
2.6
1.2
0.98
0.89
g/l
0.58
14
156
5
44
1.14
0.10
1.8
1.4
97.00
77.95
umol/l
—
5
44
14
130
1.08
0.04
6.5
1.4
—
—
—
0
0
43
423
1.02
0.01
1.2
1.2
—
—
—
0
0
31
312
0.99
0.00
2.6
1.9
—
—
—
0
0
0
5
0.00
0.00
0.0
1.6
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
2.2
—
0.43
—
0
6
6
60
1.00
-0.00
2.3
2.7
—
—
—
0
0
0
6
0.00
-0.00
0.0
2.3
—
31.67
—
0
6
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0

Mortality – FinRegistry

↥

Association

Association between endpoint AB1_PNEUMOCYSTOSIS and mortality.

Females

Parameter HR [95% CI] p-value
AB1_PNEUMOCYSTOSIS 10.609 [7.15, 15.75] < 0.001
Birth year 1.003 [0.99, 1.01] 0.449

During the follow-up period (1.1.1998 — 31.12.2019), 296 out of 647 females with AB1_PNEUMOCYSTOSIS died.

Males

Parameter HR [95% CI] p-value
AB1_PNEUMOCYSTOSIS 5.697 [4.03, 8.05] < 0.001
Birth year 0.985 [0.98, 0.99] 0.002

During the follow-up period (1.1.1998 — 31.12.2019), 404 out of 853 males with AB1_PNEUMOCYSTOSIS died.

Mortality risk

Mortality risk for people of age

years, who have AB1_PNEUMOCYSTOSIS.

N-year risk Females Males
1 1.668% 1.058%
5 7.866% 6.012%
10 18.753% 14.416%
15 32.72% 25.087%
20 51.67% 40.573%

Relationships between endpoints

↥

Index endpoint: AB1_PNEUMOCYSTOSIS – Pneumocystosis

GWS hits: -

Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
loading spinner Loading data